[{"cove_id":442,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Hydroxychloroquine 200mg per day for 60 days (high risk patients); Hydroxychloroquine 200mg per day for 60 days (low risk patients)","n_enrollment":400,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":4,"blinding":"double blind","population_condition":"COVID-19; Severe Acute Respiratory Syndrome","control":"Placebo (high risk patients); Placebo (low risk patients)","out_primary_measure":"Symptomatic COVID-19 infection rate","start_date":"01. Apr 20","end_date":"31. Mar 21","source_id":"NCT04318015","title":"Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04318015","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":443,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"diagnostic","intervention_name":"VivaDiag™ COVID-19 lgM/IgG Rapid Test","n_enrollment":200,"country":"Italy","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Coronavirus Infection","control":"Not applicable","out_primary_measure":"Number of patients with constant negative results; Number of patients with positive test with a positive PCR for COVID-19; Overall Number of patients positive for COVID-19; Overall Number of patients negative for COVID-19; Number of patients with contrasting results","start_date":"2020-03","end_date":"2020-11","source_id":"NCT04316728","title":"Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04316728","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":444,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Tocilizumab Injection","n_enrollment":330,"country":"Italy","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"na","out_primary_measure":"One-month mortality rate","start_date":"2020-03","end_date":"2022-12","source_id":"NCT04317092","title":"Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04317092","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":445,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"CD24Fc, single dose at Day 1, 480mg, diluted to 100ml with normal saline, IV infusion in 60 minutes","n_enrollment":230,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"Severe Coronavirus Disease (COVID-19)","control":"Placebo, single dose at Day 1, normal saline solution 100ml, IV infusion in 60 minutes.","out_primary_measure":"Improvement of COVID-19 disease status","start_date":"2020-05","end_date":"2022-05","source_id":"NCT04317040","title":"A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","url":"https://clinicaltrials.gov/ct2/show/record/NCT04317040","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":446,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Hydroxychloroquine tablet 200mg every 12 hours for 10 days","n_enrollment":500,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19; Severe Acute Respiratory Syndrome","control":"Placebo, one tablet every 12 hours for 10 days","out_primary_measure":"All-cause hospital mortality","start_date":"2020-03","end_date":"2021-03","source_id":"NCT04315896","title":"Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04315896","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":447,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"biologic","intervention_name":"NestCell® (1x10^6 cells/kg weight on days 1, 3 and 7) plus standard care; NestCell® (dose based Safety Monitoring Board recommendation) plus standard of care","n_enrollment":24,"country":"","status":"not yet recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"na","out_primary_measure":"Disappear time of ground-glass shadow in the lungs","start_date":"2020-04","end_date":"2020-06","source_id":"NCT04315987","title":"Exploratory Clinical Study to Assess the Efficacy of NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04315987","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":448,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Sarilumab high dose; Sarilumab low dose","n_enrollment":400,"country":"United States","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"double blind","population_condition":"COVID-19","control":"Placebo","out_primary_measure":"Time to resolution of fever for at least 48 hours without antipyretics for 48 hours; Percentage of patients reporting each severity rating on a 6-point ordinal scale","start_date":"2020-03","end_date":"2021-03","source_id":"NCT04315298","title":"An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04315298","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":449,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"Hydroxychloroquine Sulfate in addition to standard of care","n_enrollment":202,"country":"Norway","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Coronavirus Infection","control":"Standard of care","out_primary_measure":"Rate of decline in SARS-CoV-2 viral load","start_date":"2020-03","end_date":"2025-03","source_id":"NCT04316377","title":"Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04316377","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":450,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"PUL-042 Inhalation Solution given by nebulization on study days 1,3, 6, and 10","n_enrollment":200,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"Exposed to COVID-19","control":"Placebo, sterile normal saline for inhalation given by nebulization on study days 1, 3, 6, and 10","out_primary_measure":"Prevention of COVID-19","start_date":"2020-04","end_date":"2020-10","source_id":"NCT04313023","title":"A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing COVID-19 Infection in Adults Exposed to COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04313023","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":451,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"biologic","intervention_name":"Wharton's Jelly-Mesenchymal Stem Cells suspended in 25 ml of Saline solution containing 0.5% human serum Albumin","n_enrollment":5,"country":"Jordan","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19","control":"na","out_primary_measure":"Clinical outcome; CT Scan; RT-PCR results","start_date":"2020-03","end_date":"2020-09","source_id":"NCT04313322","title":"Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","url":"https://clinicaltrials.gov/ct2/show/record/NCT04313322","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":452,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"inhaled nitric oxide gas at the end of every shift","n_enrollment":460,"country":"","status":"not yet recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"Coronavirus Infections; Healthcare Associated Infection","control":"No intervention","out_primary_measure":"COVID-19 diagnosis","start_date":"2020-03","end_date":"2022-03","source_id":"NCT04312243","title":"Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","url":"https://clinicaltrials.gov/ct2/show/record/NCT04312243","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":453,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"PUL-042 Inhalation Solution given by nebulization on study days 1, 3 and 6; ","n_enrollment":100,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19","control":"Placebo, sterile normal saline for Inhalation given by nebulization on study days 1, 3 and 6","out_primary_measure":"Severity of COVID-19","start_date":"2020-04","end_date":"2020-10","source_id":"NCT04312997","title":"A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04312997","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":454,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"Remdesivir (200 mg intravenous loading dose then 100 mg once-daily intravenous maintenance dose up to a 10 days total course) plus standard of care; Lopinavir/ritonavir  (400 lopinavir mg/100 mg ritonavir every 12 h for 14 days) plus standard of care; Lopinavir/ritonavir (400 lopinavir mg/100 mg ritonavir every 12 h for 14 days) plus Interferon ß1 (44 µg subcutaneously for a total of 3 doses in 6 days) plus standard of care.","n_enrollment":3200,"country":"International","status":"not yet recruiting","randomized":"randomized","n_arms":4,"blinding":"none","population_condition":"Coronavirus Infection","control":"Standard of care\n","out_primary_measure":"Percentage of subjects reporting each severity rating on a 7-point ordinal scale","start_date":"2020-03","end_date":"2023-03","source_id":"NCT04315948","title":"Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","url":"https://clinicaltrials.gov/ct2/show/record/NCT04315948","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":455,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Losartan","n_enrollment":516,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"Corona Virus Infection; Acute Respiratory Distress Syndrome with exposure  to laboratory-proven SARS-CoV-2-infected person; SARS-CoV Infection\n","control":"Placebo","out_primary_measure":"Hospital Admission","start_date":"2020-03","end_date":"2021-04","source_id":"NCT04311177","title":"Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","url":"https://clinicaltrials.gov/ct2/show/record/NCT04311177","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":456,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Tetrandine 60 mg per day for 1 week","n_enrollment":60,"country":"China","status":"enrolling by invititation","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Standard care","out_primary_measure":"Survival rate","start_date":"2020-03-05","end_date":"2021-03-01","source_id":"NCT04308317","title":"Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04308317","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":457,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Lopinavir/ritonavir; Hydroxychloroquine","n_enrollment":150,"country":"Korea, Republic of","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"Viral load","start_date":"2020-03-11","end_date":"2020-05","source_id":"NCT04307693","title":"Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04307693","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":458,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Nitric Oxide (NO) will be delivered together with the standard of care for a period of 20-30 minutes 2 times per day for 14 consecutive days from time of enrollment. Targeted No inhaled concentration will be maintained between 140 and 180 ppm. The gas will be delivered through a CPAP circuit ensuring an end-expiratory pressure between 2 and 10 cmH2O or through a non-rebreathing mask without positive end-expiratory pressure, depending on the clinical needs of the patient.","n_enrollment":240,"country":"United States","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation","start_date":"2020-03-21","end_date":"2021-04-01","source_id":"NCT04305457","title":"Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04305457","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":459,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 800 mg per day In mild COVID19; \nDarunavir 400 mg every 8 hours Ritonavir 200 mg (or 2.5 mg/kg ) per day plus plus Oseltamivir 300mg ( or 4-6 mg/kg) per day plus Hydroxychloroquine 400mg per day in Mild COVID19; \nLopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In mild COVID19; \nLopinavir 800 mg ( or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg ( or 4-6 mg /kg ) per day In moderate to critically ill COVID19; \nLopinavir 800 mg (or 10 mg/kg ) per day and Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day in Mild COVID19 In moderate to critically ill COVID19; \nDarunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Oseltamivir 300 mg (or 4-6 mg /kg ) per day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19; \nDarunavir 400 mg every 8 hours Ritonavir 200 mg ( or 2.5 mg/kg ) per day plus Favipiravir 2400 mg, 2400 mg, and 1200 mg every 8 h on day 1, and a maintenance dose of 1200 mg twice a day plus Hydroxychloroquine 400 mg per day In moderate to critically ill COVID19","n_enrollment":80,"country":"Thailand","status":"not yet recruiting","randomized":"randomized","n_arms":8,"blinding":"none","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"SARS-CoV-2 eradication time","start_date":"2020-03-15","end_date":"2020-10-31","source_id":"NCT04303299","title":"A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Chloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine in Mild COVID19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Chloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Chloroquine in Moderate to Critically Ill COVID19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04303299","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":460,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"darunavir 800 mg / cobicistat 150 mg tablets (oral, 1 tablet q24h, taking for 7 days) and hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4, 5, 6 and 7.\nContacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2,3,4.","n_enrollment":3040,"country":"Spain","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases","start_date":"2020-03-18","end_date":"2020-06-15","source_id":"NCT04304053","title":"Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04304053","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":461,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"A loading dose of 10 mg base/ kg followed by 155 mg daily (in Asia: 250mg chloroquine phosphate salt; in Europe: 200mg of or hydroxychloroquine sulphate) will be taken for 3 months","n_enrollment":40000,"country":"International","status":"not yet recruiting","randomized":"randomized","n_arms":3,"blinding":"double blind","population_condition":"Healthcare providers; volunteers potentially exposed to COVID-19 infection","control":"Placebo","out_primary_measure":"Number of symptomatic COVID-19 infections","start_date":"2020-04","end_date":"2021-04","source_id":"NCT04303507","title":"Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04303507","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":463,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Bevacizumab 7.5mg/kg body weight + 0.9% NaCl 100ml, intravenous drip","n_enrollment":140,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 pneumonia","control":"Standard care","out_primary_measure":"The time from randomization to clinical improvement","start_date":"2020-03-17","end_date":"2020-06-30","source_id":"NCT04305106","title":"The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multi-Centered Randomized Controlled Clinical Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04305106","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":464,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Sildenafil citrate tablets 0.1g/day for 14 days","n_enrollment":10,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19","control":"","out_primary_measure":"Rate of disease remission; Rate of entering the critical stage; Time of entering the critical stage","start_date":"2020-02-09","end_date":"2020-03-01","source_id":"NCT04304313","title":"A Pilot Study of Sildenafil in the Treatment of COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04304313","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":465,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"Yinhu Qingwen Granula is a kind of herbal granula made from \"Yinhu Qingwen Decoction\", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.","n_enrollment":116,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 pneumonia","control":"Low dose Yinhu Qingwen Granula. This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).","out_primary_measure":"changes in the ratio of PaO2 to FiO2 from baseline","start_date":"2020-03-20","end_date":"2021-03-30","source_id":"NCT04310865","title":"An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04310865","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":466,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"vaccine","intervention_name":"Pathogen-specific artificial antigen presenting cells. The subjects will receive three injections of 5x10^6 each Covid-19/aAPC vaccine via subcutaneous injections","n_enrollment":100,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Healthy volunteers","control":"","out_primary_measure":"Frequency of vaccine events; Frequency of serious vaccine events; Proportion of subjects with positive T cell response","start_date":"2020-02-15","end_date":"2023-07-31","source_id":"NCT04299724","title":"Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","url":"https://clinicaltrials.gov/ct2/show/record/NCT04299724","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":468,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Losartan; 25 mg daily; oral administration. Other Name: Cozaar","n_enrollment":200,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19","control":"Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration","out_primary_measure":"Sequential Organ Failure Assessment (SOFA) Respiratory Score","start_date":"2020-03-16","end_date":"2021-04-01","source_id":"NCT04312009","title":"Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","url":"https://clinicaltrials.gov/ct2/show/record/NCT04312009","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":469,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"other","intervention_name":"Stem Cell Educator therapy treat patients with SARS-CoV-2\nSCE therapy circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SC in vitro, and returns the \"educated\" autologous immune cells to the patient's circulation.","n_enrollment":20,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"single blind","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"Determine the number of Covid-19 patients who were unable to complete SCE Therapy","start_date":"2020-04-10","end_date":"2020-10-09","source_id":"NCT04299152","title":"Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04299152","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":470,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"device","intervention_name":"Medical Mask (known also as Surgical Mask). Medical Mask worn when providing care to patient with febrile respiratory illness","n_enrollment":576,"country":"Canada","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"outcome only","population_condition":"Healthcare workers (nurses)","control":"N95 respirator worn when providing care to patient with febrile respiratory illness","out_primary_measure":"RT-PCR confirmed COVID-19 infection","start_date":"2020-04-01","end_date":"2020-12-01","source_id":"NCT04296643","title":"Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04296643","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":472,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Standard therapy+Huaier granule Huaier granule 20g, po, tid for 2 weeks( or until discharge)","n_enrollment":550,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"standard therapy","out_primary_measure":"Mortality rate","start_date":"01. Apr 20","end_date":"01. Sep 20","source_id":"NCT04291053","title":"The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","url":"https://clinicaltrials.gov/ct2/show/record/NCT04291053","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":473,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"continued standard of care therapy together with Remdesivir (RDV) 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5","n_enrollment":400,"country":"International","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.","out_primary_measure":"Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14","start_date":"2020-03-06","end_date":"2020-05","source_id":"NCT04292899","title":"A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04292899","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":474,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\nWeaning criteria: maintenance of a PaO2/FiO2 ratio \u003e/= 300 for at least 24 hours consecutively.","n_enrollment":200,"country":"United States","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"single blind","population_condition":"COVID-19; Severe Acute Respiratory Syndrome","control":"No Intervention","out_primary_measure":"Change of arterial oxygenation at 48 hours from enrollment","start_date":"2020-03-21","end_date":"2021-03-22","source_id":"NCT04306393","title":"Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04306393","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":475,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4 and 5; Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10","n_enrollment":600,"country":"International","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"COVID-19","control":"Participants will receive continued standard of care therapy","out_primary_measure":"Proportion of Participants Discharged by Day 14","start_date":"2020-03-15","end_date":"2020-05","source_id":"NCT04292730","title":"A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","url":"https://clinicaltrials.gov/ct2/show/record/NCT04292730","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":477,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Patients will be administered Aviptadil IV in escalating doses of 50 pmol, 100 pmol, 150 pmol/kg/hr","n_enrollment":120,"country":"International","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"Acute Respiratory Distress Syndrome; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Corona Virus Infection","control":"atients will first be treated with placebo infusion + maximal intensive care","out_primary_measure":"Mortality; PaO2:FiO2 ratio","start_date":"2020-04","end_date":"2020-09","source_id":"NCT04311697","title":"Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","url":"https://clinicaltrials.gov/ct2/show/record/NCT04311697","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":478,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"other","intervention_name":"3 times of Mesenchymal Stem Cell (MSC)s (4.0*10E7 cells per time) intravenously at Day 0, Day 3, Day 6.","n_enrollment":90,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 (severe)","control":" 3 times of placebo - Saline containing 1% Human serum albumin intravenously at Day 0, Day 3, Day 6）","out_primary_measure":"Size of lesion area and severity of pulmonary fibrosis by chest CT","start_date":"2020-03-05","end_date":"2021-12-31","source_id":"NCT04288102","title":"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04288102","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":480,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"basic treatment + Carrimycin","n_enrollment":520,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"none","population_condition":"COVID-19","control":"any of basic treatment + lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate","out_primary_measure":"Fever to normal time (day); Pulmonary inflammation resolution time (HRCT) (day); Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","start_date":"2020-02-23","end_date":"2021-02-28","source_id":"NCT04286503","title":"The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","url":"https://clinicaltrials.gov/ct2/show/record/NCT04286503","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":481,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"","ipd_sharing":"no","intervention_type":"other","intervention_name":"Besides a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), all subjects in the T89 treatment group will receive 30 pills of T89 each time, orally, BID(every morning and evening), for 10 days (Depending on clinical need and practicability, the use can be extended for up to 14 days)","n_enrollment":120,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"non-critical type of coronavirus pneumonia (COVID-19)","control":"All subjects in the blank control group will only receive a standard background treatment (antiviral drug + antibacterial + oxygen therapy + Traditional Chinese Medicine decoction), for 10 days.","out_primary_measure":"The time to oxygen saturation recovery to normal level (≥97%); The proportion of patients with normal level of oxygen saturation(≥97%)","start_date":"2020-02-26","end_date":"2020-09-15","source_id":"NCT04285190","title":"A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04285190","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":482,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Fingolimod 0.5 mg","n_enrollment":30,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"No Intervention","out_primary_measure":"The change of pneumonia severity on X-ray images","start_date":"2020-02-22","end_date":"2020-07-01","source_id":"NCT04280588","title":"Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04280588","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":483,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"vaccine","intervention_name":"Patients will receive approximately 5x10^6 LV-DC vaccine and 1x10^8 CTLs via sub-cutaneous injections and iv infusions","n_enrollment":100,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19 Infection or healthy volunteers","control":"","out_primary_measure":"Clinical improvement based on the 7-point scale; Lower Murray lung injury score","start_date":"2020-24-03","end_date":"2024-12-31","source_id":"NCT04276896","title":"Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","url":"https://clinicaltrials.gov/ct2/show/record/NCT04276896","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":484,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"100mg thalidomide，po，qn，for 14 days.","n_enrollment":100,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 pneumonia","control":"100mg placebo，po，qn，for 14 days.","out_primary_measure":"Time to Clinical recoveryTime to Clinical Recovery (TTCR)","start_date":"2020-02-20","end_date":"2020-06-30","source_id":"NCT04273529","title":"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","url":"https://clinicaltrials.gov/ct2/show/record/NCT04273529","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":485,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Thalidomide, 100mg/d，qn，for 14 days","n_enrollment":40,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 (severe)","control":"Placebo, 100mg/d，qn，for 14 days.","out_primary_measure":"Time to Clinical Improvement (TTCI)","start_date":"2020-02-18","end_date":"2020-04-30","source_id":"NCT04273581","title":"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","url":"https://clinicaltrials.gov/ct2/show/record/NCT04273581","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":486,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"Yin Hu Qing Wen Decoction plus standard western medicine","n_enrollment":300,"country":"China","status":"active, not recruiting","randomized":"randomized","n_arms":3,"blinding":"double blind","population_condition":"COVID-19","control":"Yin Hu Qing Wen Decoction low dose plus standard western medicine (placebo comparator);  Integrated Chinese and Western Medicine (active comparator)","out_primary_measure":"Mean clinical recovery time (hours)","start_date":"2020-02","end_date":"2021-01","source_id":"NCT04278963","title":"Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","url":"https://clinicaltrials.gov/ct2/show/record/NCT04278963","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":487,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":" Bromhexine Hydrochloride Tablets plus Arbidol Hydrochloride Granules plus  Recombinant Human Interferon α2b Spray\n","n_enrollment":60,"country":"China","status":"enrolling by invititation","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Arbidol Hydrochloride Granules plus  Recombinant Human Interferon α2b Spray (active comparator)\n","out_primary_measure":"Time to clinical recovery after treatment; Rate of aggravation","start_date":"2020-02","end_date":"2020-04","source_id":"NCT04273763","title":"Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04273763","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":488,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Anti-PD-1 antibody, 200mg, IV, one time plus standard treatment; Thymosin, 1.6 mg sc qd, last for 5 days plus standard treatment","n_enrollment":120,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"single blind","population_condition":"2019 nCoV; severe pneumonia associated with lymphocytopenia","control":"Standard treatment","out_primary_measure":"lung injury score","start_date":"2020-02","end_date":"2020-10","source_id":"NCT04268537","title":"Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","url":"https://clinicaltrials.gov/ct2/show/record/NCT04268537","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":489,"source":"clinicaltrials.gov","review_status":"in manual extraction","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Methylprednisolone","n_enrollment":400,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"control","out_primary_measure":"the incidence of treatment failure in 14 days","start_date":"2020-02","end_date":"2020-05","source_id":"NCT04273321","title":"Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","url":"https://clinicaltrials.gov/ct2/show/record/NCT04273321","is_covid":"yes","is_trial":"yes","is_observational":"unclear","is_duplicate":false},{"cove_id":491,"source":"clinicaltrials.gov","review_status":"in manual extraction","results_available":"no","ipd_sharing":"no","intervention_type":"","intervention_name":"UC-MSCs (Umbilical cord mesenchymal stem cell) 3.3 * 107 cell number / 50ml / bag, 3 bags each time, infused intravenously on the 1st, 3rd, 5th, and 7th days after enrollment, 1 time each day.","n_enrollment":10,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Pneumonia, Viral; Pneumonia, Ventilator-Associated; 2019-nCoV infection","control":"na","out_primary_measure":"Oxygenation index","start_date":"2020-02","end_date":"2020-09","source_id":"NCT04269525","title":"Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04269525","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":492,"source":"clinicaltrials.gov","review_status":"in manual extraction","results_available":"no","ipd_sharing":"","intervention_type":"","intervention_name":" Immunoglobulin of cured patients 0.2g/kg, ivdrip, once a day, for 3 day","n_enrollment":10,"country":"China","status":"not yet recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia (severe)","control":"γ-Globulin 0.2g/kg, ivdrip, once a day, for 3 days","out_primary_measure":"Time to Clinical Improvement (TTCI)","start_date":"2020-03","end_date":"2020-05","source_id":"NCT04264858","title":"An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","url":"https://clinicaltrials.gov/ct2/show/record/NCT04264858","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":493,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Eculizumab","n_enrollment":0,"country":"na","status":"planned","randomized":"unclear","n_arms":1,"blinding":"none","population_condition":"Inclusion Criteria:\nAge 18 or older.\nConfirmed Covid-19 infection\nARDS\nICU patient\n\nExclusion Criteria:\nActive Neisseria infection.\nConcomitant enrollment in another experimental/off-label immunosuppressive therapy trial.","control":"Unclear","out_primary_measure":"Mortality\nTime in the ICU\nTime on a ventilator","start_date":"Unclear","end_date":"Unclear","source_id":"NCT04288713","title":"Soliris to Stop Immune Mediated Death In Covid 19 Infected Patients. A Trial of Distal Complement Inhibition.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04288713","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":494,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"vaccine","intervention_name":"25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29. n=15 (4 sentinel, 11 non-sentinel).\nIntervention: Biological: mRNA-1273","n_enrollment":45,"country":"United States","status":"recruiting","randomized":"non-randomized","n_arms":3,"blinding":"none","population_condition":"Coronavirus Infection","control":"100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29. n=15 (4 sentinel, 11 non-sentinel).\nIntervention: Biological: mRNA-1273;\n\n250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29. n=15 (4 sentinel, 11 non-sentinel).\nIntervention: Biological: mRNA-1273","out_primary_measure":"Frequency of solicited local reactogenicity adverse events (AEs); Frequency of any medically-attended adverse events (MAAEs); Frequency of any new-onset chronic medical conditions (NOCMCs); Frequency of any serious adverse events (SAEs); Frequency of any unsolicited adverse events (AEs); Frequency of solicited systemic reactogenicity adverse events (AEs); Grade of any unsolicited adverse events (AEs); Grade of solicited local reactogenicity adverse events (AEs); Grade of solicited systemic reactogenicity adverse events (AEs)","start_date":"2020-03-03","end_date":"2020-06-21","source_id":"NCT04283461","title":"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","url":"https://clinicaltrials.gov/ct2/show/record/NCT04283461","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":495,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Drug: N-acetylcysteine+ Fuzheng Huayu Tablet\nThe subjects will be taking 1 N-acetylcysteine capcule and 4 Fuzheng Huayu tablets three times a day for 24 weeks.","n_enrollment":136,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"Pulmonary Fibrosis Due to 2019-nCoV","control":"Placebo Comparator: Basic Treatment+Placebo\nCapcule with N-acetylcysteine+ Tablet with starch\nIntervention: Drug: N-acetylcysteine+Placebo","out_primary_measure":"High-resolution computed tomography (HRCT) score; Lung function including FVC, FVC as a percentage of projected value and DLco","start_date":"20-02-15","end_date":"20-12-31","source_id":"NCT04279197","title":"A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","url":"https://clinicaltrials.gov/ct2/show/record/NCT04279197","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":496,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min","n_enrollment":20,"country":"International","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Coronavirus Infections","control":"","out_primary_measure":"Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio; Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio; Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio","start_date":"2020-02-15","end_date":"2020-05","source_id":"NCT04275414","title":"A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04275414","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":497,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Intravenous Immunoglobulin IVIG 0.5g/kg/d for 5 days","n_enrollment":80,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"Standard care","out_primary_measure":"Clinical improvement based on the 7-point scale; Lower Murray lung injury score; Lower Murray lung injury score","start_date":"2020-02-10","end_date":"2020-04-30","source_id":"NCT04261426","title":"A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04261426","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":498,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"biologic","intervention_name":"Conventional treatment plus mesenchymal stem cells (MSCs) Participants will receive conventional treatment plus 3 times of MSCs(3.0*10E7 MSCs intravenously at Day 0, Day 3, Day 6)","n_enrollment":20,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Without MSCs Therapy but conventional treatment should be received.","out_primary_measure":"Size of lesion area by chest radiograph or CT; Side effects in the MSCs treatment group","start_date":"2020-01-27","end_date":"2020-20","source_id":"NCT04252118","title":"Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With 2019 Novel Coronavirus","url":"https://clinicaltrials.gov/ct2/show/record/NCT04252118","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":499,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Ganovo+ritonavir+/-Interferon nebulization\nGanovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.","n_enrollment":11,"country":"China","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"","out_primary_measure":"Rate of composite adverse outcomes","start_date":"2020-02-17","end_date":"2020-03-19","source_id":"NCT04291729","title":"An Open and Controlled Clinical Trial to Evaluate Ganovo（Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus（2019-nCoV） Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04291729","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":500,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":308,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"double blind","population_condition":"COVID-19","control":"","out_primary_measure":"Time to Clinical recoveryTime to Clinical Recovery (TTCR)","start_date":"12. Feb 20","end_date":"27. Apr 20","source_id":"NCT04252664","title":"A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate 2019-nCoV Respiratory Disease.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04252664","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":502,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":150,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"none","population_condition":"Pneumonia Caused by Human Coronavirus (Disorder)","control":"","out_primary_measure":"Time to complete remission of 2019-nCoV infection-associated symptoms","start_date":"22. Jan 20","end_date":"22. Jan 21","source_id":"NCT04251871","title":"Effects of Traditional Chinese Medicines (TCMs) on Patients With 2019-nCoV Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04251871","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":503,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"single blind","population_condition":"COVID-19 pneumonia (severe)","control":"","out_primary_measure":"Rate of disease remission; Rate and time of entering the critical stage","start_date":"01. Feb 20","end_date":"01. Jul 20","source_id":"NCT04263402","title":"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04263402","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":504,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":60,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"single blind","population_condition":"COVID-19 pneumonia","control":"","out_primary_measure":"Rate of comprehensive adverse outcome","start_date":"01. Feb 20","end_date":"01. Jul 20","source_id":"NCT04261270","title":"A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04261270","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":505,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":400,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"single blind","population_condition":"COVID-19","control":"","out_primary_measure":"Rate of disease remission; Time for lung recovery","start_date":"01. Feb 20","end_date":"01. Jul 20","source_id":"NCT04255017","title":"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04255017","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":506,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"single blind","population_condition":"COVID-19","control":"","out_primary_measure":"Rate of disease remission; Time for lung recovery","start_date":"01. Feb 20","end_date":"01. Jul 20","source_id":"NCT04254874","title":"An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04254874","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":507,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":1500,"country":"United States","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"double blind","population_condition":"Corona Virus Infection; Acute Respiratory Distress Syndrome; SARS-CoV Infection","control":"","out_primary_measure":"Incidence of COVID19 Disease; Ordinal Scale of COVID19 Disease Severity","start_date":"17. Mär 20","end_date":"Mai 21","source_id":"NCT04308668","title":"Post-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04308668","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":508,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":394,"country":"International","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"double blind","population_condition":"Coronavirus Infection","control":"","out_primary_measure":"Percentage of subjects reporting each severity rating on the 7-point ordinal scale","start_date":"21. Feb 20","end_date":"01. Apr 23","source_id":"NCT04280705","title":"A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","url":"https://clinicaltrials.gov/ct2/show/record/NCT04280705","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":509,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":380,"country":"","status":"planned","randomized":"randomized","n_arms":0,"blinding":"none","population_condition":"COVID-19","control":"","out_primary_measure":"Virus negative conversion rate in the first week","start_date":"07. Feb 20","end_date":"30. Dez 20","source_id":"NCT04260594","title":"Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","url":"https://clinicaltrials.gov/ct2/show/record/NCT04260594","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":510,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":140,"country":"China","status":"","randomized":"randomized","n_arms":0,"blinding":"double blind","population_condition":"Vitamin C; Pneumonia, Viral; Pneumonia, Ventilator-Associated","control":"","out_primary_measure":"Ventilation-free days","start_date":"14. Feb 20","end_date":"30. Sep 20","source_id":"NCT04264533","title":"Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04264533","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":511,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":230,"country":"China","status":"planned","randomized":"","n_arms":0,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"","out_primary_measure":"Screening accuracy","start_date":"Feb 20","end_date":"Mär 20","source_id":"NCT04281693","title":"Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04281693","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":512,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days;Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization, for 7-14 days ","n_enrollment":80,"country":"","status":"planned","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"opinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization","out_primary_measure":"Clinical recovery time","start_date":"2020-03-14","end_date":"2020-17-14","source_id":"NCT04295551","title":"Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04295551","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":513,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"Remdesivir\nRDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.","n_enrollment":453,"country":"China","status":"","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19","control":"placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.","out_primary_measure":"Time to Clinical Improvement (TTCI) [Censored at Day 28]","start_date":"2020-03-06","end_date":"2020-05-01","source_id":"NCT04257656","title":"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe 2019-nCoVRespiratory Disease.","url":"https://clinicaltrials.gov/ct2/show/record/NCT04257656","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":514,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"drug","intervention_name":"hydroxychloroquine 400mg per day for 5 days + also take conventional treatments","n_enrollment":30,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Pneumonia, Pneumocystis; Coronavirus; COVID-19","control":" Conventional treatments","out_primary_measure":"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3; The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5; The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7; The mortality rate of subjects at weeks 2","start_date":"2020-02-06","end_date":"2020-02-25","source_id":"NCT04261517","title":"Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )","url":"https://clinicaltrials.gov/ct2/show/record/NCT04261517","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":515,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Darunavir and cobicistat one tablet per day for 5 days in addition to conventional treatments","n_enrollment":30,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Conventional treatment, without darunavir and cobicistat","out_primary_measure":"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7","start_date":"2020-01-30","end_date":"2020-08-31","source_id":"NCT04252274","title":"Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV","url":"https://clinicaltrials.gov/ct2/show/record/NCT04252274","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":516,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"other","intervention_name":"Human Umbilical Cord Mesenchymal Stem Cells (US-MSC) 4 times 0.5*10E6 UC-MSCs/kg body weight intravenously at Day 1, Day 3, Day 5, Day 7","n_enrollment":48,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 severe pneumonia","control":"Placebo","out_primary_measure":"Pneumonia severity index; Oxygenation index (PaO2/FiO2)","start_date":"2020-02-16","end_date":"2022-02-15","source_id":"NCT04273646","title":"Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04273646","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":517,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"biologic","intervention_name":"10mg Meplazumab (Anti-CD147 Humanized) by intravenous infusion, every day for 2 days","n_enrollment":20,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"na","out_primary_measure":"2019 nCoV nucleic acid detection","start_date":"2020-02","end_date":"2020-12","source_id":"NCT04275245","title":"Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04275245","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":518,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"biologic","intervention_name":"Tocilizumab (RoActemra) single intravenous administration 8mg/Kg","n_enrollment":30,"country":"Italy","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"SARS Pneumonia Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia","control":"na","out_primary_measure":"arrest in deterioration of pulmonary function; improving in pulmonary function","start_date":"2020-03","end_date":"2020-05","source_id":"NCT04315480","title":"Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 Infection With Severe Multifocal Interstitial Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04315480","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":519,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"vaccine","intervention_name":"Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) 5E10 vp Ad5-nCoV","n_enrollment":108,"country":"","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Healthy volunteers negative for serum antibodies (IgG and IgM) for COVID-19","control":"","out_primary_measure":"Safety indexes of adverse reactions","start_date":"19. Mär 20","end_date":"20. Dez 22","source_id":"NCT04313127","title":"A Single-center,Open-label，Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","url":"https://clinicaltrials.gov/ct2/show/record/NCT04313127","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":520,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"","intervention_type":"drug","intervention_name":"Remdesivir (RDV,GS-5734)","n_enrollment":0,"country":"USA","status":"other","randomized":"unclear","n_arms":0,"blinding":"none","population_condition":"COVID-19; Department of Defense-affiliated personnel","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"NCT04302766","title":"Intermediate-Size Patient Population Expanded Access Treatment Protocol for Coronavirus Disease 2019 (COVID-19) Remdesivir (RDV; GS-5734™)","url":"https://clinicaltrials.gov/ct2/show/record/NCT04302766","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":521,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"other","intervention_name":"Natural killer cells: twice a week of NK cells (0.1-2*10E7 cells/kg body weight)","n_enrollment":30,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Standard care","out_primary_measure":"Improvement of clinical symptoms including duration of fever; Improvement of clinical symptoms including respiratory frequency; Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0","start_date":"2020-02-20","end_date":"2020-12-30","source_id":"NCT04280224","title":"Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","url":"https://clinicaltrials.gov/ct2/show/record/NCT04280224","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":522,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"ASC09/ritonavir(300mg/100mg tablet), one tablet each time, twice daily, for 14 days, +conventional standardized treatment","n_enrollment":160,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Lopinavir/ritonavir tablets(200mg / 50mg tablet), two tablets each time, twice daily, for 14 days, +conventional standardized treatment","out_primary_measure":"The incidence of composite adverse outcome","start_date":"2020-02-07","end_date":"2020-06-30","source_id":"NCT04261907","title":"A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04261907","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":523,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Xiyanping injection in combination wit conventional treatments: Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization","n_enrollment":348,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"conventional treatments: Lopinavir tablet or Ritonavir tablet+Alpha-interferon nebulization","out_primary_measure":"Clinical recovery time","start_date":"14. Feb 20","end_date":"14. Dez 21","source_id":"NCT04275388","title":"A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia","url":"https://clinicaltrials.gov/ct2/show/record/NCT04275388","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":524,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Methylprednisolone 40mg q12h for 5 days","n_enrollment":80,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV","control":"Standard of care","out_primary_measure":"Lower Murray lung injury score","start_date":"26. Jan 20","end_date":"25. Dez 20","source_id":"NCT04244591","title":"Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial","url":"https://clinicaltrials.gov/ct2/show/record/NCT04244591","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":525,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Favipiravir: On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days. Tocilizumab:The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.; ","n_enrollment":150,"country":"China","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"COVID-19","control":"On the 1st day, 1600mg each time, twice a day; from the 2nd to the 7th day, 600mg each time, twice a day. Oral administration, the maximum number of days taken is not more than 7 days.; The first dose is 4 ~ 8mg/kg and the recommended dose is 400mg. For fever patients, an additional application (the same dose as before) is given if there is still fever within 24 hours after the first dose and the interval between two medications ≥ 12 hours.Intravenous infusion, The maximum of cumulative number is two, and the maximum single dose does not exceed 800mg.","out_primary_measure":"Clinical cure rate","start_date":"2020-03-08","end_date":"2020-05","source_id":"NCT04310228","title":"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","url":"https://clinicaltrials.gov/ct2/show/record/NCT04310228","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":526,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"other","intervention_name":"Dental pulp mesenchymal stem cells were injected intravenously","n_enrollment":24,"country":"China","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19","control":"","out_primary_measure":"Disppear time of ground-glass shadow in the lungs","start_date":"2020-03-05","end_date":"2020-07-30","source_id":"NCT04302519","title":"Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","url":"https://clinicaltrials.gov/ct2/show/record/NCT04302519","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":527,"source":"clinicaltrials.gov","review_status":"in manual extraction","results_available":"no","ipd_sharing":"no","intervention_type":"","intervention_name":"Recombinant Human Interferon α1β","n_enrollment":328,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 hospitalized patients","control":"Standard of care","out_primary_measure":"The incidence of side effects","start_date":"01. Mär 20","end_date":"30. Jun 20","source_id":"NCT04293887","title":"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon α1β in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","url":"https://clinicaltrials.gov/ct2/show/record/NCT04293887","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":529,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Drug: Lopinavir/ritonavir\n400mg/100mg twice daily for 14 days\nDrug: Ribavirin\n400mg twice daily for 14 days\nDrug: Interferon Beta-1B\n0.25mg subcutaneous injection alternate day for 3 days","n_enrollment":70,"country":"Hong Kong","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19","control":"Drug: Lopinavir/ritonavir","out_primary_measure":"Time to negative NPS","start_date":"10. Feb 20","end_date":"31. Jul 22","source_id":"NCT04276688","title":"An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04276688","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":534,"source":"clinicaltrials.gov","review_status":"in manual extraction","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Pirfenidone orally three times a day, with two tablets each time, for a course of 4 weeks or longer","n_enrollment":294,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia","control":"Standard of care","out_primary_measure":"chest CT; Finger pulse oxygen; blood gas; K-BILD","start_date":"2020-02","end_date":"2020-06","source_id":"NCT04282902","title":"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","url":"https://clinicaltrials.gov/ct2/show/record/NCT04282902","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":573,"source":"PubMed","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"unclear","intervention_type":"diagnostic","intervention_name":"Rapid IgM-IgG Combined Antibody Test ","n_enrollment":525,"country":"China","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Patients with suspected case of COVID-19 ","control":"","out_primary_measure":"clinical detection sensitivity and specificity","start_date":"","end_date":"","source_id":"32104917","title":"Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","url":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25727","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":815,"source":"PubMed","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"methylprednisolone via intravenous injection at a doseof 1-2mg/kg/day for 3 days","n_enrollment":48,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Patients with serve COVID","control":"None","out_primary_measure":" clinical improvement rate","start_date":"","end_date":"","source_id":"32149773","title":"Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial.","url":"https://journals.lww.com/cmj/Abstract/publishahead/Effectiveness_of_glucocorticoid_therapy_in.99358.aspx","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":1284,"source":"PubMed","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Hydroxychloroquine sulfate 200 mg, three times per day during ten days ","n_enrollment":36,"country":"France","status":"completed","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"Hospitalized patients with confirmed COVID-19 were included in this study if they fulfilled two primary criteria: i) age \u003e12 years; ii) PCR documented SARS-CoV-2 carriage in nasopharyngeal sample at admission whatever their clinical status.\n\nPatients were excluded if they had a known allergy to hydroxychloroquine or chloroquine or had another known contraindication to treatment with the study drug, including retinopathy, G6PD deficiency and QT prolongation. Breastfeeding and pregnant patients were excluded based on their declaration and pregnancy test results when required.","control":"Patients who refused the treatment or had an exclusion criteria, served as controls in Marseille centre. Patients in other centers did not receive hydroxychloroquine and served as controls","out_primary_measure":"virological clearance at day-6 post-inclusion","start_date":"Early march","end_date":"16.03.2020","source_id":"32205204","title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","url":"https://www.sciencedirect.com/science/article/pii/S0924857920300996","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":1500,"source":"PubMed","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"undecided","intervention_type":"other","intervention_name":"Graded waiting areas for patients with different risks of infection","n_enrollment":214,"country":"Taiwan","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Patients presenting ad Emergency department","control":"","out_primary_measure":"Positive predicted value for COVID-19 infection in waiting areas","start_date":"","end_date":"","source_id":"32205268","title":"Buffer areas in emergency department to handle potential COVID-19 community infection in Taiwan.","url":"https://www.sciencedirect.com/science/article/pii/S1477893920301034?via%3Dihub","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":1540,"source":"PubMed","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"procedure","intervention_name":"High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation","n_enrollment":60,"country":"China","status":"completed","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Adults with clinically-confirmed COVID-19 pneumonia and hypoxaemia and requiring intubation in the ICU","control":"standard mask oxygenation assisted tracheal intubation","out_primary_measure":"The lowest SpO2 during intubation","start_date":"","end_date":"","source_id":"32200994","title":"High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial.","url":"https://bjanaesthesia.org/article/S0007-0912(20)30135-5/pdf","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2003,"source":"PubMed","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"lopinavir/ritonavir","n_enrollment":0,"country":"India","status":"unclear","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Hospitalized adult patients with laboratory-confirmed SARS-CoV-2 infection with any one of predefined risk criteria ","control":"","out_primary_measure":"hospital length of stay","start_date":"","end_date":"","source_id":"32202256","title":"Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.","url":"http://www.ijmr.org.in/preprintarticle.asp?id=280484;type=0","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2049,"source":"PubMed","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"lopinavir–ritonavir (400 mg and 100 mg, respectively) twice a day plus standard of care for 14 days","n_enrollment":199,"country":"China","status":"completed","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID positive patients with Pneumonia","control":"standard of care","out_primary_measure":"time to clinical improvement","start_date":"18.01.2020","end_date":"","source_id":"32187464","title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2001282","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2213,"source":"ICTRP","review_status":"manual extraction completed","results_available":"","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","n_enrollment":100,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"","out_primary_measure":"Length of hospital stay;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029935","title":"A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49607","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2214,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;","n_enrollment":200,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"The acute stage New Coronavirus Pneumonia ","control":"control group :western medicine symptomatic treatment  ","out_primary_measure":"Lung function;","start_date":"2020-03","end_date":"2020-06","source_id":"ChiCTR2000029947","title":"A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49599","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2216,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"Conventional treatment+Anti-aging Active Freeze-dried Powder Granules","n_enrollment":60,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"Conventional treatment","out_primary_measure":"Time to disease recovery;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029811","title":"Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49355","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2217,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR\u0026#32;product\u0026#32;of\u0026#32;SARS-CoV-2.;","n_enrollment":10000300,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SEN, SPE, ACC, AUC of ROC;","start_date":"16.02.20","end_date":"","source_id":"ChiCTR2000029810","title":"Development and application of a novel high sensitivity nucleic acid assay for novel coronavirus pneumonia (COVID-19)  based on CRISPR-cas protein                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49407","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2218,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"standardized comprehensive treatment combined with convalescent plasma treatment;","n_enrollment":20,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19)","control":"standardized comprehensive treatment;","out_primary_measure":"Fatality rate;","start_date":"2020-02","end_date":"2022-02","source_id":"ChiCTR2000029850","title":"Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49533","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2219,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Integrated Traditional Chinese and Western Medicine","n_enrollment":30,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia(COVID-19)","control":"Western Medicine","out_primary_measure":"Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029814","title":"Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49387","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2220,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Guidelines for novel coronavirus pneumonia (fifth edition);Index test:Diagnosis\u0026#32;model\u0026#32;based\u0026#32;on\u0026#32;Artificial\u0026#32;Intelligence\u0026#32;(Epidemiological\u0026#32;history,\u0026#32;clinical\u0026#32;information,\u0026#32;laboratory\u0026#32;examination,\u0026#32;ho","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Chest CT findings;Epidemiological history;Laboratory examination;Pulmonary function test;SEN, SPE, ACC, AUC of ROC;","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000029779","title":"Study for the key issues of the diagnosis and treatment of novel coronavirus pneumonia (COVID-19) based on the medical imaging                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49378","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2221,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"TCM Group:herbal medicine and conventional treatment;\nQFPD decoction group:QFPD decoction and conventional treatment;\nSFJD capsuale group:SFJD capsuale and conventional treatment;\n","n_enrollment":600,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":4,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19)    ","control":"conventional treatment","out_primary_measure":"Length of hospital stay;fever clearance time;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000029778","title":"Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49422","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2223,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"TCM based on symptomatic treatment","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19)  ","control":"Placebo TCM based on symptomatic treatment","out_primary_measure":"St. George's Respiratory Questionnaire;","start_date":"2020-02","end_date":"2021-06","source_id":"ChiCTR2000029789","title":"Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49348","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2224,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Truncation and Torsion Formula and Routine treatment of Western Medicine","n_enrollment":160,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"Routine treatment of Western Medicine","out_primary_measure":"Primary indicator (14 day outcome of the subjects, including: recovery, improvement, turning critical, death.)\nPrimary indicator (lung CT)","start_date":"2020-02","end_date":"2020-06","source_id":"ChiCTR2000029777","title":"A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49380","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2225,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Polyinosinic-Polycytidylic Acid Injection and conventional therapy","n_enrollment":40,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)         ","control":"conventional therapy","out_primary_measure":"Time to Clinical recovery;","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029776","title":"A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49342","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2228,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"General patients treated with normal treatment( Normal Treatment)\nGeneral patients experimental group(Normal Treatment plus Sodium Aescinate for Injection)\nSevere patients experimental group(Normal Treatment plus Sodium Aescinate for Injection)","n_enrollment":90,"country":"China","status":"recruiting","randomized":"randomized","n_arms":5,"blinding":"","population_condition":"patients with pneumonia (COVID-19)  ","control":"Severe patients control group 1( Normal treatment plus hormonotherapy) \nSevere patients control group 2 (Normal Treatment)","out_primary_measure":"Chest imaging (CT);","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029742","title":"A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49297","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2229,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Chloroquine Phosphate","n_enrollment":112,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"mild/general novel coronavirus (CoVID-19) ","control":"Lopinavir / Ritonavir","out_primary_measure":"Length of stay;Length of severe;oxygenation index during treatment;all-cause mortality in 28 days;Peripheral blood cell count (including white blood cells, lymphocytes, neutrophils, etc.);procalcitonin;C-reactive protein;Inflammatory factors (including IL-6, IL-10, TNF-α, etc.); Lymphocyte subsets and complement ;  Coagulation indicators (prothrombin time, activated partial prothrombin time, fibrinogen, D-dimer, platelet count) ; Virus nucleic acid ","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029741","title":"Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49263","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2231,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Conventional standardized treatment and vMIP atomized inhalation;","n_enrollment":40,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)","control":"","out_primary_measure":"2019-nCoV nucleic acid turning negative time (from respiratory secretion), or the time to release isolation;","start_date":"2020-02","end_date":"2020-07","source_id":"ChiCTR2000029636","title":"Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49215","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2232,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:RT-PCR of the novel coronavirus;Index test:Exhaled\u0026#32;breath\u0026#32;detection\u0026#32;by\u0026#32;mass\u0026#32;spectrometry;","n_enrollment":300300,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Sensitivity of detection of NCP;Specificity of detection of NCP;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000029695","title":"Early Detection of Novel Coronavirus Pneumonia (COVID-19) Based on a Novel High-Throughput Mass Spectrometry Analysis With Volatile Organic Compounds in Exhaled Breath                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49219","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2233,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Standard treatment and methylprednisolone for injection","n_enrollment":100,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)  ","control":"Standard treatment","out_primary_measure":"ECG;Chest imaging;Complications;vital signs;NEWS2 score;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029656","title":"A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49086","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2234,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: \u003cbr\u003e1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-CoV-2; \u003cbr\u003e2. Gene sequencing of respiratory or blood samples is highly ","n_enrollment":2000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"detection of SARS-CoV-2 nucleic acid;SEN;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029883","title":"A comparative study on the sensitivity of nasopharyngeal and oropharyngeal swabbing for the detection of SARS-CoV-2 by real-time PCR                                                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49549","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2235,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Truncated Torsion' Formula and Routine treatment of Western ","n_enrollment":300,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"Routine treatment of Western Medicine","out_primary_measure":"14 day outcome of the subjects, including: recovery, improvement, turning critical, death.;lung CT;","start_date":"2020-02","end_date":"2020-06","source_id":"ChiCTR2000029869","title":"A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49486","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2236,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Traditional Chinese medicine compound granules + western medicine symptomatic treatment ","n_enrollment":200,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"western medicine symptomatic treatment ","out_primary_measure":" Number of worsening events;","start_date":"2020-03","end_date":"2020-06","source_id":"ChiCTR2000029941","title":"A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49596","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2237,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":" conventional treatment combined with Chloroquine Phosphate.","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":" Novel Coronavirus Pneumonia (COVID-19)","control":"The conventional treatment group will be treated according to the guidance of the “Diagnosis and Treatment Scheme of COVID-19” published by the National Health Commission.","out_primary_measure":"Length of hospital stay;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029939","title":"A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49612","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2240,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Reduning injection combined with basic western medical therapies","n_enrollment":60,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":" Novel Coronavirus Pneumonia (COVID-19)                   ","control":" \t\n\nbasic western medical therapies","out_primary_measure":"Antipyretic time;","start_date":"2020-02","end_date":"2021-12","source_id":"ChiCTR2000029589","title":"An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49104","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2241,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Integrated Traditional Chinese and Western Medicine","n_enrollment":1000,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"na","out_primary_measure":"Cure rate;The cure time;The rate and time at which the normal type progresses to the heavy type;Rate and time of progression from heavy to critical type and even death","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029578","title":"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49080","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2242,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Carrimycin","n_enrollment":520,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"\tNovel Coronavirus Pneumonia (COVID-19) ","control":"Lopinavir and Ritonavir Tablets","out_primary_measure":"Body temperature returns to normal time;Pulmonary inflammation resolution time (HRCT);Mouthwash (pharyngeal swab) at the end of treatment COVID-19 RNA negative rate","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029867","title":"The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49514","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2243,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"unclear","intervention_name":"Regulating intestinal flora and standard of care","n_enrollment":60,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"standard of care","out_primary_measure":"Length of admission;mortality rate;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029849","title":"Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49530","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2244,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Normal group:No;Severe group:No;","n_enrollment":1010,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"TCR sequencing;BCR sequencing;HLA sequencing;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029626","title":"Immune Repertoire (TCR \u0026 BCR) Evaluation and Immunotherapy Research in Peripheral Blood of Novel Coronavirus Pneumonia (COVID-19) Patients                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49170","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2246,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"(ordinary) Chinese and Western Medicine Group; \t\n(severe) Chinese and Western Medicine Group","n_enrollment":140,"country":"China","status":"recruiting","randomized":"randomized","n_arms":4,"blinding":"double blind","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"(ordinary) Western medicine group\n(severe) Western medicine group","out_primary_measure":"Recovery time;Ratio and time for the general type to progress to heavy;Ratio and time of severe progression to critical or even death;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029518","title":"A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48860","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2247,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Chinese medicine decoction","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"placebo","out_primary_measure":"Relief of clinical symptoms and duration;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029517","title":"Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48861","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2248,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Nucleic acid detection method of novel Coronavirus pneumonia ;Index test:IgM/IgG;","n_enrollment":500100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Positive/Negtive;SEN, SPE, ACC, AUC of ROC;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000029870","title":"Evaluation of Rapid Diagnostic Kit (IgM/IgG) for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49563","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2249,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Traditional Chinese medicine qingfei prescription treatment; Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment","n_enrollment":180,"country":"China","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"standard of care","out_primary_measure":"TCM symptom score;Antifebrile time;The time and rate of transition of new coronavirus to Yin;","start_date":"2020-02","end_date":"","source_id":"ChiCTR2000029855","title":"A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49543","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2250,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"honeysuckle decoction;","n_enrollment":110,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":" patients with novel coronavirus (COVID-19)","control":"placebo","out_primary_measure":"rate of cure;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029822","title":"A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49502","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2252,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine","n_enrollment":400,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"Health education+Basic treatment of western medicine","out_primary_measure":"the negative conversion ratio;the proportion of general patients with advanced severe disease;confirmed rate of suspected cases;","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000029601","title":"Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48988","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2253,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","n_enrollment":30,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)","control":"Conventional treatment ","out_primary_measure":"PSI;","start_date":"2020-02","end_date":"2021-04","source_id":"ChiCTR2000029569","title":"Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49062","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2254,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"experimental group:Traditional Chinese Medicine+psychological intervention;\t ","n_enrollment":90,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"Patients with 2019-nCOV Caused Pneumonia(Convalescent Period)","control":"Control group:Traditional Chinese Medicine;Control group:psychological intervention;","out_primary_measure":"Self-rating depression scale, SDS;Self-Rating Anxiety Scale, SAS;ocial support rate scale, SSRS;","start_date":"2020-02","end_date":"2021-12","source_id":"ChiCTR2000029495","title":"Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48971","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2255,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"TCM decoctions+basic western medical therapies","n_enrollment":100,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","control":"basic western medical therapies ;","out_primary_measure":"pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;","start_date":"2020-02","end_date":"2021-12","source_id":"ChiCTR2000029493","title":"Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48931","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2256,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Conventional Treatment \u0026 Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);","n_enrollment":72,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":" Novel Coronavirus Pneumonia (COVID-19)                                                                             ","control":"Conventional Treatment;","out_primary_measure":"Time of viral nucleic acid turns negative;Antipyretic time;","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000029813","title":"Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49425","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2257,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;\nPD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;","n_enrollment":120,"country":"China","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"","population_condition":"Severe Novel Coronavirus Pneumonia (COVID-19) ","control":"Conventional treatment;","out_primary_measure":"Proportion of patients with a lung injury score reduction of 1-point or more 7 days after randomization;","start_date":"2020-01","end_date":"2021-01","source_id":"ChiCTR2000029806","title":"Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49161","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2258,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Oral administration of 5 tablets of 1mg Azvudine tablets daily;","n_enrollment":20,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19)                                                                              ","control":"According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.","out_primary_measure":"time and rate of temperature return to normal;;time and rate of improvement of respiratory symptoms and signs (lung rhones, cough, sputum, sore throat, etc.);time and rate of improvement of diarrhea, myalgia, fatigue and other symptoms;  \ttime and rate of pulmonary imaging improvement ;  time and rate of change to negative COVID-19 nucleic acid test ; \ntime and rate of improvement of oxygenation measurement  ;  improvement time and rate of CD4 count ; rate of mild/modorate type to severe type, rate of severe type to critical type ;  \nlength of hospitalization ; mortality","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029853","title":"A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49532","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2260,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Chloroquine;","n_enrollment":20,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19)   ","control":"conventional management;","out_primary_measure":"viral negative-transforming time;30-day cause-specific mortality;","start_date":"2020-02","end_date":"2020-07","source_id":"ChiCTR2000029542","title":"A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48968","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2261,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"conventional standardized treatment and Lopinavir-Ritonavir","n_enrollment":328,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"mild novel coronavirus pneumonia (COVID-19)        ","control":"Conventional standardized treatment;","out_primary_measure":"The incidence of adverse outcome within 14 days after admission: Patients with conscious dyspnea, SpO2 = 94% or respiratory frequency = 24 times / min in the state of resting without oxygen inhalation;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029539","title":"A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48991","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2262,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Western medicine basic treatment combined with traditional Chinese medicine;","n_enrollment":120,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"novel coronavirus pneumonia (COVID-19)    ","control":"Western medicine basic treatment","out_primary_measure":"TCM symptoms efficacy;","start_date":"2020-02","end_date":"2020-10","source_id":"ChiCTR2000029790","title":"Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49453","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2263,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","n_enrollment":60,"country":"China","status":"","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"novel coronavirus pneumonia (COVID-19)","control":"Western medicine routine treatment plan","out_primary_measure":"Antipyretic time;Pharyngeal swab nucleic acid negative time;Blood gas analysis;Traditional Chinese medicine syndrome score;","start_date":"2020-03","end_date":"2020-12","source_id":"ChiCTR2000029788","title":"Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49452","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2264,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.","n_enrollment":72,"country":"China","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)             ","control":"na","out_primary_measure":"Time for body temperature recovery;Chest X-ray absorption;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029432","title":"A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48881","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2265,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;","n_enrollment":45,"country":"China","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"","population_condition":"novel coronavirus pneumonia (COVID-19)     ","control":"C:Critical Treatment in Critical Period;\nA:Critical Treatment in Critical Period + Ankylosaurus;","out_primary_measure":"CT of lung;CT and MRI of hip;","start_date":"2020-01","end_date":"2021-12","source_id":"ChiCTR2000029431","title":"Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48907","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2266,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Observation  group:TCM prevention;Health  education unit:Health  education;","n_enrollment":300100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CD4+;CD3+;HAMA;HAMD;STAI;","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000029821","title":"Based on Delphi Method to Preliminarily Construct a Recommended Protocol for the Prevention of Novel Coronavirus Pneumonia (COVID-19) in Deyang Area by Using Chinese Medicine Technology and its Clinical Application Evaluation                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49306","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2267,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Conventional treatment + take Ba-Bao-Dan","n_enrollment":80,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":" novel coronavirus infection (COVID-19) ","control":"Conventional treatment;","out_primary_measure":"Clinical and laboratory indicators;Viral load;chest CT;serum cell factor;","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000029819","title":"Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49490","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2269,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Conventional medicine + TCM;","n_enrollment":100,"country":"China","status":"","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"severe novel coronavirus pneumonia (COVID-19)   ","control":"western medical therapie","out_primary_measure":"CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;","start_date":"2020-02","end_date":"2021-12","source_id":"ChiCTR2000029438","title":"A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48911","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2270,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"conventional  therapy+tocilizumab;","n_enrollment":188,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"new coronavirus pneumonia (COVID-19)                   ","control":"conventional therapy;","out_primary_measure":"cure rate;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000029765","title":"A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49409","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2271,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"TCM and general treatment","n_enrollment":408,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Novel Coronavirus Pneumonia (COVID-19)","control":"general treatment;","out_primary_measure":"Rate of conversion to severe or critical illness;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000029763","title":"Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49408","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2272,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:NA;","n_enrollment":100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inpatient mortality;","start_date":"12.02.20","end_date":"","source_id":"ChiCTR2000029804","title":"Optimization of treatment and diagnosis plan for critically ill patients                                                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49178","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2273,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Routine treatment + Babaodan 6 capsules, bid orally","n_enrollment":40,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"evere novel coronavirus pneumonia patients  ","control":"Conventional treatment;","out_primary_measure":"28-day survival;Inflammatory factor levels;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000029769","title":"Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49415","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2274,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"TCM syndrome differentiation treatment+ Western medicine treatment","n_enrollment":100,"country":"China","status":"","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19)                                                                                          ","control":"Western medicine treatment;","out_primary_measure":"Duration of PCR normalization;Clinical symptom score;","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029436","title":"The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48884","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2275,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Combined Treatment of Chinese medicine and western medicine","n_enrollment":42,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Severe pneumonia caused by new coronavirus. ","control":"Western medicine treatment;","out_primary_measure":"Critically ill patients (%);","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000029418","title":"Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48886","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2277,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Xiyanping injection;","n_enrollment":238,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"single blind","population_condition":"novel coronavirus pneumonia (COVID-19)                                                                                               ","control":"alpha-interferon;","out_primary_measure":"vital signs (Body temperature, blood pressure, heart rate, breathing rate);Respiratory symptoms and signs (Lung sounds, cough, sputum);Etiology and laboratory testing;PaO2/SPO2;Liquid balance;Ventilator condition;Imaging changes;","start_date":"2020-02","end_date":"2022-02","source_id":"ChiCTR2000029756","title":"Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49222","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2278,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;","n_enrollment":60,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":" novel coronavirus pneumonia (COVID-19)","control":"clinical standard antiviral treatment;","out_primary_measure":"Time to Clinical recovery;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000029768","title":"A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate","url":"http://www.chictr.org.cn/showproj.aspx?proj=49131","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2280,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"umbilical cord mesenchymal stem cells","n_enrollment":60,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":" novel coronavirus pneumonia (COVID-19) ","control":"convention treatment;","out_primary_measure":"pulmonary function;Novel coronavirus pneumonic nucleic acid test;","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000030173","title":"Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49229","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2281,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":" (Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules","n_enrollment":20,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":" novel coronavirus pneumonia (COVID-19) ","control":"Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;","out_primary_measure":"CT scan of the lungs;Nucleic acid detection of throat secretion;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000030166","title":"Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49696","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2284,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Traditional Chinese Medicine","n_enrollment":200,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":" Novel Coronavirus Pneumonia (COVID-19)                                                                                                       ","control":"Basic treatment of modern medicine;","out_primary_measure":"Chest CT;Routine blood test;liver and renal function;TCM syndrome;","start_date":"2020-02","end_date":"2021-02","source_id":"ChiCTR2000029747","title":"Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49287","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2285,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"device","intervention_name":"Hydrogen-Oxygen Nebulizer;","n_enrollment":440,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19)           ","control":"Oxygen concentrator;","out_primary_measure":"the condition worsens and develops into severe or critical condition;the condition improves significantly and reaches the discharge standard;The overall treatment time is no longer than 14 days;","start_date":"2020-02","end_date":"2021-08","source_id":"ChiCTR2000029739","title":"A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49283","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2286,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Traditional Chinese medicine soup;","n_enrollment":120,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":" novel coronavirus pneumonia (COVID-19)                                                                                   ","control":"Western antiviral;","out_primary_measure":"Chest CT scan;Nucleic acid of novel coronavirus;Routine blood test;Routine urine test;Stool routine test;","start_date":"2020-02","end_date":"2020-06","source_id":"ChiCTR2000030118","title":"A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49594","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2287,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"Two groups:Different stem cell doses;","n_enrollment":16,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19) ","control":"","out_primary_measure":"Time to leave ventilator on day 28 after receiving MSCs infusion;","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000030116","title":"Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49901","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2289,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"doctors group:Psychological intervention;\nnurses group:Psychological intervention;\nsuspected cases group:Psychological intervention or drug intervention;\ncases group:Psychological intervention or drug intervention;","n_enrollment":172,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":4,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"","out_primary_measure":"Physical examination;Nucleic acid;Oxygenation index;GAD-7;PHQ-9;SASRQ;PSQI;Lymphocyte subsets;","start_date":"2020-02","end_date":"2020-09","source_id":"ChiCTR2000029639","title":"Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49187","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2291,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Arbidol tablets + basic treatment","n_enrollment":380,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 pneumonia ","control":"Basic treatment;","out_primary_measure":"Virus negative conversion rate in the first week;","start_date":"2020-01","end_date":"2020-12","source_id":"ChiCTR2000029621","title":"Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49165","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2293,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcome;Index test:early\u0026#32;warning\u0026#32;and\u0026#32;prediction\u0026#32;system;","n_enrollment":800,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lymphocyte subpopulation analysis;Cytokine detection;Single cell sequencing of bronchial lavage fluid cells;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029625","title":"Construction of Early Warning and Prediction System for Patients with Severe / Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49177","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2294,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"health education, follow-up condition management by team of family doctors, Chinese medicine treatment;\n","n_enrollment":600,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"health education, follow-up condition management by team of family doctors;","out_primary_measure":"Incidence of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia;\ndays of onset at home / designated isolation population who progressed to designated isolation treatment or were diagnosed with novel coronavirus-infected pneumonia ","start_date":"2020-02","end_date":"2020-08","source_id":"ChiCTR2000029602","title":"Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48985","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2295,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","n_enrollment":90,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":3,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19)                                                                                  ","control":"Group A:alpha-Interferon atomization;","out_primary_measure":"Declining speed of Novel Coronavirus by PCR;Negative Time of Novel Coronavirus by PCR;Incidentce rate of chest imaging;Incidence rate of liver enzymes;Incidence rate of kidney damage;","start_date":"2020-01","end_date":"2020-04","source_id":"ChiCTR2000029600","title":"Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49042","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2296,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"Supportive psychotherapy;","n_enrollment":60,"country":"China","status":"not yet recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19)              ","control":"Simplify cognitive behavior","out_primary_measure":"State anxiety;","start_date":"2020-02","end_date":"2020-03","source_id":"ChiCTR2000030093","title":"Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49932","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2297,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"other","intervention_name":"Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;","n_enrollment":180,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression ","control":" \t\n\nGeneral Treatment","out_primary_measure":"the score of Hamilton depression scale;the score of Hamilton anxiety scale;the score of Self-Rating Depression Scale;the score of Self-Rating Anxiety Scale;the score of Athens Insomnia Scale;","start_date":"2020-02","end_date":"2022-02","source_id":"ChiCTR2000030084","title":"A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49952","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2298,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"conventional treatment combined with umbilical cord blood mononuclear cells group;","n_enrollment":30,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"severe and critically novel coronavirus pneumonia(COVID-19)","control":"Conventional treatment;","out_primary_measure":"PSI;","start_date":"2020-02","end_date":"2021-04","source_id":"ChiCTR2000029572  ","title":"Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=41760","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2299,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;\nexperimental group 2:Hydroxychloroquine 0.2 oral 2/ day;","n_enrollment":300,"country":"China","status":"recruiting","randomized":"randomized","n_arms":3,"blinding":"double blind","population_condition":"novel coronavirus pneumonia (COVID-19)","control":"Starch pill oral 2/ day","out_primary_measure":"The time when the nucleic acid of the novel coronavirus turns negative;T cell recovery time;","start_date":"2020-01","end_date":"2020-02","source_id":"ChiCTR2000029559","title":"Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)                                                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48880","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2300,"source":"ICTRP","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;\nExperimental group 2:current antiviral treatment+fabiravir tablets;\n","n_enrollment":30,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":3,"blinding":"","population_condition":" novel coronavirus pneumonia (COVID-19) ","control":"current antiviral treatment;","out_primary_measure":"Time to viral negativity by RT-PCR;Time to clinical improvement;","start_date":"2020-02","end_date":"2020-05","source_id":"ChiCTR2000029544","title":"A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49013","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2301,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"DDarunavir/cobicistat DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD); Lopinavir/ritonavir LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);","n_enrollment":100,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":3,"blinding":"none","population_condition":"novel coronavirus pneumonia (COVID-19) ","control":"Conventional treatment containing thymosin (1.6 mg SC QOD)","out_primary_measure":"Time to conversion of 2019-nCoV RNA result from RI sample;","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000029541","title":"A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48992","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2302,"source":"ICTRP","review_status":"in manual extraction","results_available":"no","ipd_sharing":"yes","intervention_type":"biologic","intervention_name":"Routine treatment + plasma treatment","n_enrollment":100,"country":"China","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"Novel Coronavirus Pneumonia (COVID-19) ","control":"Routine treatment","out_primary_measure":"Cure rate;Mortality","start_date":"2020-02","end_date":"2020-04","source_id":"ChiCTR2000030179","title":"Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50059","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2303,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Isolation and oral  Gubiao Jiedu Ling Chinese medicine;Control group:Isolated observation;","n_enrollment":100100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"body temperature;Whole blood count and five classifications;C-reactive protein;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000029487","title":"Clinical Study for Gu-Biao Jie-Du-Ling in Preventing of Novel Coronavirus Pneumonia (COVID-19) in Children                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48965","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2304,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","n_enrollment":6060,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Patient survival rate;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000029468","title":"The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48919","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2305,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate","n_enrollment":0,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"virus nucleic acid negative-transforming time;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000029609","title":"A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49145","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2306,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental","n_enrollment":181511021010,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Mortality in patients;","start_date":"25.01.20","end_date":"","source_id":"ChiCTR2000029606","title":"Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49146","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2307,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"traditional medicine","intervention_name":"Conventional treatment and Shenfu injection;","n_enrollment":300,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"","population_condition":"","control":"Conventional treatment;","out_primary_measure":"pneumonia severity index (PSI); Incidence of new organ dysfunction;","start_date":"2020-02","end_date":"2020-12","source_id":"ChiCTR2000030043","title":"Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49866","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2308,"source":"ICTRP","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"yes","intervention_type":"drug","intervention_name":"Case series:FNC;","n_enrollment":40,"country":"China","status":"","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"","control":"","out_primary_measure":"The novel coronavirus nucleic acid negative rate;","start_date":"2020-02","end_date":"2020-06","source_id":"ChiCTR2000030041","title":"A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49891","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2310,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM interventi","n_enrollment":202020202020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Viral nucleic acid detection;CT Scan of the Lungs;Blood routine examination;Temperature;Height;Weight;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000029435","title":"Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48827","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2311,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Co","n_enrollment":100100100100,"country":"Wuhan","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;","start_date":"06.02.20","end_date":"","source_id":"ChiCTR2000029605","title":"A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49051","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2312,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","n_enrollment":8080,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The incidence of composite adverse outcome within 14 days after admission: Defined as (one of them) SPO2\u003c= 93% without oxygen supplementation, PaO2/FiO2 \u003c= 300mmHg or RR \u003c=30 breaths per minute.;","start_date":"06.02.20","end_date":"","source_id":"ChiCTR2000029603","title":"A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49075","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2314,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","n_enrollment":202020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"the rate of remission;","start_date":"29.01.20","end_date":"","source_id":"ChiCTR2000029400","title":"Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48824","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2316,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","n_enrollment":1515,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Blood routine tests, Liver function examination, Renal function examination, Blood gas analysis, Chest CT examination;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030113","title":"Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49988","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2317,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"single arm:Chinese medicine treatment combined with western medicine treatment;","n_enrollment":200,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"blood routine;urine routines;CRP;PCT;ESR;creatase;troponin;myoglobin;D-Dimer;arterial blood gas analysis;Nucleic acid test for 2019-nCoV ;chest CT;Biochemical complete set;","start_date":"29.01.20","end_date":"","source_id":"ChiCTR2000029558","title":"Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48792","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2318,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipira","n_enrollment":101010,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to viral negativityby RT-PCR;Time to clinical improvement: Time from start of study drug to hospital discharge or to NEWS2\u003c2 for 24 hours.;","start_date":"04.02.20","end_date":"","source_id":"ChiCTR2000029548","title":"Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49015","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2321,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"pulmonary function;Antipyretic time;Time of virus turning negative;","start_date":"03.02.20","end_date":"","source_id":"ChiCTR2000029461","title":"A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48927","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2322,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"pulmonary function;St Georges respiratory questionnaire, SGRQ;Modified Barthel Index, MBI;Incidence of adverse events;","start_date":"02.02.20","end_date":"","source_id":"ChiCTR2000029460","title":"The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48930","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2323,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","n_enrollment":8844,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Body temperature;TCM syndrome integral;Murray lung injury score;The transition time of novel coronavirus nucleic acid;MuLBSTA score;","start_date":"07.02.20","end_date":"","source_id":"ChiCTR2000030034","title":"Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49647","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2325,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcome and Viral nucleic acid detection;Index test:critical\u0026#32;care\u0026#32;ultrasound\u0026#32;examination;","n_enrollment":400,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"28day mortality;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030185","title":"The Value of Critical Care Ultrasound in Rapid Screening, Diagnosis, Evaluation of Effectiveness and Intensive Prevention of Novel Coronavirus Pneumonia (COVID-19)                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50058","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2326,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Anti-2019-nCoV virus inactivated plasma;","n_enrollment":10,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The changes of clinical symptom, laboratory and radiological data ;Oxyhemoglobin saturation.;dyspnea;Body temperature;Radiological characteristic sign;Blood routine;C-reaction protein;lymphocyte count;Liver function: TBIL(total bilirubin), AST(alanine ami","start_date":"07.02.20","end_date":"","source_id":"ChiCTR2000030046","title":"A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49861","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2328,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"pulmonary function;St Georges respiratory questionnaire, SGRQ;","start_date":"03.02.20","end_date":"","source_id":"ChiCTR2000029459","title":"Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48929","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2329,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","n_enrollment":6060,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Antipyretic time;Time of virus turning negative;","start_date":"02.02.20","end_date":"","source_id":"ChiCTR2000029439","title":"Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48904","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2330,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Suramin( IV.);","n_enrollment":20,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"clinical cure rate;Incidence of mechanical ventilation by day28;All-cause mortality by day28;Incidence of ICU admission by day28;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030029","title":"A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49824","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2331,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Neutrophil count;Lymphocyte count;Monocyte / macrophage count;Monocyte / macrophage function test;NK cell count;DC cell count;PD-1( immunosuppressive biomarker );PD-L1(immunosuppressive biomarker );CTLA4 (immunosuppressive biomarker );CD79;Blnk;Il7r;T lym","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030028","title":"Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49840","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2332,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","n_enrollment":130230,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme","start_date":"04.02.20","end_date":"","source_id":"ChiCTR2000030016","title":"Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49799","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2333,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","n_enrollment":100100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptoms;Blood routine;the viral load of 2019-nCOV of throat swab;TBNK cell subsets;TH1/TH2 Cytokine;Chest CT;","start_date":"03.02.20","end_date":"","source_id":"ChiCTR2000030007","title":"Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49619","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2334,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental Group:Conventional Treatment \u0026 Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks)","n_enrollment":4040,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CD8+ T cells numbers;CD4+ T cell numbers;NK cell numbers;Fatality rate;Clinical recovery time;Critical (severe or critical) conversion rate;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030167","title":"Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49567","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2335,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","n_enrollment":301515,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Chest CT;Whole blood cell analysis;Recovery rate;Oxygenation index;Inflammatory response index;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030165","title":"Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49947","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2336,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","n_enrollment":12002200,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"pneumonia severity index (PSI);","start_date":"24.01.20","end_date":"","source_id":"ChiCTR2000029381","title":"A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48768","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2337,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","n_enrollment":60,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Release rate of discharge standards for isolation;Change in Critical Illness;Traditional Chinese medicine syndrome score;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030027","title":"Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49852","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2338,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:NA;","n_enrollment":20,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"NA;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030012","title":"Development of 2019-nCoV  therapeutic antibody                                                                                                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49718","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2339,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","n_enrollment":232116,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery time;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030117","title":"A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49762","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2341,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","n_enrollment":8040,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"TCM symptom score;Becomes negative time of COVID-19;Cure / mortality rate;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030188","title":"Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50025","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2342,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the even","n_enrollment":88,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Severe NCP group: Time to clinical improvement (TTCI) [time window: 28 days];Acute exacerbation NCP group: Time to clinical recovery [time window: 28 days] and the ratio of common to severe and critically severe.;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030170","title":"Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50017","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2344,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Exercise prescription group:Exercise prescription;Control group:None;","n_enrollment":200200,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Mood index;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030090","title":"A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49910","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2345,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030010","title":"A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49777","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2346,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration ","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Recovery;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029996","title":"A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49510","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2347,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","n_enrollment":1010101010,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Rate of composite advers outcomes:SpO2,PaO2/FiO2, respiratory rate;","start_date":"16.02.20","end_date":"","source_id":"ChiCTR2000030000","title":"An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49748","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2348,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","n_enrollment":6060,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Quality of life;Anxiety assessment;Depression assessment;Major symptoms improved;","start_date":"18.02.20","end_date":"","source_id":"ChiCTR2000029956","title":"Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49618","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2349,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group :Oral leflunomide;Control group:Oral placebo;","n_enrollment":100100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The days from positive to negative for viral nucleic acid testing;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030058","title":"A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49831","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2351,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical index;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030138","title":"Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50004","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2354,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","n_enrollment":100100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"lung function;ADL;6min walk;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000029994","title":"Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49309","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2355,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","n_enrollment":12762276276,"country":"Chinese","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Proportion of COVID-19 close contacts who have developed as confirmed cases;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030033","title":"A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49703","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2357,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","n_enrollment":9393,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Length of hospital stay;","start_date":"21.02.20","end_date":"","source_id":"ChiCTR2000029978","title":"A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49702","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2358,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","n_enrollment":3070,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"TCM syndrome;","start_date":"28.02.20","end_date":"","source_id":"ChiCTR2000029960","title":"Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49639","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2359,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":300,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"menstruation changes;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030015","title":"Study for the correlation between the incidence and outcome of novel coronary pneumonia (COVID-2019) and ovarian function in women                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49800","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2361,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","n_enrollment":10030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"recovery time;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030136","title":"The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)                                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50005","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2362,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:","n_enrollment":303030303030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Chest imaging;RNA test of COVID-19;Time to remission/disappearance of primary symptoms: defined as the number of days when the three main symptoms of fever, cough, and shortness of breath are all relieved / disappeared;Completely antipyretic time: complet","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030102","title":"A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49747","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2363,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Recovery rate;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030006","title":"A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49737","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2364,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","n_enrollment":120120,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical recovery;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030001","title":"The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49723","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2365,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"TTCI (Time to Clinical Improvement);","start_date":"28.02.20","end_date":"","source_id":"ChiCTR2000030089","title":"A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49889","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2366,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (1Ã—10^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The nucleic acid of the novel coronavirus is negative;CT scan of ground glass shadow disappeared;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030088","title":"Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49902","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2367,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","n_enrollment":8080,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Disappearance rate of fever symptoms;","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000029781","title":"A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49138","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2368,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","n_enrollment":5424,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"oxygen index;max respiratory rate;lung radiography;count of lymphocyte;temperature;other infection;time when the nuleic acid of the novel coronavirus turns negative;prognosis;","start_date":"11.02.20","end_date":"","source_id":"ChiCTR2000029740","title":"Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49317","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2372,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Diagnostic criteria for severe novel coronavirus pneumonia.;Index test:early\u0026#32;warning\u0026#32;and\u0026#32;prediction\u0026#32;system.;","n_enrollment":1200,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Cytokine detection;Lymphocyte subpopulation analysis ;SEN, SPE, ACC, AUC of ROC;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029866","title":"Early warning prediction of patients with severe novel coronavirus pneumonia (COVID-19) based on multiomics                                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49519","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2374,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","n_enrollment":3434,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SOFA;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000029851","title":"A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49534","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2375,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Mild Group:probiotics;Severe Group:probiotics;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"gut microbiome;Fecal metabolomics;Blood routine;albumin;serum potassium;CRP;ALT;AST;urea;Cr;urea nitrogen;D-Dimer;ESR;IgG;IgM;IgA;hepatitis B surface antigen;ÃŸ2-microglobulin;IFN-gama;IL-6;TNF-beta;IL-10;IL-2;IL-4;IL-13;IL-12;chest CT;abdominal CT;ECG;We","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029999","title":"A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49717","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2376,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel","n_enrollment":404020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery time;Clinical recovery time;Changes in viral load of upper and lower respiratory tract samples compared with the baseline;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029992","title":"An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49574","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2377,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel","n_enrollment":404020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery time;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030054","title":"An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49869","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2378,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","n_enrollment":3060,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SARS-CoV-2 DNA;SARS-CoV-2  antibody levels;thoracic spiral CT;","start_date":"31.05.20","end_date":"","source_id":"ChiCTR2000030039","title":"Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)                                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49544","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2379,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:mesenchymal stem cells;control group:saline;","n_enrollment":6060,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Improved respiratory system function (blood oxygen saturation) recovery time;","start_date":"30.01.20","end_date":"","source_id":"ChiCTR2000029990","title":"Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49674","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2380,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Pneumonia diagnosis and treatment plan of the national health commission for new coronavirus infection (5th edition) and the diagnostic criteria of Hubei province: including clinical diagnosis and Pathogenic nucleic acid test of pharynx swab","n_enrollment":600,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SARS-COV-2 nucleic acid;SEN, SPE, ACC, AUC of ROC;","start_date":"18.02.20","end_date":"","source_id":"ChiCTR2000029981","title":"Study for nucleic acid detection of novel coronavirus pneumonia (COVID-2019) in female vaginal secretions                                                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49692","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2382,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:mesenchymal stem cells therapy;","n_enrollment":20,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Coronavirus nucleic acid markers negative rate;Symptoms improved after 4 treatments;Inflammation (CT of the chest);","start_date":"06.02.20","end_date":"","source_id":"ChiCTR2000030020","title":"The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49812","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2383,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","n_enrollment":150150,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical recovery;Butyrate in feces;","start_date":"09.02.20","end_date":"","source_id":"ChiCTR2000029974","title":"A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49321","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2384,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","n_enrollment":180280180280,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Number of patients who have progressed to suspected or confirmed within 24 days of exposure to new coronavirus;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029803","title":"A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49428","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2387,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","n_enrollment":8080,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Recovery time;","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000029780","title":"A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49220","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2388,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","n_enrollment":112022403120,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"hospital stay;Discharge rate;Site-specific hospital metastasis rate or severe conversion rate;Body temperature normalization time;Clinical symptoms disappearance rate;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030003","title":"Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49770","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2389,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:conventional therapy;Experience group:conventional therapy and Tranilast;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"cure rate;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030002","title":"Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49738","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2390,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","n_enrollment":150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Arterial Blood Oxygen Saturation;TTCR,Time to Clinical recovery;temperature;respiratory rate;Lung CT;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029989","title":"A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49720","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2391,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Chloroquine Phosphate;Control group:No;","n_enrollment":4040,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Recovery;","start_date":"13.02.20","end_date":"","source_id":"ChiCTR2000029988","title":"Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49218","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2393,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","n_enrollment":2020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"the rate of Coronary virus nucleic acid negative at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;Symptom recovery at 7 days, 14 days, 21 days, and 28 days after Ultra Short Wave Electrotherapy;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029972","title":"A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49664","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2394,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medic","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Psychological status;Treatment compliance;To evaluate the difference in isolation and rehabilitation of patients after discharge;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030420","title":"A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50286","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2395,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group","n_enrollment":10011002100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Recovery time;Pneumonia psi score;","start_date":"30.04.20","end_date":"","source_id":"ChiCTR2000029954","title":"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49402","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2396,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","n_enrollment":4040,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PCL;PSQI;FSI;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030432","title":"Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50268","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2397,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potas","n_enrollment":170170,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Pharynx swabs, lower respiratory tract samples (sputum/endotracheal aspiration/alveolar lavage), and anal swabs rt-pcr of novel coronavirus nucleic acid negative conversion rate.;","start_date":"27.02.20","end_date":"","source_id":"ChiCTR2000030398","title":"A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50173","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2398,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Postive result of SARS-CoV-2 nucleic acid examination;Index test:Diagnostic\u0026#32;Assistance\u0026#32;Decision\u0026#32;Support\u0026#32;System;","n_enrollment":30000,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CT;SEN, SPE, ACC, AUC of ROC;","start_date":"01.01.20","end_date":"","source_id":"ChiCTR2000030390","title":"Research and Development of Diagnostic Assistance Decision Support System for novel coronavirus pneumonia (COVID-19) Based on Big Data Technology                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50224","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2400,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"one group:Rehabilitation Lung Health Eight - Stage Exercise ;","n_enrollment":80,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PCL;HRQL;IPAQ;PASE;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030433","title":"The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50273","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2401,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","n_enrollment":140240,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Post-traumatic stress disorder checklist;Clinical prognostic outcome;Il-6;Health-related quality of life inventory;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030418","title":"Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50341","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2404,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:moxibustion;","n_enrollment":1000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"mood assessment;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030386","title":"Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50323","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2406,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:NA;","n_enrollment":498,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030331","title":"Construction of a Bio information platform for novel coronavirus pneumonia (COVID-19) patients follow-up in Anhui                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50271","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2409,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lung CT after 3 days;Lung CT after 7 days;Oxygenation parameters: SpO2, Partial arterial oxygen pressure (PaO2), PaO2/FiO2;Hospital stay;Novel coronavirus nucleic acid detection;Recurrence rate;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030328","title":"Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50241","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2410,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Combination of Tocilizumab, IVIG and CRRT;","n_enrollment":100,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inhospital time;","start_date":"05.03.20","end_date":"","source_id":"ChiCTR2000030442","title":"The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50380","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2411,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","n_enrollment":40,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"temperature;respiratory symptoms;","start_date":"28.02.20","end_date":"","source_id":"ChiCTR2000030314","title":"Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50248","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2413,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:COVID-19 viral PCR;Index test:MicroRNA;","n_enrollment":2525,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SEN, SPE, ACC, AUC of ROC;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030334","title":"microRNA as a marker for early diagnosis of novel coronavirus infection (COVID-19)                                                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49491","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2414,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","n_enrollment":147145,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"K-bld questionnaire survey;Refers to the pulse oxygen;chest CT;blood gas;","start_date":"04.03.20","end_date":"","source_id":"ChiCTR2000030333","title":"A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48801","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2415,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","n_enrollment":150150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"During the operation, the patient's volume of local exhaled air from the mouth and nose, the patient's heart rate, respiratory rate and blood oxygen saturation;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030317","title":"A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50247","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2417,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","n_enrollment":102102,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time to 2019-nCoV RNA negativity in patients;","start_date":"27.02.20","end_date":"","source_id":"ChiCTR2000030288","title":"Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine                                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50202","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2418,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:N/A;","n_enrollment":200,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"GHQ-20;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030263","title":"Investigation and analysis of psychological status of hospital staff during the novel coronavirus pneumonia (COVID-19) epidemic                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50140","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2419,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Dia","n_enrollment":30,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time.;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030424","title":"A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50174","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2421,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 2:Once for two days;Group 3:Once for one day;Group 1:Control Group;","n_enrollment":210310110,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Viral load;Clinical features;Inflammation;Pulmonary imaging;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030262","title":"Clinical study for combination of anti-viral drugs and type I interferon and inflammation inhibitor TFF2 in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50136","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2422,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","n_enrollment":1010,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"NRS 2002 score;BMI;triceps skinfold thickness (TSF);prealbumin;total albumin;leucocyte count;CRP;lymphocyte percentage;TNF- alpha;IL-6;","start_date":"27.02.20","end_date":"","source_id":"ChiCTR2000030260","title":"Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50130","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2425,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:mesenchymal stem cells therapy;","n_enrollment":9,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;Exacerbation (transfer to RICU) time;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030300","title":"Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50022","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2427,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Two groups:Chinese massage versus control;","n_enrollment":40,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Temperature;Respiratory symptoms;","start_date":"28.02.20","end_date":"","source_id":"ChiCTR2000030324","title":"Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)                                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50231","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2429,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","n_enrollment":-200100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clearance rate and time of main symptoms (fever, fatigue, cough);","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030255","title":"Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50089","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2430,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Detection of novel coronavirus by fluorescence RT-PCR;Index test:Detection\u0026#32;of\u0026#32;viral\u0026#32;nucleic\u0026#32;acids\u0026#32;in\u0026#32;eye\u0026#32;swabs,\u0026#32;throat\u0026#32;swabs,\u0026#32;oral\u0026#32;saliva,\u0026#32;feces,\u0026#32;urine\u0026#32;and\u0026#32;plasma;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SEN, SPE, ACC, AUC of ROC;","start_date":"27.02.20","end_date":"","source_id":"ChiCTR2000030253","title":"Exploration and Research for a new method for detection of novel coronavirus (COVID-19) nucleic acid                                                                                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50143","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2431,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","n_enrollment":1313,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lung CT;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030261","title":"A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49963","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2433,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","n_enrollment":101010,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inflammation factor;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030265","title":"Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49691","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2436,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Rate of composite advers outcomes: SpO2, PaO2/FiO2, respiratory rate;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030259","title":"Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49918","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2437,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Integration of traditional Chinese and Western Medicine;","n_enrollment":120,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptoms;TCM syndrome;Lung imaging;Time of nucleic acid turning negative;","start_date":"21.01.20","end_date":"","source_id":"ChiCTR2000030219","title":"Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50110","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2438,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Exercise prescription;Control group:none;","n_enrollment":100100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Mood index;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030091","title":"A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)                                                                                           ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49914","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2439,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery time;Pneumonia Severity Index (PSI) score;","start_date":"22.01.20","end_date":"","source_id":"ChiCTR2000030218","title":"Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50115","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2441,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kangua","n_enrollment":120202202032020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Routine physical examination;Vital signs: breathing, body temperature (armpit temperature);Blood routine;C-reactive protein;Liver and kidney function test;Myocardial enzyme content;ESR;T cell subsets;Cytokine;Liver, gallbladder, thyroid, and lymph node im","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000030215","title":"Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50107","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2442,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"pulmonary function;","start_date":"24.08.20","end_date":"","source_id":"ChiCTR2000030198","title":"Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50066","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2443,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional drug therapy plus hydrogen inhalation;Control group:Conventional drug therapy;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"temperature;respiratory rate;Blood oxygen saturation;Cough symptom;Lung CT;Fatality rate;","start_date":"21.02.20","end_date":"","source_id":"ChiCTR2000030258","title":"A multicenter, randomized, controlled trial for efficacy and safety of hydrogen inhalation in the treatment of novel coronavirus pneumonia (COVID-19) patients                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49887","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2446,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Chloroquine phosphate;","n_enrollment":10,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"viral negative-transforming time;30-day cause-specific mortality;co-infections;Time from severe and critical patients to clinical improvement;","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000029975","title":"Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49592","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2448,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Negative conversion rate of 2019-nCoV nucleic acid ;Lung inflammation absorption ratio;","start_date":"13.02.20","end_date":"","source_id":"ChiCTR2000029761","title":"Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49400","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2449,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:conventional therapy+tocilizumab;","n_enrollment":60,"country":"china","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"the relive of CRS;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030196","title":"A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49883","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2450,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"COVID-19 nucleic acid detection time from positive to negative (respiratory secretion) or (3,5,7,10 days from positive to negative rate);;Lung CT observation of inflammation absorption;;Proportion of cases with progressive disease;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030022","title":"A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49797","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2452,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatment \u0026 Acupuncture;Control Group:Conventional treatment;","n_enrollment":9393,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Length of hospital stay;Discharge time of general type;Discharge time of severe type;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030225","title":"Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49945","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2453,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Negative conversion rate of COVID-19 nucleic acid;Lung inflammation absorption ratio;","start_date":"12.02.20","end_date":"","source_id":"ChiCTR2000029762","title":"A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49404","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2454,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","n_enrollment":120120,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to clinical recovery;","start_date":"12.02.20","end_date":"","source_id":"ChiCTR2000029760","title":"A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49369","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2455,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:recombinant human interferon a1b spray;Control group:Blank;","n_enrollment":300150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Blood routine examination;Chest CT;Arterial Blood Oxygen Saturation;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030013","title":"A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49796","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2456,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","n_enrollment":242424,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"cough;","start_date":"18.02.20","end_date":"","source_id":"ChiCTR2000029991","title":"A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49666","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2457,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","n_enrollment":12022020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"time to recovery.;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000029759","title":"A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49352","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2458,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgÂ·d for 3 days.;Control group:Without any glucocorticoid therapy;","n_enrollment":2424,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SOFA score;","start_date":"29.01.20","end_date":"","source_id":"ChiCTR2000029386","title":"A study on treatment strategies of novel coronavirus pnueumonia patients                                                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48777","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2460,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Cancelled;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030162","title":"Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49570","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2461,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","n_enrollment":6060,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Validity observation index;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000029755","title":"A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49301","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2463,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Recovery, TTCR;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029899","title":"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49536","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2464,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"TTCI (Time to Clinical Improvement);","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029898","title":"Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49482","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2465,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","n_enrollment":363636,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time to 2019-nCoV RNA negativity in patients;","start_date":"25.01.20","end_date":"","source_id":"ChiCTR2000029387","title":"Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48782","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2470,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Nucleic acid test;Index test:Nano-nasal\u0026#32;COVID-19\u0026#32;diagnostic\u0026#32;screening\u0026#32;model;","n_enrollment":200200,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Volatile organic compounds, VOCs;SEN, SPE, ACC, AUC of ROC;","start_date":"15.03.20","end_date":"","source_id":"ChiCTR2000030556","title":"Clinical study of nano-nose and its extended technology in diagnosis of novel coronavirus pneumonia (COVID-19)                                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50672","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2471,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical therapeutic course;Pathogenic detectio;Chest CT;Laboratory indicators (blood routine, myocardial enzyme spectrum, inflammatory cytokines, etc.);","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030535","title":"Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine                                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49790","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2472,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Recovery (TTCR);","start_date":"09.03.20","end_date":"","source_id":"ChiCTR2000030522","title":"Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=44213","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2476,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","n_enrollment":7676,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Chest imaging;Oxygenation index;Extravascular pulmonary water;pulmonary vascular permeability index, PVPI;Inflammatory factors;Tissue kallikrein;","start_date":"08.03.20","end_date":"","source_id":"ChiCTR2000030540","title":"Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50658","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2479,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Mortality;","start_date":"20.01.20","end_date":"","source_id":"ChiCTR2000030503","title":"Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49632","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2480,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health an","n_enrollment":10,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Sputum/nasal swab/pharyngeal swab/lower respiratory tract secretions were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested daily after two days starting the azvudine tablets) and the negative conversion time;","start_date":"04.03.20","end_date":"","source_id":"ChiCTR2000030487","title":"A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50507","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2482,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","n_enrollment":100,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Cure rate;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030490","title":"To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50487","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2483,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","n_enrollment":1515,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Tempreture;Virus nucleic acid detection;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030627","title":"Study on the application of convalescent plasma therapy in severe COVID-19                                                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50727","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2486,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","n_enrollment":1010,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Rate of composite advers outcomes: SPO2, PaO2/FiO2 and respiratory rate;","start_date":"25.02.20","end_date":"","source_id":"ChiCTR2000030472","title":"An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49753","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2488,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 da","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Real-time fluorescent RT-PCR detection of pharyngeal swab were used to detect the negative conversion rate of the new coronavirus nucleic acid (tested after the end of medication) and the negative conversion time(measured every other day after the start o","start_date":"29.02.20","end_date":"","source_id":"ChiCTR2000030518","title":"Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50586","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2489,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time of duration of COVID-19 nucleic acid RT-PCR test results of respiratory specimens (such as throat swabs) or blood specimens change to negative.;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030481","title":"The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50453","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2490,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological int","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Psychological status;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030467","title":"A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50378","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2491,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","n_enrollment":197197,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Progression rate from mild to critical/severe;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030471","title":"Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50421","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2492,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","n_enrollment":4848,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"fever clearance time;Effective rate of TCM symptoms;","start_date":"27.02.20","end_date":"","source_id":"ChiCTR2000030469","title":"A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50082","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2493,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Pulmonary function;6 minutes walking distance;The Short Form -36 Healthy Survey;","start_date":"07.03.20","end_date":"","source_id":"ChiCTR2000030578","title":"Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50690","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2496,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"COVID-2019 patients in Tongji Hospital:none;COVID-2019 patients in Mobile field hospital:none;Medical staff in Tongji Hospital:none;Control:none;","n_enrollment":0,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Nuclei acid test of SARS-CoV-2 of conjunctival swab;Nuclei acid test of SARS-CoV-2 of throat swab;Nuclei acid test of SARS-CoV-2 of peripheral blood sample;Eye symptoms;Clinical symptoms;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030489","title":"Study for the route of ocular surface transmission of novel coronavirus pneumonia (COVID-19) infection and related eye diseases                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50490","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2501,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"treatment group1:HUMSCs: intravenous infusion, 5 Ã— 10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5 Ã— 107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intraveno","n_enrollment":13023030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PaO2 / FiO2 or respiratory rate (without oxygen);Frequency of respiratory exacerbation;Observe physical signs and symptoms and record clinical recovery time;The number and range of lesions indicated by CT and X-ray of lung;Time for cough to become mild or","start_date":"02.02.20","end_date":"","source_id":"ChiCTR2000030484","title":"HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50263","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2503,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","n_enrollment":235135,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SpO2 during intubation;the total time of intubation;Mask ventilation for SpO2 \u003c 90%;","start_date":"02.03.20","end_date":"","source_id":"ChiCTR2000030465","title":"Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50388","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2504,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:pulmonary training;control group:Conventional medication;","n_enrollment":150150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"MRC breathlessness scale;6MWD;","start_date":"19.02.20","end_date":"","source_id":"ChiCTR2000030014","title":"Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49802","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2506,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","n_enrollment":164164,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Incidence of side effects;","start_date":"03.03.20","end_date":"","source_id":"ChiCTR2000030480","title":"Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50470","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2507,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:cytokine removal therapy with Cytosorb;","n_enrollment":19,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"28 day mortality;","start_date":"04.03.20","end_date":"","source_id":"ChiCTR2000030475","title":"The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50452","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2508,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":200,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical characteristics;","start_date":"03.03.20","end_date":"","source_id":"ChiCTR2000030464","title":"Study for the clinical characteristics of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50382","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2509,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Anti-SARS-CoV-2 virus inactivated plasma;","n_enrollment":24,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","start_date":"29.02.20","end_date":"","source_id":"ChiCTR2000030312","title":"A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50258","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2511,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical L","n_enrollment":5050,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000030479","title":"Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50450","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2512,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:oXiris membrane;","n_enrollment":19,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"28 day mortality;","start_date":"04.03.20","end_date":"","source_id":"ChiCTR2000030477","title":"The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50458","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2514,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","n_enrollment":2020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Main symptom relief time;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029993","title":"A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49435","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2515,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":1000,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Epidemiological and clinical characteristics;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030256","title":"Epidemiological and clinical characteristics of COVID-19: a large-scale investigation in epicenter Wuhan, China                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50078","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2516,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","n_enrollment":11501150,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CRP;ESR;PCT;Tn;Mb;D-Dimer;blood routine examination;chest CT;creatase;","start_date":"29.01.20","end_date":"","source_id":"ChiCTR2000029550","title":"Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48775","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2518,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","n_enrollment":3535,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Safety;","start_date":"31.01.20","end_date":"","source_id":"ChiCTR2000029580","title":"Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49088","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2519,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptoms;Blood routine;Biochemical and myocardial enzymes;C-reactive protein;Erythrocyte sedimentation rate;Inflammatory cytokines;Chest CT;Etiology Inspection;Vital signs;","start_date":"03.02.20","end_date":"","source_id":"ChiCTR2000029638","title":"A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49224","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2523,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","n_enrollment":200200,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Severe conversion rate;Oxygenation index;2019-nCoV nucleic acid test;Chest CT;","start_date":"03.02.20","end_date":"","source_id":"ChiCTR2000029549","title":"Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49014","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2524,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;","n_enrollment":1000010000,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inccidence of 2019-nCoV pneumonia;","start_date":"30.01.20","end_date":"","source_id":"ChiCTR2000029479","title":"Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48773","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2525,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","n_enrollment":120120,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000029433","title":"A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48898","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2526,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","n_enrollment":8080,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical improvement time of 28 days after randomization;The 7-point scale;7 points: death;6 points: admission to ECMO and / or mechanical ventilation;5 points: Hospitalized for non-invasive ventilation and / or high-flow oxygen therapy;4 points: hospital","start_date":"10.01.20","end_date":"","source_id":"ChiCTR2000029308","title":"A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48684","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2527,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","n_enrollment":120120,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptoms (fever, weakness, cough) recovery rate and recovery time;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000029434","title":"A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48889","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2528,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","n_enrollment":100100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"the number of days between randomised grouping and clinical improvement;","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000029757","title":"Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49081","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2529,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:traditional Chinese medicine and Western medicine treatment;","n_enrollment":24,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Improvement of symptoms;","start_date":"06.02.20","end_date":"","source_id":"ChiCTR2000030896","title":"Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51028","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2531,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;","n_enrollment":190230330,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical cure rate;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030894","title":"Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51126","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2535,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":90,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CT;","start_date":"27.02.19","end_date":"","source_id":"ChiCTR2000030861","title":"Development and application of a new intelligent robot for novel coronavirus (2019-nCOV) oropharygeal sampling                                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51103","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2538,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Western medicine plus Qingfei Paidu decoction;","n_enrollment":50,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"2019-ncov-RNA;Chest CT;Routine blood test;Blood biochemistry;TCM symptom;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030864","title":"Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50662","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2544,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Average discharge time;WBC;ALT, AST, gama-GT, BUN, Cr, CK-MB;turn serious/crisis ratio;","start_date":"23.02.20","end_date":"","source_id":"ChiCTR2000030810","title":"Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese\u0026Western Medicine                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50986","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2548,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:external diaphragmatic pacing;","n_enrollment":200,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Length of stay in ICU;Diaphragm movement;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030855","title":"Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51090","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2550,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:dexmedetomidine;","n_enrollment":200,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CK-MB;CTnI;neuron-specific enolase,NSE;BUN;scr.;lactic acid;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030853","title":"Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51081","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2552,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","n_enrollment":1010,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"serum albumin;siderophilin;prealbumin;lung CT scanning result;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030897","title":"Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50462","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2553,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","n_enrollment":55,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Improvement (TTCI);","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000030841","title":"Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients                                                                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51072","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2554,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Laboratory examination and pulmonary CT;","n_enrollment":100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SAA;Detection of respiratory pathogen serotype;Lymphocyte subgroup detection;IgM and IgG detection;Pulmonary CT;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030839","title":"Preliminary screening of Coronavirus Disease (COVID-19) by special laboratory examination and CT imaging before surgery                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50904","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2557,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:RT-PCR test results;Index test:Typing\u0026#32;and\u0026#32;prediction\u0026#32;accuracy\u0026#32;of\u0026#32;artificial\u0026#32;intelligence\u0026#32;models;","n_enrollment":10000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Precision;SEN, SPE, ACC, AUC of ROC;","start_date":"20.01.20","end_date":"","source_id":"ChiCTR2000030838","title":"Development of warning system with clinical differential diagnosis and prediction for severe type of SARS-Cov-2 patients based on artificial intelligence and CT images                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51071","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2558,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","n_enrollment":21501150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"14 day outcome of the subjects, including: recovery, improvement, turning critical, death. ;Lung CT;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030836","title":"Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51054","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2559,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Pirfenidone;Control group:Blank;","n_enrollment":2020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"HRCT pulmonary fibrosis score;","start_date":"06.03.20","end_date":"","source_id":"ChiCTR2000030892","title":"Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51118","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2561,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","n_enrollment":1200220032004200,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PHQ-9;GAD-7;PHQ-15;PSS-14;ISI;SHARPS;ACTH;cortisol;24-hour ECG;Magnetic resonance spectroscopy;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030832","title":"Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51044","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2563,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","n_enrollment":1010,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"14.02.20","end_date":"","source_id":"ChiCTR2000030835","title":"Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51050","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2568,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","n_enrollment":6464,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Cough Score;Expectoration score;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030804","title":"Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51018","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2569,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","n_enrollment":1456,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time for the positive nucleic acid of the novel coronavirus to turn negative;Incidence of deterioration;The defervescence time;Chest CT;Primary symptom remission rate;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030759","title":"Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49284","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2573,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:RT-PCR test results;Index test:Artificial\u0026#32;intelligence\u0026#32;model;","n_enrollment":600100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"sensitivity;SPE;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030856","title":"An artificial intelligence assistant system for suspected new coronavirus pneumonia based on chest CT                                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51091","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2574,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Psychological intervention;","n_enrollment":81,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SCL-90 scale;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030849","title":"Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51086","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2575,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcome;Index test:artificial\u0026#32;intelligence\u0026#32;prediction\u0026#32;model;","n_enrollment":10000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"cure rate;propotion of progression;SEN, SPE, ACC, AUC of ROC;","start_date":"20.01.20","end_date":"","source_id":"ChiCTR2000030799","title":"Establishment and validation of Premonitory model of deterioration of the 2019 novel corona virus pneumonia                                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50995","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2581,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:PCR Nucleic acid detection;Index test:high-throughput\u0026#32;novel\u0026#32;coronavirus\u0026#32;(2019-nCoV)\u0026#32;screening\u0026#32;detection\u0026#32;kit;","n_enrollment":4000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"RNA of 2019-nCov;SPE, SEN, ACC, AUC of ROC;","start_date":"22.03.20","end_date":"","source_id":"ChiCTR2000030833","title":"Clinical validation and application of high-throughput novel coronavirus (2019-ncov) screening detection kit                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51035","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2585,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","n_enrollment":5050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"blood gas;SOFA score;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030779","title":"A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50973","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2589,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:CRRT;","n_enrollment":20,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CRP;IL-6;TNF-alpha;IL-8;","start_date":"31.05.20","end_date":"","source_id":"ChiCTR2000030761","title":"Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50956","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2590,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:2019 nCOV detection;Index test:SARS-CoV-2 IgM;","n_enrollment":300,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"false positive rate of SARS-CoV-2 IgM antibody;SEN, SPE, ACC, AUC of ROC;","start_date":"11.03.20","end_date":"","source_id":"ChiCTR2000030754","title":"Accuracy analysis of SARS-CoV-2 IgM antibody screening for diagnosis of COVID-19                                                                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50824","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2593,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Epidemiological history + CT + clinical manifestations + sars-cov-2 nucleic acid positive;Index test:Elisa\u0026#32;analysis\u0026#32;of\u0026#32;validation\u0026#32;factors,\u0026#32;inflammatory\u0026#32;factors,\u0026#32;adhesion\u0026#32;factors;","n_enrollment":2257,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030800","title":"Study on levels of inflammatory factors in peripheral blood of patients with novel coronavirus pneumonia and their diagnostic and prognostic value                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50997","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2599,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:no;","n_enrollment":450,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"anxiety;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030768","title":"Risk Factors for Anxiety of Otolaryngology Workers in Hubei Province Fighting Against novel coronavirus pneumonia (COVID-19)                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50968","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2600,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Traditional Mongolian Medicine;","n_enrollment":60,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;","start_date":"25.01.20","end_date":"","source_id":"ChiCTR2000030751","title":"Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50941","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2606,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Early initiation of blood purification;","n_enrollment":20,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"death;Number of failure organs;Length of hospital stay;","start_date":"12.02.20","end_date":"","source_id":"ChiCTR2000030773","title":"Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50934","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2608,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Nucleic acid test for new coronavirus, RT-PCR;Index test:RT-PCR\u0026#32;product\u0026#32;of\u0026#32;SARS-CoV-2.;","n_enrollment":300200,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Sensitivity, specificity and accuracy;","start_date":"09.02.20","end_date":"","source_id":"ChiCTR2000030706","title":"Application of cas13a-mediated RNA detection in the detection of novel coronavirus nucleic acid                                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50001","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2610,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical characteristics according to TCM;","start_date":"01.12.19","end_date":"","source_id":"ChiCTR2000030762","title":"Diagnosis and treatment of novel coronavirus pneumonia (COVID-19) in common and severe cases based on the theory of ''Shi-Du-Yi (damp and plague)''                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50950","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2614,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","n_enrollment":260160,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Medical imaging improvement rate in patients during recovery period;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030720","title":"Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50793","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2616,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"ECMO group:ECMO therapy;the conventional treatment group:no;","n_enrollment":1020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inpatient mortality;ICU hospital stay;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030744","title":"Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50910","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2617,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","n_enrollment":30303030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Shorten the duration of the disease;Antipyretic rate;Severe rate;Time of virus nucleic acid turning negative;Negative rate of viral nucleic acid;Time for improvement of lung image;PCT;CRP;IL-17;WBC;Lymphocyte subtype analysis;Blood gas analysis;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030750","title":"A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50928","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2618,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:chloroquine phosphate ;Control group:none;","n_enrollment":4040,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Clinical Recovery;","start_date":"12.02.20","end_date":"","source_id":"ChiCTR2000030718","title":"Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection                                                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50843","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2620,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Patients with mild or light COVID-19 confirmed by testing for novel coronavirus of the respiratory tract;Index test:1.\u0026#32;throat\u0026#32;swab\u003cbr\u003e2.\u0026#32;induced\u0026#32;sputum;","n_enrollment":500,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"detection of SARS-CoV-2 RNA;SEN, SPE, ACC, AUC of ROC;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030721","title":"A comparative study for the sensitivity of induced sputum and throat swabs for the detection of SARS-CoV-2 by real-time PCR in patients with novel coronavirus pneumonia (COVID-19)                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50759","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2621,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","n_enrollment":2525,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to clinical recovery after randomization;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030702","title":"Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial                                                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50537","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2623,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Two groups:Nil;","n_enrollment":30,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lymphocyte grouping;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030690","title":"Study on immune cell subsets in convalescent patients with SARS-CoV-2 infection                                                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50261","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2624,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"chest computerized tomography;Nucleic acid detection of novel coronavirus;TNF-alpha;IL-6;IL-10;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030580","title":"Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50693","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2628,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","n_enrollment":2020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lung CT;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030703","title":"A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50251","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2629,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Virus Eradication;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030701","title":"A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50795","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2630,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to Virus Eradication;","start_date":"09.03.20","end_date":"","source_id":"ChiCTR2000030700","title":"An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50786","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2631,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Infection without renal injury group:none;Infection with proteinuria group:Bailing Capsule;Infection with hematuria group:Bailing Capsule;Infection with impaired renal function group:Bailing Capsule, Renal replacement therapy;","n_enrollment":30303030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"temperature;heart rate;respiratory rate;blood pressure;Urine volume;blood routine;C-reactive protein;erythrocyte sedimentation rat;pulmonary CT;liver function;coagulation function;renal function;immunoglobulin;complement;T cell subsets;electrolytes;Urine ","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030687","title":"COVID-19 infection associated kidney injury in children                                                                                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50572","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2632,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients ","n_enrollment":10011002100,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Recovery time;Pneumonia psi score;","start_date":"04.02.20","end_date":"","source_id":"ChiCTR2000030545","title":"Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50126","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2635,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcomes;Index test:MEWS\u0026#32;and\u0026#32;other\u0026#32;scores;","n_enrollment":2340,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"In-hospital mortality;ACC, SEN, SPE, ROC;","start_date":"09.03.20","end_date":"","source_id":"ChiCTR2000030683","title":"The prediction value of prognosis of COVID-19 in elderly patients by modified early warning score (MEWS): a retrospective observational study                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50633","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2636,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common ","n_enrollment":60606060,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"cough;agitation;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030681","title":"An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50763","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2637,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1:Throat swab virus nucleic acid test combined with low-dose chest CT;2:Throat swab virus nucleic acid test combined with low-dose chest CT;","n_enrollment":11322132,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CT image features;Fever;Throat swab virus nucleic acid tes;lymphocyte;","start_date":"07.03.20","end_date":"","source_id":"ChiCTR2000030558","title":"Epidemiological research of novel coronavirus pneumonia (COVID-19) suspected cases based on virus nucleic acid test combined with low-dose chest CT screening in primary hospital                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50678","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2638,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.6Ã—10E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.6Ã—10E8/kg) were injected twice every other day.;","n_enrollment":303030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Status of immune function;The time of nucleic acid turns to negative;Length of stay in-hospital;","start_date":"05.03.20","end_date":"","source_id":"ChiCTR2000030329","title":"Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49779","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2640,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The percentage of patients who convert to moderate one;The rate of shock;Endotracheal intubation ratio;Time spent on the ventilator;mortality;Time of virus nucleic acid test turning negative;","start_date":"18.02.20","end_date":"","source_id":"ChiCTR2000030388","title":"Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50306","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2644,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"treatment group :Ba duanjin;","n_enrollment":16,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030483","title":"A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50495","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2646,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":960,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"sleep status and related factors of insomnia;","start_date":"31.01.20","end_date":"","source_id":"ChiCTR2000030221","title":"Study for sleep status of medical staffs of hospitals administrating suspected cases of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50071","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2647,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Chest CT examination;Index test:Lung\u0026#32;ultrasound\u0026#32;examination;","n_enrollment":1500,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Lung ultrasound;Chest computed tomography (CT);Respiratory and oxygenation indicators;Prognostic indicators (length of stay, mortality);","start_date":"24.02.20","end_date":"","source_id":"ChiCTR2000030114","title":"Lung ultrasound in the diagnosis, treatment and prognosis of pulmonary lesions of novel coronavirus pneumonia(COVID-19)                                                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49987","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2648,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time when the nucleic acid of the novel coronavirus turns negative;Conversion to heavy/critical type;","start_date":"23.02.20","end_date":"","source_id":"ChiCTR2000030082","title":"Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49915","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2650,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*107â€”1*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time and rate of novel coronavirus become negative.;","start_date":"13.03.20","end_date":"","source_id":"ChiCTR2000030509","title":"Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49956","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2651,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western med","n_enrollment":6060,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"lasting time of fever;lasting time of novel coronavirus pneumonia virus nucleic acid detected by RT-PCR and negative result rate of the novel coronavirus disease nucleic acid;","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000030478","title":"Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)                                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50460","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2652,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Routine treatment group:Conventional treatment of 2019-nCoV pneumonia;Dipyridamole treatment group:Conventional treatment of 2019-nCoV pneumonia and Dipyridamole;","n_enrollment":230230,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Complete Blood Count;CRP;blood coagulation;D-dimer;Virological examination of pharyngeal swab;Pulmonary imaging;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030055","title":"Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49864","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2653,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Endotracheal intubation rate;mortality;Ratio of virus nucleic acid detection to negative;","start_date":"25.02.20","end_date":"","source_id":"ChiCTR2000030187","title":"Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50057","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2654,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","n_enrollment":160,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The negative conversion rate and negative conversion time of novel coronavirus nucleic acid;","start_date":"16.02.20","end_date":"","source_id":"ChiCTR2000029895","title":"Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49569","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2655,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","n_enrollment":11002100,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Self-rating depression scale;self-rating anxiety scale;Athens Insomnia Scale;","start_date":"03.03.20","end_date":"","source_id":"ChiCTR2000030476","title":"Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50455","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2656,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","n_enrollment":1515,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Temperature returns to normal for more than 3 days;Respiratory symptoms improved significantly;Pulmonary imaging showed that acute exudative lesions were significantly improved;Negative for two consecutive tests of respiratory pathogenic nucleic acid (sam","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030417","title":"Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)                                                                                                              ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50279","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2657,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","n_enrollment":3030,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"IFN-gama;TNF-alpha;Blood routine index;Time and rate of coronavirus become negative;immunoglobulin;Exacerbation (transfer to RICU) time;Clearance rate and time of main symptoms (fever, fatigue, cough);","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000029984","title":"Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49712","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2659,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy re","n_enrollment":8040,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time of conversion to be negative of novel coronavirus nucleic acid;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030031","title":"A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49806","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2660,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:The suspected patient is confirmed by any of the following etiological evidence: 1. Real-time RT-PCR of respiratory tract or blood samples was positive for the SARS-Cov-2; 2. Gene sequencing of respiratory or blood samples is highly homologo","n_enrollment":2000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"detection of SARS-Cov-2 nucleic acid;SEN, ACC;","start_date":"21.02.20","end_date":"","source_id":"ChiCTR2000030005","title":"Nucleic acid analysis of novel coronavirus pneumonia (COVID-19) in morning sputum samples and pharyngeal swabs-a prospectively diagnostic test                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49669","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2661,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical symptom improvement rate: improvement rate of clinical symptoms = number of cases with clinical symptom improvement /number of enrolling cases * 100%;","start_date":"29.02.20","end_date":"","source_id":"ChiCTR2000030381","title":"A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50290","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2662,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:High-dose Vitamin C;Control group:Routine treatment;","n_enrollment":2613,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Ventilation-free days;mortality;","start_date":"25.02.20","end_date":"","source_id":"ChiCTR2000030135","title":"A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50002","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2663,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy re","n_enrollment":8040,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time of conversion to be negative of novel coronavirus  nucleic acid;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029837","title":"A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49495","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2664,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","n_enrollment":3015,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Mortality rate;","start_date":"17.02.20","end_date":"","source_id":"ChiCTR2000029826","title":"A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49481","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2665,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"High dose group:High-dose NK cells (\u003e5x10^9)and mesenchymal stem cells(\u003e5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (\u003e3x10^9)and mesenchymal stem cells(\u003e3x10^9),Intravenous ","n_enrollment":202020,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029817","title":"Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49384","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2666,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","n_enrollment":3030,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029812","title":"Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49374","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2667,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Nucleic acid detection method of COVID-19;Index test:IgM/IgG\u0026#32;detection\u0026#32;method\u0026#32;of\u0026#32;COVID-19;","n_enrollment":400100,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Positive/Negtive;False positive of rate  ;","start_date":"22.02.20","end_date":"","source_id":"ChiCTR2000030085","title":"Study for the false positive rate of IgM / IgG antibody test kit for novel coronavirus pneumonia (COVID-19) in different inpatients                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49948","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2668,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Fitness Qigong Yangfei prescription;control group:general advice and related psychological comfort.;","n_enrollment":4040,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Oxygen Inhalation Frequency;Oxygen Intake Time;cough;Degree of expiratory dyspnoea;","start_date":"18.02.20","end_date":"","source_id":"ChiCTR2000029976","title":"Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49631","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2669,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","n_enrollment":3030,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029818","title":"Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49382","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2670,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","n_enrollment":3030,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time to disease recovery;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000029816","title":"Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49389","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2677,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","n_enrollment":2020,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"HRCT score;","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000031138","title":"Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51416","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2678,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:Nil;","n_enrollment":150,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Abnormalities on chest CT;","start_date":"01.04.20","end_date":"","source_id":"ChiCTR2000031150","title":"Application of radiology in the prevention and control system of emergency respiratory infectious diseases                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51021","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2679,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion i","n_enrollment":20,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Pulmonary function evaluation;Changes in blood gas analysis;Evaluation of activity;Evaluation of dyspnea;CT changes from baseline;","start_date":"20.03.20","end_date":"","source_id":"ChiCTR2000031139","title":"Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51404","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2682,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","n_enrollment":150150,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"syndrome;nucleic acid of nCoV-19;","start_date":"13.03.20","end_date":"","source_id":"ChiCTR2000031089","title":"Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules                                                                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51136","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2683,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Other parts samples or other methods for virus detection;Index test:Upper\u0026#32;Respiratory\u0026#32;Tract\u0026#32;Virus\u0026#32;Detection;","n_enrollment":3000,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PT-PCR test;SEN, SPE, ACC, AUC of ROC;","start_date":"12.03.20","end_date":"","source_id":"ChiCTR2000030993","title":"Upper Respiratory Tract Virus Detection of Corona Virus Disease 2019(COVID-19)to Evaluation the value of rehabilitation patients                                                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51342","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2684,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:psychological support;Group 2:cognitive behavioral therapy;","n_enrollment":130230,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Pittsburgh sleep quality index;Self-rating anxiety scale;Self-rating depression scale;CD-RISC scale;","start_date":"23.03.20","end_date":"","source_id":"ChiCTR2000031090","title":"Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)                                                                                                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51148","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2685,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","n_enrollment":3030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"insomnia;anxiety;depression;comfort;","start_date":"18.03.20","end_date":"","source_id":"ChiCTR2000030996","title":"Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.                                                                                                                                      ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51349","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2686,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcomes;Index test:the\u0026#32;diagnosis\u0026#32;and\u0026#32;prognosis\u0026#32;prediction\u0026#32;AI\u0026#32;model;","n_enrollment":10000,"country":"","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SEN, SPE, ACC, AUC of ROC;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030992","title":"The Diagnosis and prognosis prediction of novel coronavirus pneumonia (COVID-19) based on AI and Radiomics                                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51338","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2687,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"SFBT group:Internet based SFBT;Waiting Group:Wait ;","n_enrollment":3838,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"GAD-7;STAI-Y (C);","start_date":"20.03.20","end_date":"","source_id":"ChiCTR2000030989","title":"Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51331","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2688,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 2:thymosin;Group 1:BaZhen soup;","n_enrollment":21601160,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"postoperative complication;occupancy rate of intensive care unit;2-year tumor-free survival and overall survival;","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000031023","title":"Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period                                                                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50984","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2690,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","n_enrollment":15025050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"improvement or recovery of respiratory symptoms;viral nucleic acid shedding;","start_date":"05.03.20","end_date":"","source_id":"ChiCTR2000030987","title":"Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)                                                                                                                            ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51329","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2694,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","n_enrollment":102102,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Inflammation absorption on Chest CT;","start_date":"23.03.20","end_date":"","source_id":"ChiCTR2000030988","title":"Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51317","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2697,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","n_enrollment":180240,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The biochemical indicators;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030946","title":"Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia                                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51265","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2699,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:RT-PCR test;Index test:artificial\u0026#32;intelligence\u0026#32;triage\u0026#32;system;","n_enrollment":2500500,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"CT image;sensitivity;Specificity;Time efficiency;","start_date":"20.03.20","end_date":"","source_id":"ChiCTR2000030951","title":"Developing and evaluating of artificial intelligence triage system for suspected novel coronavirus pneumonia (COVID-19): a retrospective study                                                                                                                 ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51283","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2701,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"the patients of 2019 new coronavirus pneumonia:None;","n_enrollment":201950,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Nucleic acid;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030950","title":"Study for novel coronavirus pneumonia (COVID-19) patients etiology and immune response and guidance for vaccine design                                                                                                                                         ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51272","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2702,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","n_enrollment":3838,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Quantitative table of main symptom grading;Quantitative table of lung physical signs grading;","start_date":"01.02.20","end_date":"","source_id":"ChiCTR2000030940","title":"Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51061","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2703,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Case series:oral CSA0001;","n_enrollment":10,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"nuclear acid test of faeces;nuclear acid test of the upper respiratory tract;IgM;IgG;CT test of lung;glutamic oxalacetic transaminase;glutamic-pyruvic transaminase;total bilirubin;direct bilirubin;urea nitrogen;lactic dehydrogenase;creatinine;lymphocyte;C","start_date":"16.03.20","end_date":"","source_id":"ChiCTR2000030939","title":"Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51059","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2704,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","n_enrollment":1010,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Changes of serum inflammatory factors;Patient death risk;Drug related adverse reactions and events;","start_date":"01.09.20","end_date":"","source_id":"ChiCTR2000030944","title":"An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia                                                                                                                ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50199","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2706,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","n_enrollment":136236336,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Maximal inspiratory pressure;Respiratory muscle evaluation;","start_date":"31.03.20","end_date":"","source_id":"ChiCTR2000030933","title":"Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques                                                                                          ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51184","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2709,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"CM group:Xinguan No. 2 / Xinguan No. 3 alone or + regular treatment;WM group:Regular Ttreatment;","n_enrollment":2130710,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Body temperature returns to normal time;After the medication, the disappearance rate of TCM symptoms;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030936","title":"Hospital of Chengdu University of Traditional Chinese Medicine jointly launched a real-world study on the clinical efficacy evaluation of the Inner hospital preparation                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51100","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2710,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","n_enrollment":7272,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The change of TCM syndrome integral of deficiency of Fei-Pi-Qi-Xu Zhen;The results and changes of fatigue assessment scale at each time point;","start_date":"19.03.20","end_date":"","source_id":"ChiCTR2000030937","title":"Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51240","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2713,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medici","n_enrollment":1501505050,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Incidence of COVID-19 pneumonia;COVID-19 pneumonia rate of improvement;","start_date":"15.02.20","end_date":"","source_id":"ChiCTR2000030923","title":"The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51139","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2715,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Improvement of clinical symptoms (Clinical improvement is defined as a reduction of 2 points on the 6-point scale of the patient's admission status or discharge from the hospital);","start_date":"17.03.20","end_date":"","source_id":"ChiCTR2000030929","title":"A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)                                                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50696","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2717,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcome;Index test:Based\u0026#32;on\u0026#32;proteomics,\u0026#32;genomics,\u0026#32;and\u0026#32;epigenomics\u0026#32;to\u0026#32;detect\u0026#32;molecular\u0026#32;markers\u0026#32;in\u0026#32;peripheral\u0026#32;blood\u0026#32;of\u0026#32;patients\u0026#32;with\u0026#32;mild\u0026#32;and\u0026#32;severe\u0026#32;COVID-19\u0026","n_enrollment":300,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"RNA;DNA;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000030771","title":"Screening and identification of peripheral blood biomarkers in patients with COVID-19 infection based on multiomics studies                                                                                                                                    ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50961","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2718,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","n_enrollment":25252525,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Albumin;Cellular immune indicators (total lymphocyte count (TLC) and T lymphocyte subsets (CD3, CD4));","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030920","title":"Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50476","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2719,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Bufonis venenum injection;control group:NS;","n_enrollment":2525,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"PO2/FiO2;ROX INDEX;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000030704","title":"Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50778","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2720,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","n_enrollment":2020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"novel coronavirus nucleic acid;","start_date":"06.03.20","end_date":"","source_id":"ChiCTR2000030539","title":"Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50660","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2722,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","n_enrollment":1515,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"COVID-19 nucleic acid negative conversion rate;Causal mortality;All-cause mortality;","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000030922","title":"Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51141","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2723,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1:Low dose (5E10vp);2:Middle dose (1E11vp);3:High dose (1E11vp);","n_enrollment":136236336,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"adverse reactions 7 days post injection;","start_date":"10.03.20","end_date":"","source_id":"ChiCTR2000030906","title":"A single-center, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) in healthy adults aged between 18 and 60 years                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=51154","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2724,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Gold Standard:Clinical outcome, meet the guideline of novel coronavirus pneumonia diagnosis and treatment plan (trial version fifth) was confirmed by 2019-nCoV.;Index test:First\u0026#32;pass\u0026#32;perfusion\u0026#32;imaging\u0026#32;parameters\u0026#32;(slope,\u0026#32;tip,\u0026#32;PT","n_enrollment":8020,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"First pass perfusion i;Delayed enhancement;T1 /T2 mapping;Extracellular volume;MRS;CEST;","start_date":"01.03.20","end_date":"","source_id":"ChiCTR2000029955","title":"Evaluation of myocardial injury of novel coronavirus pneumonia (COVID-19) assessed by multimodal MRI imaging                                                                                                                                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49531","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2727,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:Farpiravir tablets;Control group:Abidole tablets;","n_enrollment":120120,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery rate of day 7;","start_date":"20.02.20","end_date":"","source_id":"ChiCTR2000030254","title":"the Efficacy and Safety of Favipiravir for novel coronavirusâ€“infected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study                                                                                               ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50137","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2728,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"prognosis;","start_date":"01.12.19","end_date":"","source_id":"ChiCTR2000030765","title":"Clinical guidance of diagnose and treatment for novel coronavirus pneumonia (COVID-19) based on ''Shi-Du-Yi''                                                                                                                                                  ","url":"http://www.chictr.org.cn/showproj.aspx?proj=50964","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2729,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","n_enrollment":3030,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"the lowest SpO2 during intubation;","start_date":"10.02.20","end_date":"","source_id":"ChiCTR2000029658","title":"Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial                                                                                       ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49074","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2730,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","n_enrollment":18283848,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"SP02;lesions of lung CT;temperature;Blood routine;Inflammatory biomarkers;","start_date":"26.02.20","end_date":"","source_id":"ChiCTR2000030224","title":"Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)                                                                                                                                                             ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49968","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2732,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy T","n_enrollment":8080160160,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The time required for RNA Yin conversion of novel coronavirus in respiratory or blood specimens was compared between treatment groups The difference of;","start_date":"06.02.20","end_date":"","source_id":"ChiCTR2000029573","title":"A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection                        ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49065","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2733,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / riton","n_enrollment":303030,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"novel coronavirus nucleic acid clearance rate;","start_date":"29.01.20","end_date":"","source_id":"ChiCTR2000029496","title":"A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)                                   ","url":"http://www.chictr.org.cn/showproj.aspx?proj=48809","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2734,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","n_enrollment":180180,"country":"China","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Viral nucleic acid test;","start_date":"11.02.20","end_date":"","source_id":"ChiCTR2000029868","title":"Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial                                                                                                                                     ","url":"http://www.chictr.org.cn/showproj.aspx?proj=49524","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2735,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid","n_enrollment":500,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"mortality","start_date":"25. Jan 20","end_date":"","source_id":"NCT04246242","title":"A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","url":"https://clinicaltrials.gov/show/NCT04246242","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2737,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Drug: Lopinavir and Ritonavir Tablets;Drug: Arbidol","n_enrollment":125,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The rate of virus inhibition","start_date":"28. Jan 20","end_date":"","source_id":"NCT04252885","title":"A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","url":"https://clinicaltrials.gov/show/NCT04252885","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2782,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Drug: Recombinant human interferon a1ÃŸ","n_enrollment":328,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The incidence of side effects;The incidence of side effects;The incidence of side effects","start_date":"01. Mar 20","end_date":"","source_id":"NCT04293887","title":"Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1ÃŸ in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","url":"https://clinicaltrials.gov/show/NCT04293887","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2785,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection;Drug: Lopinavir/ritonavir treatment","n_enrollment":80,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery time","start_date":"14. Mar 20","end_date":"","source_id":"NCT04295551","title":"Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","url":"https://clinicaltrials.gov/show/NCT04295551","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2806,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","n_enrollment":60,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Improvement time of clinical critical treatment index within 28 days;Side effects in the MSCs treatment group","start_date":"05. Mar 20","end_date":"","source_id":"NCT04288102","title":"Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Mesenchymal Stem Cell(MSC) for the Treatment of Severe Corona Virus Disease 2019(COVID-19)","url":"https://clinicaltrials.gov/show/NCT04288102","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2827,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","n_enrollment":150,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical cure rate","start_date":"08. Mar 20","end_date":"","source_id":"NCT04310228","title":"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","url":"https://clinicaltrials.gov/show/NCT04310228","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":2856,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"\u003cbr\u003eTrade Name: MYLAN\u003cbr\u003eProduct Name: lopinavir/ritonavir\u003cbr\u003ePharmaceutical Form: \u003cbr\u003eINN or Proposed INN: LOPINAVIR\u003cbr\u003eCAS Number: 192725-17-0\u003cbr\u003eINN or Proposed INN: RITONAVIR\u003cbr\u003eCAS Number: 155213-67-5\u003cbr\u003e\u003cbr\u003eTrade Name: REBIF\u003cbr\u003ePharmaceutical Form: ","n_enrollment":3300,"country":"France","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Timepoint(s) of evaluation of this end point: day 15;Primary end point(s): Clinical status of subject at day 15 (on a 7-point ordinal scale):\u003cbr\u003e1.\tNot hospitalized, no limitations on activities\u003cbr\u003e2.\tNot hospitalized, limitation on activities;\u003cbr\u003e3.\tHosp","start_date":"09.03.20","end_date":"","source_id":"EUCTR2020-000936-23-FR","title":"Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults                                                                                                                                           ","url":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000936-23","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2857,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"\u003cbr\u003eProduct Name: Interferon beat-1a (IFN-ÃŸ1a)\u003cbr\u003eProduct Code: SNG001\u003cbr\u003ePharmaceutical Form: Inhalation solution\u003cbr\u003eINN or Proposed INN: Interferon beta-1a\u003cbr\u003eCurrent Sponsor code: SNG001\u003cbr\u003eConcentration unit: million IU million international units\u003cbr","n_enrollment":400,"country":"United Kingdom","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Main Objective: To assess whether SNG001 is well tolerated, and can prevent or accelerate recovery of lower respiratory tract illness in patients with SARS-CoV-2 infection.;Secondary Objective: To understand more about the biology of how SNG001 affects pa","start_date":"17.03.20","end_date":"","source_id":"EUCTR2020-001023-14-GB","title":"A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNÃŸ-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection - Phase II trial of inhaled anti-viral (SNG001) for SAR","url":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2858,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"\u003cbr\u003eTrade Name: Plaquenil 200 mg, comprimÃ© pelliculÃ©\u003cbr\u003ePharmaceutical Form: Coated tablet\u003cbr\u003e\u003cbr\u003e","n_enrollment":25,"country":"France","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Timepoint(s) of evaluation of this end point: Day 1, Day 4, Day 7 and Day 14;Primary end point(s): Results of SARS-COV2 virus detection ;Secondary Objective: To evaluate the clinical effectiveness of treatment on time to apyrexia, normalization of respira","start_date":"05.03.20","end_date":"","source_id":"EUCTR2020-000890-25-FR","title":"Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine                                                                                                                                                             ","url":"https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000890-25","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2860,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + oseltamivir +lopinavir/ritonavir), patients will receive interferon ÃŸ, sub-type 1b with dose of 250 mcg subcutaneously every other day","n_enrollment":30,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.;Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.","start_date":"15.03.20","end_date":"","source_id":"IRCT20100228003449N27","title":"Evaluating efficacy and safety of interferone ÃŸ-1b (IFN ÃŸ-1b) in the treatment of COVID-19                                                                                                                                                                   ","url":"http://en.irct.ir/trial/46545","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2861,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Intervention group: Hospitalized patients will receive 10 cc Corostop solution and 30 cc Coroguard syrup three times daily for 10 days in addition to receiving standard treatments recommended by the corona county committee. Intervention 2:","n_enrollment":150,"country":"Iran (Islamic Republic of);Iran (Islamic Republic of);Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Response to the treatment (Significant clinical improvement). Timepoint: At baseline and on the third, fifth, seventh, and tenth days after starting the treatment. Method of measurement: According to the clinical, paraclinical and laboratory findings. Cli","start_date":"16.03.20","end_date":"","source_id":"IRCT20200316046792N1","title":"Formulation of two natural products (syrup and solution) and evaluation of their effects in patients with coronavirus disease 2019 (COVID-19): A randomized controlled trial                                                                                   ","url":"http://en.irct.ir/trial/46554","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2862,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + Oseltamivir +Lopinavir/ritonavir), patients will receive interferon B, sub type 1a (CinnaGen Company) with dose of 44 mcg subcutaneousl","n_enrollment":30,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Complications of the treatment. Timepoint: Daily. Method of measurement: Interview and patient's record.;Response to the treatment. Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.","start_date":"15.03.20","end_date":"","source_id":"IRCT20100228003449N28","title":"Evaluating efficacy and safety of interferone ÃŸ-1a in the treatment COVID-19 infection                                                                                                                                                                        ","url":"http://en.irct.ir/trial/46538","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2863,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Intervention group: Treatment group which received Noscapine   mg, tds. Intervention 2: Control group: Group receiving Placebo with no API.","n_enrollment":125,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Cough. Timepoint: Daily. Method of measurement: Clinical finding.;O2 Saturation. Timepoint: daily. Method of measurement: Pulse Oximeter.;Radiographic features Findings. Timepoint: Before/After. Method of measurement: Radiography- CT SCAN.","start_date":"19.03.20","end_date":"","source_id":"IRCT20160625028622N1","title":"The effect of  NOSCOVID on pulmonary \u0026 other clinical manifestations of COVID-19 patients                                                                                                                                                                      ","url":"http://en.irct.ir/trial/46576","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2864,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 da","n_enrollment":20,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical response to therapy. Timepoint: Daily. Method of measurement: Clinical symptoms.","start_date":"03.03.20","end_date":"","source_id":"IRCT20151227025726N12","title":"Evaluting the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with novel Coronavirus (COVID-19)                                                                                                                 ","url":"http://en.irct.ir/trial/46561","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2865,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (Tab hydroxychloroquine 400 mg single dose + Cap oseltamivir 75 mg twice daily + Tab lopinavir/ritonavir 200/50 mg two tablets twice daily for at least 5 day","n_enrollment":50,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Response to the treatment (improvement of patients' chief complaint, abnormal paraclinic and radiologic findings). Timepoint: Daily. Method of measurement: According the clinical, paraclinical and laboratory findings.;Gastrointestinal complications. Timep","start_date":"18.03.20","end_date":"","source_id":"IRCT20100228003449N29","title":"Evaluating efficacy and safety of sofosbuvir/ ledipasvir in  treatment of COVID-19                                                                                                                                                                             ","url":"http://en.irct.ir/trial/46567","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2866,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of ","n_enrollment":70,"country":"Iran (Islamic Republic of)","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Clinical recovery (composite) within 14 days from initiation of study treatment until normalization of fever (=37.2 Â°C oral), respiratory rate (=24/minute on room air), and oxygen saturation (=94% on room air),  sustained for at least 24 hours. Timepoint","start_date":"26.03.20","end_date":"","source_id":"IRCT20200128046294N2","title":"A prospective randomized controlled trial comparing Sovodak (Sofosbuvir+Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment                                                             ","url":"http://en.irct.ir/trial/46463","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2867,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Intervention group: Patients in this group will receive triple-drug regimen including hydroxychloroquine 200 mg two tablets singe dose + cap oseltamivir 75 mg twice daily + lopinavir/ritonavir 200/50 mg two tablets twice daily or atazanavir/ritonavir 300/","n_enrollment":50,"country":"Iran (Islamic Republic of)","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Adverse drug reactions. Timepoint: Every other day. Method of measurement: Interview and laboratory data.;Paraclinical response. Timepoint: Every other day. Method of measurement: Laboratory and radiological findings.;Clinical response. Timepoint: Every o","start_date":"15.03.20","end_date":"","source_id":"IRCT20100228003449N30","title":"Evaluating efficacy and safety of Hydroxychloroquine + Oseltamivir + Lopinavir or Atazanavir/ritonavir combination  in patients with COVID-19                                                                                                                  ","url":"http://en.irct.ir/trial/46536","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2868,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient fo","n_enrollment":500,"country":"United Kingdom","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Time from COVID-19 test being requested to the result being available to clinical teams in minutes and hours, recorded during hospitalisation","start_date":"20.03.20","end_date":"","source_id":"ISRCTN14966673","title":"Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)                                           ","url":"http://isrctn.com/ISRCTN14966673","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2869,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"\u003cbr\u003e                The trial will initially be two-arm, comparing COVID-19 swabbing plus standard care to COVID-19 swabbing plus hydroxychloroquine with usual care.\u003cbr\u003e\u003cbr\u003e                The trial will be implemented in the first instance in practices t","n_enrollment":3000,"country":"United Kingdom","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"The need for hospital admission or death, for patients aged =50 years with comorbidity, and aged =65 with or without comorbidity and suspected COVID-19 infection during time of prevalent COVID-19 infections, measured by hospital admission or mortality rel","start_date":"25.03.20","end_date":"","source_id":"ISRCTN86534580","title":"Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)                                                                                                                                                                        ","url":"http://isrctn.com/ISRCTN86534580","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2870,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir","n_enrollment":50,"country":"Japan","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","start_date":"27.02.20","end_date":"","source_id":"JPRN-jRCTs031190227","title":"A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.                                                           ","url":"https://jrct.niph.go.jp/latest-detail/jRCTs031190227","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2871,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"oral administration of favipiravir","n_enrollment":50,"country":"Japan","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"expected value and 95% CI of ratio of C-reactive protein before versus after the treatment","start_date":"27.02.20","end_date":"","source_id":"JPRN-jRCTs031190226","title":"A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.                                                                                                                                   ","url":"https://jrct.niph.go.jp/latest-detail/jRCTs031190226","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":2872,"source":"ICTRP","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2\u003cbr\u003eDelayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice","n_enrollment":86,"country":"Japan","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"Proportion of subjects with clearance of SARS-CoV2 in nasopharyngeal swab on Day 6","start_date":"02.03.20","end_date":"","source_id":"JPRN-jRCTs041190120","title":"Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction                                                                                           ","url":"https://jrct.niph.go.jp/latest-detail/jRCTs041190120","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":9771,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19549","title":"Plano de contingência estadual para infecção humana pelo novo Coronavírus (2019-nCoV) no Pará","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9778,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"hydroxychloroquine (600 mg/d for 10 days) and azithromycin (500 mg Day 1 and 250 mg days 2 to 5)","n_enrollment":11,"country":"France","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID 19 positive patients in hospital","control":"","out_primary_measure":"viral clearance in nasopharyngeal swabs","start_date":"","end_date":"","source_id":"19145","title":"No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection","url":"https://www.sciencedirect.com/science/article/pii/S0399077X20300858?via%3Dihub","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":9780,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19511","title":"Flujograma de manejo en la paciente embarazada en el contexto de IRA","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9781,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19518","title":"Higiene de establecimientos de salud y afines","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9782,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19519","title":"Orientaciones para el manejo, traslado y disposición final de cadáveres generados ante la introducción del SARS-CoV-2","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9783,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19514","title":"Guia técnica de prevención y control de infecciones durante la atención sanitaria de casos sospechosos o confirmados de COVID-19","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9784,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19512","title":"CORONAVIRUS COVID-19 Manejo Clínico en Pediatría","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9785,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19513","title":"Equipos de Protección Individual (EPI) Categorización de riesgo de acuerdo al nivel de atención","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9786,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19515","title":"Campaña coronavirus acciones inmediatas en las escuelas de la nación paraguaya","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9787,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19526","title":"Plano estadual de contingência para emergência em saúde pública: infecção humana pelo SARS-CoV-2 (Doença pelo Coronavirus - COVID-2019)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9816,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19524","title":"Plano estadual de contingência para o enfrentamento da infecção humana pelo novo Coronavírus (2019- nCoV)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9827,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"unclear","intervention_type":"diagnostic","intervention_name":"VivaDiagTM COVID-19 IgM/IgG Rapid Test lateral flow immunoassay (LFIA)","n_enrollment":110,"country":"Italy","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Covid positive and negative patients","control":"","out_primary_measure":"Sensitivity and specificity ","start_date":"","end_date":"","source_id":"19180","title":"Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department","url":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jmv.25800","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":9832,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19123","title":"COVID-19 - Journal de bord - 10/03/2020: Pandémie virale: s’inquiéter, organiser, prévoir","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9904,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"18546","title":"[El desafio de comunicar y controlar la epidemia por coronavirus]","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":9980,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"18452","title":"Plano de contingência para epidemia da doença pelo Coronavirus 2019 (COVID-19) do Distrito Federal","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10088,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19547","title":"Plano estadual de contingência do novo Coronavírus 2019-nCoV","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10096,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"yes","ipd_sharing":"unclear","intervention_type":"diagnostic","intervention_name":"Nucle 1 ocapsid and Spike Protein-based ELISAs","n_enrollment":314,"country":"China","status":"completed","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19 positive patients and healthy controls","control":"","out_primary_measure":"diagnostic feasibility (sensitivity and specifitiy)","start_date":"18.01.2020","end_date":"","source_id":"19481","title":"Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2","url":"https://jcm.asm.org/content/early/2020/03/27/JCM.00461-20","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":10114,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19517","title":"Comunicado a la opinión pública uso de Hidroxicloroquina","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10115,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19516","title":"Comunicado al público en general","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10144,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"18474","title":"Plano de contingência estadual para o infecção humana pelo SARS-CoV-2 (COVID-19)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10171,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"16700","title":"Comparison of Hospitalized Patients with Acute Respiratory Distress Syndrome Caused by COVID-19 and H1N1","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":10272,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"17858","title":"La maldita pandemia: una oportunidad para la Atención Primaria de Salud","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10323,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"17897","title":"The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients","url":"","is_covid":"yes","is_trial":"yes","is_observational":"unclear","is_duplicate":false},{"cove_id":10355,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"17656","title":"[Prevention and control of SARS-CoV-2 (Covid-19) coronavirus infection in hemodialysis units]","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10380,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"18162","title":"","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10515,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"15266","title":"Ventilatory Ratio in Hypercapnic Mechanically Ventilated Patients with COVID-19 Associated ARDS","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10516,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"14753","title":"Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10562,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"15229","title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":10564,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"15109","title":"Coronavirus: Stay proactive","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10630,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"15308","title":"Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use","url":"","is_covid":"yes","is_trial":"yes","is_observational":"","is_duplicate":false},{"cove_id":10639,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"14937","title":"Plano de Contingência Estadual para Infecção Humana pelo novo Coronavírus 2019-nCoV","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10643,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"14966","title":"Plano de Contingência e Ação Estadual do Acre para Infecção Humana pelo novo Coronavírus (2019-nCoV)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10647,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"12638","title":"Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferon\u0026#x03B1;-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":10697,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"12481","title":"Use of antiviral drugs to reduce COVID-19 transmission","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"no","is_duplicate":false},{"cove_id":10865,"source":"WHO Literature","review_status":"manual extraction completed","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"9136","title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":10920,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"9015","title":"Plano de Contingência do Estado de São Paulo para Infecção Humana pelo novo Coronavírus - 2019 nCov","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10928,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"8856","title":"Nuevo coronavirus 2019-ncov: impacto en salud global","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":10935,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"9000","title":"Misión de repatriación de connacionales en riesgo de contagio al nuevo coronavirus COVID 19: procedimiento de desembarque y traslado de Catam a Oasis","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11222,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"7438","title":"L’informazione utile sul coronavirus (SARS-CoV-2) non è controllata?","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11310,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6568","title":"Early antiviral therapy of abidor combined with lopinavir/ritonavir and re-combinant interferonα-2b in patients with novel coronavirus pneumonia in Zhejiang: A multicenter and prospective study","url":"","is_covid":"yes","is_trial":"yes","is_observational":"","is_duplicate":false},{"cove_id":11352,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6682","title":"Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective cohort study","url":"","is_covid":"yes","is_trial":"yes","is_observational":"","is_duplicate":false},{"cove_id":11451,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"11687","title":"Aminoquinolines Against Coronavirus Disease 2019 (COVID-19): Chloroquine or Hydroxychloroquine","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11550,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"10270","title":"High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: a prospective randomised controlled trial","url":"","is_covid":"yes","is_trial":"yes","is_observational":"","is_duplicate":false},{"cove_id":11606,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"8823","title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","url":"","is_covid":"yes","is_trial":"yes","is_observational":"","is_duplicate":false},{"cove_id":11622,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"8777","title":"2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11668,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"8677","title":"Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11699,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5998","title":"Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":11708,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5813","title":"Nuevo coronavirus 2019-ncov: impacto en salud global","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11730,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4916","title":"オープンサイエンスの効果と課題―新型コロナウイルスおよびCOVID-19に関する学術界の動向","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11735,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5618","title":"Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"yes","is_duplicate":false},{"cove_id":11761,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4792","title":"Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":11774,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4651","title":"Evidence for gastrointestinal infection of SARS-CoV-2","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"no","is_duplicate":false},{"cove_id":11932,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6799","title":"Manifestaciones neuroftalmológicas como complicación de una infección por Mycoplasma pneumoniae y desarrollo posterior de una encefalitis aguda diseminada","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":11947,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3947","title":"Myocardial injury in patients with COVID-19 pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11948,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4322","title":"2019_nCoV/SARS-CoV-2: rapid classification of betacoronaviruses and identification of Traditional Chinese Medicine as potential origin of zoonotic coronaviruses","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11949,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4460","title":"Chinese expert consensus on the perinatal and neonatal management for the prevention and control of the 2019 novel coronavirus infection (First edition)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11954,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4581","title":"Prediction modeling with data fusion and prevention strategy analysis for the COVID-19 outbreak","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11955,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3946","title":"Cardiac manifestations of patients with COVID-19 pneumonia and related treatment recommendations","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11961,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4534","title":"Virus Isolation from the First Patient with SARS-CoV-2 in Korea","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11963,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4582","title":"Noninvasive Respiratory Support for Novel Coronavirus Pneumonia: Enough is Enough","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11967,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4565","title":"Histopathologic Evaluation and Scoring of Viral Lung Infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11970,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3703","title":"Public health might be endangered by possible prolonged discharge of SARS-CoV-2 in stool","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11976,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2218","title":"Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11977,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2176","title":"Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11978,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2211","title":"Dose prediction of lopinavir/ritonavir for 2019-novel coronavirus (2019-nCoV) infection based on mathematic modeling","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11979,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2210","title":"Imported cases of 2019-novel coronavirus (2019-nCoV) infections in Thailand: Mathematical modelling of the outbreak","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11980,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2221","title":"Antiviral Action of Tryptanthrin Isolated from Strobilanthes cusia Leaf against Human Coronavirus NL63 Outbreak of Novel Coronavirus (SARS-Cov-2): First Evidences From International Scientific Literature and Pending Questions","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11981,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2147","title":"Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11983,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2242","title":"Latest assessment on COVID-19 from the European Centre for Disease Prevention and Control (ECDC)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11984,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2233","title":"COVID-19: combining antiviral and anti-inflammatory treatments","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11986,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1927","title":"Nepal’s First Case of COVID-19 and public health response","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11990,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1978","title":"Recent discovery and development of inhibitors targeting coronaviruses","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11992,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2238","title":"Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11993,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2206","title":"Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11994,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2204","title":"Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11996,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2140","title":"Anesthetic Management of Patients with Suspected 2019 Novel Coronavirus Infection During Emergency Procedures","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":11998,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2235","title":"Looming threat of COVID-19 infection in Africa: act collectively, and fast","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12001,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2187","title":"Secondary attack rate and superspreading events for SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12002,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2237","title":"Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12003,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2198","title":"Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12004,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2201","title":"Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12009,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2205","title":"Identification of Coronavirus Isolated from a Patient in Korea with COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12011,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2219","title":"Q\u0026A: The novel coronavirus outbreak causing COVID-19 A mathematical model for simulating the phase-based transmissibility of a novel coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12020,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2239","title":"Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12021,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2220","title":"On the Coronavirus (COVID-19) Outbreak and the Smart City Network: Universal Data Sharing Standards Coupled with Artificial Intelligence (AI) to Benefit Urban Health Monitoring and Management Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019—2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12022,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1487","title":"Burden of acute respiratory disease of epidemic and pandemic potential in the WHO Eastern Mediterranean Region: A literature review","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12025,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1318","title":"Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12026,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1501","title":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infection: Chest CT Findings","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12027,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1475","title":"Comparative Serological Study for the Prevalence of Anti-MERS Coronavirus Antibodies in High- and Low-Risk Groups in Qatar","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12032,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1393","title":"EuNPs-mAb fluorescent probe based immunochromatographic strip for rapid and sensitive detection of porcine epidemic diarrhea virus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12033,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1626","title":"A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":12039,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1189","title":"De-isolating COVID-19 Suspect Cases: A Continuing Challenge","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12040,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1329","title":"COVID-19, Australia: Epidemiology Report 4 (Reporting week ending 19:00 AEDT 22 February 2020)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12041,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1374","title":"Characteristics of COVID-19 infection in Beijing","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12043,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1625","title":"Two clinical cases of Novel coronavirus pneumonia (NCP) in renal transplant recipients","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12047,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1655","title":"Novel coronavirus pneumonia combined with viral conjunctivitis: three cases report","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12050,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1327","title":"Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12052,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1540","title":"A climatologic investigation of the SARS-CoV outbreak in Beijing, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12055,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1326","title":"2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12058,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1421","title":"Genetic diversity and potential recombination between ferret coronaviruses from European and American lineages","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12059,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1415","title":"Swine acute diarrhea syndrome coronavirus (SADS-CoV) antagonizes interferon-β production via blocking IPS-1 and RIG-I","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12061,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1468","title":"Nucleocapsid Protein Recruitment to Replication-Transcription Complexes Plays a Crucial Role in Coronaviral Life Cycle","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12062,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1461","title":"A time delay dynamic system with external source for the local outbreak of 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12067,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1637","title":"Manifestations of Digestive system in hospitalized patients with novel coronavirus pneumonia in Wuhan, China: a single-center, descriptive study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12069,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1460","title":"Visualising the expansion and spread of coronavirus disease 2019 by cartograms","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12071,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1585","title":"Advance in human coronaviruses research of host interactions","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12072,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1325","title":"Passengers' destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12073,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1331","title":"Emergent Strategies for the Next Phase of COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12076,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1673","title":"Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12078,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1631","title":"A correlation study ofCT and clinical features of different clinical types of 2019 novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12079,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1383","title":"2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12080,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1663","title":"Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12081,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1408","title":"Efficacy of orally administered porcine epidemic diarrhea vaccine-loaded hydroxypropyl methylcellulose phthalate microspheres and RANKL-secreting L. lactis","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12082,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1177","title":"The 2019‐new coronavirus epidemic: Evidence for virus evolution","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12083,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1402","title":"Application of the ARIMA model on the COVID-2019 epidemic dataset","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12088,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1418","title":"Effect of TLR agonist on infections bronchitis virus replication and cytokine expression in embryonated chicken eggs","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12089,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1422","title":"Genetic characterization and phylogenetic analysis of porcine deltacoronavirus (PDCoV) in Shandong Province, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12091,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1324","title":"Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12092,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1619","title":"Clinical characteristics of 28 patients with novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12100,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1677","title":"Key points for the prevention and treatment of the novel coronavirus pneumonia in the elderly","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12115,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5809","title":"First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12116,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6043","title":"Biological characters analysis of COVID-19 patient accompanied with aplastic anemia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12120,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5824","title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12123,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5995","title":"Detection of Novel Coronavirus by RT-PCR in Stool Specimen from Asymptomatic Child, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12128,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5993","title":"Structure of mouse coronavirus spike protein complexed with receptor reveals mechanism for viral entry","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12134,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5925","title":"VSI: COVID-19 Therapeutic","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12135,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5897","title":"Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12140,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5990","title":"The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12142,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5835","title":"Assessing the Presence of Post-Traumatic Stress and Turnover Intention Among Nurses Post–Middle East Respiratory Syndrome Outbreak: The Importance of Supervisor Support","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12143,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6113","title":"Influence of trust on two different risk perceptions as an affective and cognitive dimension during Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea: serial cross-sectional surveys","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12145,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6030","title":"Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12150,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6095","title":"Why Your Rural Patients May Know More About Coronavirus Than You","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12153,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6005","title":"Epidemiological investigation of a family clustering of COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12156,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6001","title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12158,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6004","title":"Clinical features of respiratory coronavirus infections and relationship to otolaryngology","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12165,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5049","title":"Effective Chemicals against Novel Coronavirus (COVID-19) in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12166,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5632","title":"[Analysis of bronchoscope-guided tracheal intubation in 12 cases with COVID-19 under the personal protective equipment with positive pressure protective hood]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12168,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5594","title":"[Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12172,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5043","title":"Selection and Use of Respiratory Protection by Healthcare Workers to Protect from Infectious Diseases in Hospital Settings","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12184,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5590","title":"The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): A Chinese perspective","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12197,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5630","title":"[Epidemiological analysis on a family cluster of COVID-19]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12200,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5050","title":"China Coronavirus Outbreak: All the Latest Updates","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12204,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5604","title":"The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12205,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5634","title":"[COVID-19 complicated with DIC: 2 cases report and literatures review]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12207,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5631","title":"[Investigation and analysis on characteristics of a cluster of COVID-19 associated with exposure in a department store in Tianjin]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12219,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4960","title":"Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12223,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5000","title":"2019-novel coronavirus outbreak: A new challenge","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12229,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1444","title":"First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12232,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1635","title":"Report of the first cases of mother and infant infections with 2019 novel coronavirus in Xinyang City Henan Province","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12240,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1598","title":"Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12241,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1633","title":"Analysis of early chest high resolution CT images of novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12242,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1653","title":"Expert consensus on emergency surgery management for traumatic orthopedics under prevention and control of novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12243,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1323","title":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12244,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1639","title":"Clinical features and high resolutionCT imaging findings of preliminary diagnosis novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12246,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1634","title":"High resolution CT features of novel coronavirus pneumonia in children","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12250,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1467","title":"Distinct Roles for Sialoside and Protein Receptors in Coronavirus Infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12251,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1630","title":"The report of two cases infection with novel coronavirus (2019-ncov) after kidney transplantation and the association literature analyzation","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12256,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1594","title":"Advantages and challenges of metagenomic next-generation sequencing (mNGS) in the detection of 2019 novel coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12257,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1632","title":"Early clinical manifestations and pulmonary imaging analysis of patients with Novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12258,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1447","title":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12272,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1160","title":"High resolution CT findings and clinical features of novel coronavirus pneumonia in Guangzhou","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12273,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"992","title":"Management of corona virus disease-19 (COVID-19): the Zhejiang experience","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12277,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"999","title":"Anesthesia Procedure of Emergency Operation for Patients with Suspected or Confirmed COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12280,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"991","title":"Dynamic changes of chest CT imaging in patients with corona virus disease-19 (COVID-19)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12281,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"985","title":"One world, one health: The novel coronavirus COVID-19 epidemic","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12284,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1070","title":"A numerical study of ventilation strategies for infection risk mitigation in general inpatient wards","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12294,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"990","title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12302,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"986","title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12304,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1041","title":"Simulating and Forecasting the Cumulative Confirmed Cases of SARS-CoV-2 in China by Boltzmann Function-based Regression Analyses","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12314,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"535","title":"Clinical Features and Treatment of 2019-nCov Pneumonia Patients in Wuhan: Report of A Couple Cases","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12316,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"488","title":"Expert consensus for bronchoscopy during the epidemic of 2019 Novel Coronavirus infection (Trial version)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12320,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"709","title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12321,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"704","title":"Emerging Coronavirus 2019-nCoV Pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12323,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"82","title":"Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12329,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"701","title":"Genomic variance of the 2019-nCoV coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12330,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"71","title":"The association between domestic train transportation and novel coronavirus outbreak in China, from 2019 to 2020: A data-driven correlational report","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12333,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"","title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12338,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"702","title":"Transmission dynamics and evolutionary history of 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12344,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"697","title":"Coronavirus epidemic: preparing for extracorporeal organ support in intensive care","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12351,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"467","title":"Technical guidance for laboratory testing of 2019-nCoV infection (third edition)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12354,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"607","title":"Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020 | MMWR","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12357,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"566","title":"First case of 2019 novel coronavirus infection in children in Shanghai","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12358,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"45","title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12362,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"589","title":"CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12367,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"497","title":"Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12368,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"562","title":"Prevention and control program on 2019 novel coronavirus infection in Children's digestive endoscopy center","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12375,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"604","title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12376,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"558","title":"Pulmonary rehabilitation guidelines in the principle of 4S for patients infected with 2019 novel coronavirus (2019-nCoV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12379,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"559","title":"Early detection and disease assessment of patients with novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12385,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3739","title":"Prediction of Epidemic Spread of the 2019 Novel Coronavirus Driven by Spring Festival Transportation in China: A Population-Based Study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12386,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4579","title":"Hematologic parameters in patients with COVID-19 infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12387,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4510","title":"Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12388,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3740","title":"CT Imaging and Differential Diagnosis of COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12391,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4564","title":"Deducing the Crystal Structure of MERS-CoV Helicase","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12395,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4550","title":"First case of severe childhood novel coronavirus pneumonia in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12400,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3898","title":"COVID-19 in 2 Persons with Mild Upper Respiratory Symptoms on a Cruise Ship, Japan","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12403,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3177","title":"On the origin and continuing evolution of SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12407,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3068","title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12409,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3182","title":"Sixty seconds on . . . beards","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12410,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3110","title":"Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12411,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3106","title":"Backcalculating the Incidence of Infection with COVID-19 on the Diamond Princess","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12417,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3128","title":"Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12418,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3075","title":"Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, Shenzhen, China, 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12422,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3202","title":"Physikalischer Schutz vor respiratorischen Viren","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12424,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3077","title":"Epidemic trend of corona virus disease 2019 (COVID-19) in mainland China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12425,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3212","title":"Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12426,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3197","title":"The novel coronavirus outbreak in Wuhan, China Development and validation of knowledge, attitude and practice questionnaire for prevention of respiratory tract infections among Malaysian Hajj pilgrims","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12428,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3063","title":"Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12429,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3067","title":"Imaging changes in severe COVID-19 pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12430,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3085","title":"Fecal specimen diagnosis 2019 Novel Coronavirus-Infected Pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12434,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3173","title":"Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12439,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3208","title":"Risk of COVID-19 for cancer patients","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12440,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3079","title":"Novel coronavirus pneumonia (COVID-19) CT distribution and sign features","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12442,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3082","title":"Estimating the basic reproduction number of COVID-19 in Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12451,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3108","title":"Epidemiological Identification of A Novel Pathogen in Real Time: Analysis of the Atypical Pneumonia Outbreak in Wuhan, China, 2019-2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12458,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3086","title":"Analyzing the Epidemiological Outbreak of COVID-19: A Visual Exploratory Data Analysis (EDA) Approach","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12459,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3083","title":"Recommendations for respiratory rehabilitation of COVID-19 in adult","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12460,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3127","title":"From SARS-CoV to 2019-nCoV Outbreak: Similarities in the Early Epidemics and Prediction of Future Trends","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12461,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3124","title":"Distribution of the COVID-19 epidemic and correlation with population emigration from wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12462,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3196","title":"Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12463,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3087","title":"COVID-19. The only certainty is the uncertainty","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12467,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3204","title":"Optimization Method for Forecasting Confirmed Cases of COVID-19 in China Prevention Is Better Than the Cure: Risk Management of COVID-19 Synthesis and Bioactivity Assessment of Novel Spiro Pyrazole-Oxindole Congeners Exhibiting Potent and Selective in vitro Anticancer Effects","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12473,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2638","title":"Drug interaction monitoring of lopinavir / ritonavir in COVID-19 patients with cancer","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12478,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2640","title":"Precautions in ophthalmic practice in the prevention and control of the novel coronavirus pneumonia epidemic","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12482,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2615","title":"Study on assessing early epidemiological parameters of coronavirus disease epidemic in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12487,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2637","title":"Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12488,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2646","title":"The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12492,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2616","title":"Dynamic basic reproduction number based evaluation for current prevention and control of COVID-19 outbreak in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12502,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2644","title":"Epidemiological characteristics of novel coronavirus pneumonia in Henan","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12504,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2636","title":"Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12509,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2641","title":"A Chinese Case of COVID-19 Did Not Show Infectivity During the Incubation Period: Based on an Epidemiological Survey","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12513,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2288","title":"Department of Error: Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study (The Lancet (2020) 395(10225) (689–697), (S0140673620302609), (10.1016/S0140-6736(20)30260-9))","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12514,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2420","title":"Effects and challenges of Open Science - Academic movements related to the Novel coronavirus (2019-nCoV) and COVID-19","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":12517,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2390","title":"Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease 2019","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12520,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2389","title":"The 2019 novel coronavirus resource","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12522,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2552","title":"Imaging changes of severe COVID-19 pneumonia in advanced stage","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12523,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2551","title":"The novel coronavirus (SARS-CoV-2) infections in China: prevention, control and challenges","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12526,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2351","title":"[Analysis on epidemic situation and spatiotemporal changes of COVID-19 in Anhui]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12527,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2503","title":"Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12531,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2573","title":"Trend and forecasting of the COVID-19 outbreak in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12533,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2373","title":"Positive RT-PCR Test Results in Patients Recovered From COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12536,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2253","title":"A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12539,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2462","title":"Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12540,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2448","title":"A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12546,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2544","title":"A mathematical model for simulating the phase-based transmissibility of a novel coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12547,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2334","title":"Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12549,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2387","title":"Negative Nasopharyngeal and Oropharyngeal Swab Does Not Rule Out COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12557,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2254","title":"COVID-19 outbreak on the Diamond Princess cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12559,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2556","title":"Backcalculating the Incidence of Infection with COVID-19 on the Diamond Princess Comparative Seasonal Respiratory Virus Epidemic Timing in Utah","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12564,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2327","title":"[Recommendations for the regulation of medical practices of burn treatment during the outbreak of the coronavirus disease 2019]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12569,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2426","title":"Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12570,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2532","title":"Clinical Characteristics of Coronavirus Disease 2019 in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12571,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2352","title":"[Treatment of pancreatic diseases and prevention of infection during outbreak of 2019 coronavirus disease]","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12576,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2502","title":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12583,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2340","title":"Genome Detective Coronavirus Typing Tool for rapid identification and characterization of novel coronavirus genomes","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12585,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2555","title":"First two months of the 2019 Coronavirus Disease (COVID-19) epidemic in China: real-time surveillance and evaluation with a second derivative model","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12586,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2391","title":"Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12592,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2528","title":"Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12598,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"483","title":"The first two cases of 2019-nCoV in Italy: where they come from?","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12602,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"588","title":"Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12609,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"479","title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12610,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"494","title":"Origin and evolution of the 2019 novel coronavirus - Supplementary data","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12612,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"598","title":"2019 Novel Coronavirus (2019-nCoV) Pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12623,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1260","title":"Mensajero de la Salud: nuevo coronavirus 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12624,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1300","title":"Epitopes for a 2019-nCoV vaccine","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12625,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1169","title":"China uses mass surveillance tech to fight spread of coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12627,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1176","title":"COVID-19 pneumonia: what has CT taught us?","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12634,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1263","title":"Infecciones por Coronavirus. Diagnóstico y Tratamiento","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":12637,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1264","title":"Novo Coronavírus (2019-nCoV): nota técnica","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12638,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1297","title":"Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12639,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1271","title":"Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12640,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1272","title":"Novo Coronavírus: atendimento a pessoas com suspeita de infecção pelo novo coronavírus (2019-nCoV) na Atenção Primária à Saúde","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12641,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1273","title":"Novo Coronavírus: fluxo de atendimento na aps para o novo coronavírus (2019-NCOV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12642,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1253","title":"Assessing the Impact of Reduced Travel on Exportation Dynamics of Novel Coronavirus Infection (COVID-19)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12647,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"7","title":"Quantifying the association between domestic travel and the exportation of novel coronavirus (2019-nCoV) cases from Wuhan, China in 2020: A correlational analysis","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12648,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"261","title":"Estimation of the reproductive number of Novel Coronavirus (COVID-19) and the probable outbreak size on the Diamond Princess cruise ship: A data-driven analysis","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12649,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"164","title":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12650,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"259","title":"The continuous evolution and dissemination of 2019 novel human coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12655,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"169","title":"Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12661,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"159","title":"Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12662,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"229","title":"Asymptomatic novel coronavirus pneumonia patient outside WuHan: The value of CT images in the course of the disease","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12664,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"102","title":"Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12666,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"237","title":"Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12669,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"212","title":"Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12671,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"131","title":"Processing of the SARS-CoV pp1a/ab nsp7-10 region","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12673,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"126","title":"Detection of 2019-nCoV in the pathological paraffin embedded tissue","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12676,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"165","title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12681,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"176","title":"COVID-19, Australia: Epidemiology Report 3 (Reporting week ending 19:00 AEDT 15 February 2020)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12684,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"90","title":"Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12688,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"300","title":"Short-term Forecasts of the COVID-19 Epidemic in Guangdong and Zhejiang, China: February 13–23, 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12689,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"158","title":"Expert consensus on preventing nosocomial transmission during respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12694,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"240","title":"Genetic diversity and evolution of SARS-CoV-2","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12696,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"142","title":"Virus Isolation from the First Patient with SARS-CoV-2 in Korea","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12699,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"217","title":"Drug trials under way","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12700,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"141","title":"Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12705,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"170","title":"Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12706,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"132","title":"Risk assessment of exported risk of novel coronavirus pneumonia from Hubei Province","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12708,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"232","title":"Clinical Features of Atypical 2019 Novel Coronavirus Pneumonia with an initially Negative RT-PCR Assay","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12709,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"160","title":"Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12712,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"149","title":"SARS-CoV-2: a novel deadly virus in a globalised world","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12713,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"273","title":"Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12718,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"298","title":"Risk Assessment of Novel Coronavirus COVID-19 Outbreaks Outside China Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12719,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"154","title":"Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12720,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"130","title":"Presumed Asymptomatic Carrier Transmission of COVID-19","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12725,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"56","title":"The 2019-new coronavirus epidemic: evidence for virus evolution","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12732,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"651","title":"Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12740,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"643","title":"A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12743,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"637","title":"Directrices de Laboratorio para la detección y diagnóstico de la Infección con el Nuevo Coronavirus 2019 (2019-nCoV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12744,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"642","title":"Journey of a Thai Taxi Driver and Novel Coronavirus","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12750,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3123","title":"Single-cell RNA sequencing data suggest a role for angiotensin-converting enzyme 2 in kidney impairment in patients infected with 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12751,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1575","title":"Molecular Basis of Binding between Middle East Respiratory Syndrome Coronavirus and CD26 from Seven Bat Species Distinct Roles for Sialoside and Protein Receptors in Coronavirus Infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12753,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1613","title":"Guidance on strengthening the management processes of children′s fever in outpatient department during the novel coronavirus pneumonia epidemic period (First Edition)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12767,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"921","title":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12770,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"936","title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12771,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"923","title":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12775,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"909","title":"Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12777,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"903","title":"Another coronavirus, another epidemic, another warning","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12785,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"892","title":"COVID-19 and artificial intelligence: protecting health-care workers and curbing the spread","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12789,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"877","title":"Crowdsourcing data to mitigate epidemics","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12794,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"888","title":"Comments on \"Preliminary estimation of the basic reproduction number of novel Coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven Analysis in the early phase of the outbreak\"","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12797,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"905","title":"Pandemic: examining readiness for infectious disease outbreaks","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12798,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"161","title":"Potential of large 'first generation' human-to-human transmission of 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12799,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"682","title":"An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12800,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"646","title":"COVID-19, Australia: Epidemiology Report 2 (Reporting week ending 19:00 AEDT 8 February 2020)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12801,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"644","title":"Consistent detection of 2019 novel coronavirus in saliva","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12804,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"489","title":"Novo Coronavirus (nCoV)","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12807,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"654","title":"Preliminary prediction of the basic reproduction number of the Wuhan novel coronavirus 2019-nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12808,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"19","title":"Epitope-based peptide vaccine design and target site depiction against Middle East Respiratory Syndrome Coronavirus: An immune-informatics study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12813,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"148","title":"Gold nanoparticle\u0026#8208;adjuvanted S protein induces a strong antigen\u0026#8208;specific IgG response against severe acute respiratory syndrome\u0026#8208;related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12826,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"3","title":"Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12827,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"511","title":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12838,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"562","title":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12840,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"32","title":"The Novel Coronavirus Outbreak: What We Know and What We Don’t","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12841,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"65","title":"SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12843,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"57","title":"Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12845,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"","title":"","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12847,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"43","title":"Asymptomatic cases in a family cluster with SARS-CoV-2 infection","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12848,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"11","title":"Health protection guideline of mobile cabin hospitals during Novel Coronavirus Pneumonia (NPC) outbreak","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12849,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"10","title":"Health protection guideline of passenger transport stations and transportation facilities during novel coronavirus pneumonia (NCP) outbreak","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12851,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"18","title":"Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12855,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"83","title":"Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12859,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"80","title":"Potential of large \u0026#8220;first generation\u0026#8221; human\u0026#8208;to\u0026#8208;human transmission of 2019\u0026#8208;nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12860,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"68","title":"Host Factors Affecting Generation of Immunity Against Porcine Epidemic Diarrhea Virus in Pregnant and Lactating Swine and Passive Protection of Neonates","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12864,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"76","title":"Cross\u0026#8208;species transmission of the newly identified coronavirus 2019\u0026#8208;nCoV","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12865,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"27","title":"2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12867,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"37","title":"First Atypical case of 2019 novel coronavirus in Yan'an, China","url":"","is_covid":"","is_trial":"","is_observational":"","is_duplicate":false},{"cove_id":12940,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"1258","title":"Protocolo para la atención de personas con sospechas o infección confirmada por Coronavirus (2019-nCoN)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":12973,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"488","title":"La comunicación científica y el acceso abierto en la contención de enfermedades: El caso del Coronavirus novel 2019 (2019-nCoV)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":12974,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"273","title":"Coronavirus: Stehen wir am Beginn einer neuen Pandemie?","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13071,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"4","title":"Manual de bioseguridad para prestadores de servicios de salud que brinden atención en salud ante la eventual introducción del nuevo coronavirus (nCoV-2019) a Colombia","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13072,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"5","title":"Lineamientos para la detección y manejo de casos por los prestadores de servicios de salud, frente a la eventual introducción del nuevo coronavirus (2019-ncov) a Colombia","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13136,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"6","title":"Novo coronavirus (2019 nCov) Medidas de prevenção e controle de infecção a serem adotadas na ssistência à saúde","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13137,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"13","title":"Protocolo para la atención de personas con sospechas o infección confirmada por Coronavirus (2019-nCoN)[Spanish]","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13206,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"640","title":"Acciones en promoción de la salud, prevención y atención de la Infección Respiratoria Aguda - IRA- ante alerta internacional por Nuevo Coronavirus 2019-nCoV","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13207,"source":"WHO Literature","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"641","title":"Orientaciones a puntos de entrada al país para el tamizaje de viajeros que vienen de zonas con circulación del nuevo coronavirus (2019-nCoV)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13218,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00563","title":"Assessment of Covid-19 infection rates in healthcare workers using a desynchronization strategy","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13219,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00568","title":"Role of chest radiography and ultra low dose chest CT for the management of Coronavirus disease 2019 (COVID-19): clinical and dosimetric evaluations.","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13221,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00593","title":"Effects of measures to contain COVID-19 on sleep and social jetlag","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13222,"source":"Ethics committees (CH)","review_status":"in manual extraction","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00602","title":"GS-US-540-5773: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734TM) in Participants with Severe COVID-19","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13223,"source":"Ethics committees (CH)","review_status":"in manual extraction","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00604","title":"GS-US-540-5774: A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate\nCOVID-19 Compared to Standard of Care Treatment","url":"","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13227,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00651","title":"Manifestation of Covid 19 in chest x-ray and CT","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13229,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00672","title":"Morbidity and mortality due to deferral of aortic valve replacement in patients with severe aortic stenosis - a collateral effect of the SARS-CoV-2 pandemic (AS DEFER)","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13230,"source":"Ethics committees (CH)","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"2020-00687","title":"CT utility for prehospital triage during COVID-19 epidemic","url":"","is_covid":"yes","is_trial":"unclear","is_observational":"unclear","is_duplicate":false},{"cove_id":13231,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"undecided","intervention_type":"biologic","intervention_name":"Convalescent Plasma from patients who recently recover from COVID-19 plus supportive standard care","n_enrollment":20,"country":"Mexico","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"COVID-19","control":"na","out_primary_measure":"Side effects","start_date":"2020-04","end_date":"2021-04","source_id":"NCT04333355","title":"Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection","url":"https://clinicaltrials.gov/ct2/show/NCT04333355","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13232,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Hydroxychloroquine (Oral hydroxychloroquine 400 mg twice a day on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks.)","n_enrollment":360,"country":"United States","status":"not yet recruiting","randomized":"non-randomized","n_arms":2,"blinding":"none","population_condition":"Healthcare workers with high-risk exposure to patients infected with COVID-19","control":"Subjects who opt not to receive the study drug will undergo all procedures to form the control group","out_primary_measure":"Rate of COVID-19 positive conversion","start_date":"3-Apr-20","end_date":"30-Jul-20","source_id":"NCT04333225","title":"A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures","url":"https://clinicaltrials.gov/ct2/show/NCT04333225","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13233,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Plasma; Hydroxychloroquine; Azithromycin","n_enrollment":80,"country":"Colombia","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"Coronavirus; Coronavirus Infection","control":"Hydroxychloroquine; Azithromycin","out_primary_measure":"Change in Viral Load; Change in Immunoglobulin M COVID-19 Titers; Change in Immunoglobulin G COVID-19 Titers","start_date":"1-Apr-20","end_date":"31-Dec-20","source_id":"NCT04332835","title":"Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","url":"https://clinicaltrials.gov/ct2/show/NCT04332835","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13234,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"Aspirin 75mg; Clopidogrel 75mg; Rivaroxaban 2.5 MG; Atorvastatin 40mg; Omeprazole 20mg","n_enrollment":3170,"country":"United Kingdom","status":"not yet recruiting","randomized":"randomized","n_arms":2,"blinding":"none","population_condition":"COVID-19 with pre-existing cardiovascular disease ","control":"No intervention","out_primary_measure":"All-cause mortality","start_date":"31-Mar-20","end_date":"30-Mar-21","source_id":"NCT04333407","title":"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","url":"https://clinicaltrials.gov/ct2/show/NCT04333407","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13235,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"drug","intervention_name":"Deferoxamine","n_enrollment":50,"country":"Iran, Islamic Republic of","status":"recruiting","randomized":"randomized","n_arms":2,"blinding":"double blind","population_condition":"COVID-19 with mild, moderate or severe pneumonia","control":"standard treatment","out_primary_measure":"Mortality rate","start_date":"April 2020","end_date":"March 2021","source_id":"NCT04333550","title":"Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations","url":"https://clinicaltrials.gov/ct2/show/NCT04333550","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13236,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"no","intervention_type":"drug","intervention_name":"chloroquine; hydroxychloroquine","n_enrollment":55000,"country":"United States; Australia; Canada; Ireland; South Africa; United Kingdom","status":"not yet recruiting","randomized":"randomized","n_arms":4,"blinding":"single blind","population_condition":"COVID 19 in Healthcare Workers","control":"Placebo","out_primary_measure":"Symptomatic COVID-19; Peak severity of COVID-19 over the study period","start_date":"April 2020","end_date":"February 2021","source_id":"NCT04333732","title":"A Phase 2, International Multi-site, Bayesian Adaptive, Randomised, Double-blinded, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers","url":"https://clinicaltrials.gov/ct2/show/NCT04333732","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13237,"source":"clinicaltrials.gov","review_status":"manual extraction completed","results_available":"no","ipd_sharing":"unclear","intervention_type":"biologic","intervention_name":"Convalescent Plasma COVID-19: Plasma from patients that have recovered from COVID-19","n_enrollment":10,"country":"Colombia","status":"not yet recruiting","randomized":"non-randomized","n_arms":1,"blinding":"none","population_condition":"Coronavirus; Coronavirus Infection","control":"NA","out_primary_measure":"Change in Viral Load; Change in Immunoglobulin M COVID-19 antibodies Titers; Change in Immunoglobulin G COVID-19 antibodies Titers","start_date":"1-Apr-20","end_date":"31-Dec-20","source_id":"NCT04332380","title":"Convalescent Plasma for Patients With COVID-19: A Pilot Study","url":"https://clinicaltrials.gov/ct2/show/NCT04332380","is_covid":"yes","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13238,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":120,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","start_date":"15-Apr-20","end_date":"31-May-22","source_id":"NCT04331899","title":"A Phase 2 Randomized, Open Label Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13239,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":440,"country":"Spain","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Confirmed cases of a COVID-19","start_date":"3-Apr-20","end_date":"30-Oct-20","source_id":"NCT04331834","title":"Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13240,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":40,"country":"Israel","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Coronavirus Infection","control":"","out_primary_measure":"Duration of viral shedding in days; Time to clinical recovery (TTCR) in days; Treatment-emergent adverse events (AEs)","start_date":"6-Apr-20","end_date":"6-Jul-20","source_id":"NCT04333472","title":"Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13241,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":400,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"COVID-19-related hospitalization or all-cause death","start_date":"6-Apr-20","end_date":"31-Dec-20","source_id":"NCT04331600","title":"Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13242,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":64,"country":"Canada","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19; Pneumonia","control":"","out_primary_measure":"Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)","start_date":"6-Apr-20","end_date":"31-Jan-21","source_id":"NCT04331665","title":"A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13243,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":50,"country":"United States","status":"not yet recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Clinical response; Biochemical response","start_date":"3-Apr-20","end_date":"1-Dec-20","source_id":"NCT04331795","title":"Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13244,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":20,"country":"Mexico","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2","control":"","out_primary_measure":"Recovery of Pneumonia","start_date":"1-Apr-20","end_date":"1-Jun-20","source_id":"NCT04334044","title":"Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13245,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":130,"country":"Netherlands","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19 Pneumonia","control":"","out_primary_measure":"Change in PaO2/FiO2","start_date":"","end_date":"31-Dec-20","source_id":"NCT04333420","title":"A PRAGMATIC ADAPTIVE OPEN LABEL, RANDOMIZED PHASE II/III MULTICENTER STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13246,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":273,"country":"France","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV-2 (COVID-19) Infection; Advanced or Metastatic Hematological or Solid Tumor","control":"","out_primary_measure":"28-day survival rate","start_date":"20-Apr","end_date":"20-Aug","source_id":"NCT04333914","title":"A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13247,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":141,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Rate of SARS-CoV-2 eradication at day 14 from study enrollment","start_date":"1-Apr-20","end_date":"30-Sep-20","source_id":"NCT04330586","title":"A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13248,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":1660,"country":"Canada","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Composite of hospitalization, invasive mechanical ventilation or death within 30 days","start_date":"8-Apr-20","end_date":"31-Aug-20","source_id":"NCT04329611","title":"A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13249,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":2000,"country":"United States; United States; United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Corona Virus Infection; SARS (Severe Acute Respiratory Syndrome)","control":"","out_primary_measure":"Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection; Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection","start_date":"20-Mar","end_date":"31-Oct-20","source_id":"NCT04328961","title":"Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13250,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":2486,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Contact Person From COVID-19 Confirmed Patient","control":"","out_primary_measure":"The rate of COVID-19","start_date":"1-Apr-20","end_date":"30-Mar-22","source_id":"NCT04330144","title":"A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13251,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":800,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID 19; Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","control":"","out_primary_measure":"Incidence rate of new COVID-19 cases in both arms; Prevalence of COVID-19 cases in both arms; Mortality rate secondary to COVID-19 cases in both groups; Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups","start_date":"6-Apr-20","end_date":"6-Nov-20","source_id":"NCT04330495","title":"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13252,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":300,"country":"United States; United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"COVID Ordinal Outcomes Scale at 14 days","start_date":"1-Apr-20","end_date":"31-Dec-21","source_id":"NCT04329832","title":"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13253,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"Spain; Spain","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Patients Infected With COVID-19","control":"","out_primary_measure":"Composite of cumulative death (i.e. mortality) for all causes and for specific causes.","start_date":"10-Apr-20","end_date":"30-Jun-20","source_id":"NCT04334005","title":"Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13254,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":440,"country":"Canada","status":"active, not recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Efficacy of Intervention","start_date":"","end_date":"18-May-22","source_id":"NCT04330690","title":"A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13255,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":400,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Median release from quarantine time; Rate of hospital discharge; Rate of infection","start_date":"6-Apr-20","end_date":"1-Dec-21","source_id":"NCT04329923","title":"The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13256,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":510,"country":"United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; Acute Respiratory Infection; SARS-CoV Infection","control":"","out_primary_measure":"COVID Ordinal Outcomes Scale on Day 15","start_date":"20-Apr","end_date":"21-Jul","source_id":"NCT04332991","title":"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13257,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":2271,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; SARS-CoV-2","control":"","out_primary_measure":"Hospitalization","start_date":"1-Apr-20","end_date":"30-Jul-21","source_id":"NCT04332107","title":"Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13258,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":100,"country":"Spain","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Proportion of patients requiring ICU admission at any time within the study period.","start_date":"1-Apr-20","end_date":"20-May-20","source_id":"NCT04329650","title":"Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13259,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":40,"country":"United States","status":"not yet recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Mortality","start_date":"20-Apr","end_date":"20-Jul","source_id":"NCT04332081","title":"Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13260,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":5,"country":"United States; United States","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Change in Oxygen Saturation by Pulse Oximetry","start_date":"20-Apr","end_date":"20-Apr","source_id":"NCT04331366","title":"GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13261,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":1200,"country":"France; France; France","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)","start_date":"30-Mar-20","end_date":"30-Nov-20","source_id":"NCT04328285","title":"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13262,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":450,"country":"French Guiana; French Guiana","status":"recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections; Severe Acute Respiratory Syndrome; SARS-CoV Infection","control":"","out_primary_measure":"Evaluation of the extent of the virus transmission within households","start_date":"","end_date":"23-Mar-22","source_id":"NCT04328129","title":"Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13263,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Cytokine Storm; Infection Viral","control":"","out_primary_measure":"PO2/FiO2 (Safety); PO2/FiO2 (Efficacy); Early Warning Score (NEWS) (Safety); Early Warning Score (NEWS) (Efficacy); Immunological response (Efficacy); Mechanical ventilation (Efficacy)","start_date":"25-Apr-20","end_date":"31-Dec-22","source_id":"NCT04327505","title":"Safety and Efficacy of Hyperbaric Oxygen for Improvement of Acute Respiratory Distress Syndrome in Adult Patients With COVID-19; a Randomized, Controlled, Open Label, Multicentre Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13264,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":4000,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV-2 Infection","control":"","out_primary_measure":"NIAID COVID-19 Ordinal Severity Scale (NCOSS)","start_date":"1-Apr-20","end_date":"1-Apr-21","source_id":"NCT04328012","title":"Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13265,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":4170,"country":"Australia","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Disease 2019 (COVID-19); Febrile Respiratory Illness; Corona Virus Infection; COVID-19","control":"","out_primary_measure":"COVID-19 disease incidence; Severe COVID-19 disease incidence","start_date":"","end_date":"30-Mar-22","source_id":"NCT04327206","title":"BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13266,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":250,"country":"Vietnam; Vietnam; Vietnam; Vietnam; Vietnam","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV-2 Infection; COVID-19","control":"","out_primary_measure":"Viral clearance time","start_date":"1-Apr-20","end_date":"1-Apr-22","source_id":"NCT04328493","title":"A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13267,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":342,"country":"Belgium; Belgium; Belgium; Belgium; Belgium; Belgium; Belgium; Belgium; Belgium","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Time to Clinical Improvement","start_date":"20-Apr","end_date":"20-Dec","source_id":"NCT04330638","title":"A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13268,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":30,"country":"Iran, Islamic Republic of","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections","control":"","out_primary_measure":"Mortality changes in day 10; Mortality changes in day 30; Changes of C-reactive protein; Changes of C-reactive protein; Changes of C-reactive protein; Changes of Interleukin 6; Changes of Interleukin 6; Changes of Interleukin 6; Changes of tumor necrosis factor-Œ±; Changes of tumor necrosis factor-Œ±; Changes of tumor necrosis factor-Œ±; Changes of PaO2/FiO2 Ratio; Changes of PaO2/FiO2 Ratio; Changes of PaO2/FiO2 Ratio","start_date":"28-Mar-20","end_date":"30-Sep-20","source_id":"NCT04327349","title":"Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13269,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":400,"country":"","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability","start_date":"3-Apr-20","end_date":"30-Jun-20","source_id":"NCT04329572","title":"Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13270,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":10,"country":"United States","status":"","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"Pulmonary Alveolar Proteinosis; COPD; Idiopathic Pulmonary Fibrosis; Viral Pneumonia; Coronavirus Infection; Interstitial Lung Disease","control":"","out_primary_measure":"Incidence of Treatment-Emergent Adverse Events","start_date":"","end_date":"31-Dec-21","source_id":"NCT04326036","title":"Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13271,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":210,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Plaquenil","control":"","out_primary_measure":"Reducing virus duration (viral shedding); Reducing the number of patients going from asymptomatic to moderately disease","start_date":"20-Apr","end_date":"21-Dec","source_id":"NCT04333628","title":"Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13272,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":80,"country":"Belgium; Belgium","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure","start_date":"","end_date":"31-Dec-20","source_id":"NCT04326920","title":"A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine¬Æ) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13273,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":30,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Clear chest CT-scan; PCR test","start_date":"31-Mar-20","end_date":"20-May-20","source_id":"NCT04331470","title":"Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13274,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":554,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","control":"","out_primary_measure":"Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)","start_date":"20-Mar","end_date":"20-May","source_id":"NCT04329195","title":"ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13275,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain; Spain","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Acute Respiratory Distress Syndrome Caused by COVID-19","control":"","out_primary_measure":"60-day mortality","start_date":"1-Apr-20","end_date":"30-Oct-20","source_id":"NCT04325061","title":"Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13276,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":4,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Improved clinical status; Return to room air","start_date":"","end_date":"30-Apr-20","source_id":"NCT04324489","title":"DAS181 for Severe COVID-19: Compassionate Use","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13277,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":1500,"country":"Canada","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; Severe Acute Respiratory Syndrome","control":"","out_primary_measure":"Outpatients: Hospital Admission or Death; Inpatients: Invasive mechanical ventilation or mortality","start_date":"1-Apr-20","end_date":"31-Dec-20","source_id":"NCT04324463","title":"Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13278,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":150,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; Convalescence","control":"","out_primary_measure":"Cumulative incidence of composite outcome of disease severity","start_date":"1-Apr-20","end_date":"23-Jan","source_id":"NCT04323800","title":"Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13279,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":90,"country":"China","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Clinical response; Side effects in the treatment group","start_date":"","end_date":"30-Sep-20","source_id":"NCT04324996","title":"A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13280,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":510,"country":"United Kingdom; United Kingdom; United Kingdom; United Kingdom","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus","control":"","out_primary_measure":"Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases; Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)","start_date":"20-Mar","end_date":"21-May","source_id":"NCT04324606","title":"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13281,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":1500,"country":"Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Health Care Workers absenteeism","start_date":"","end_date":"25-Dec-20","source_id":"NCT04328441","title":"Reducing Health Care Workers Absenteeism in SARS-CoV-2 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gu√©rin Vaccination, a Randomized Controlled Trial.","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13282,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":600,"country":"Germany","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Psychosocial Stress; Mental Health","control":"","out_primary_measure":"Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score","start_date":"20-Mar","end_date":"21-Dec","source_id":"NCT04324190","title":"Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13283,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":75,"country":"Pakistan","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID19","control":"","out_primary_measure":"National Early Warning Score equal to zero","start_date":"28-Mar-20","end_date":"28-Jun-20","source_id":"NCT04328272","title":"Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13284,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":584,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Mortality all causes at day30","start_date":"27-Mar-20","end_date":"27-Jun-21","source_id":"NCT04325633","title":"Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13285,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":30,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial; Change from baseline Serum ferritin level at end of the trial; Change from baseline serum Interleukin-6 concentration at end of the trial; Change from baseline serum C-reactive protein concentration at end of the trial; Change from baseline serum Tumor necrosis factor-Œ± concentration at end of the trial; Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial","start_date":"1-Apr-20","end_date":"30-Oct-20","source_id":"NCT04323228","title":"Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13286,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":6000,"country":"Canada","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Infection","control":"","out_primary_measure":"Number of participants who die or require hospitalization due to COVID-19 infection","start_date":"","end_date":"20-Sep","source_id":"NCT04322682","title":"Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13287,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":20,"country":"United States","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Coronavirus","control":"","out_primary_measure":"RNA in SARS-CoV-2; ICU Admissions; Hospital Mortality; Hospital Length of Stay (LOS)","start_date":"1-Apr-20","end_date":"31-Dec-22","source_id":"NCT04325672","title":"Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13288,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":500,"country":"Italy","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Hospitalized Patients With Covid-19 Pneumonia","control":"","out_primary_measure":"In-hospital mortality","start_date":"","end_date":"13-Mar-21","source_id":"NCT04323514","title":"Use of Ascorbic Acid in Patients With COVID 19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13289,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":50,"country":"China","status":"not yet recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Length of hospital stay (days)","start_date":"20-Mar","end_date":"20-Apr","source_id":"NCT04323332","title":"A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13290,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":210,"country":"United States","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infection","control":"","out_primary_measure":"Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available); Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)","start_date":"","end_date":"20-May","source_id":"NCT04333654","title":"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13291,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":30,"country":"Germany","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; COVID-19; SARS-CoV Infection; Respiratory Failure; Cytokine Storm","control":"","out_primary_measure":"interleukin-6 (IL-6) level after 72 hours","start_date":"","end_date":"26-Nov-20","source_id":"NCT04324528","title":"Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13292,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":240,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Disease, Infectious; Respiratory Disease; Safety Issues; Effectiveness","control":"","out_primary_measure":"COVID-19 disease diagnosis","start_date":"26-Apr-20","end_date":"12-Oct-20","source_id":"NCT04326114","title":"Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13293,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":1000,"country":"","status":"not yet recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Clinical status of subject at day 15 (on a 7 point ordinal scale).","start_date":"20-Mar","end_date":"21-Jul","source_id":"NCT04321993","title":"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13294,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":49,"country":"Italy","status":"active, not recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"death","start_date":"","end_date":"31-May-20","source_id":"NCT04321421","title":"Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13295,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":1600,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Corona Virus Infection","control":"","out_primary_measure":"Number of participants with symptomatic, lab-confirmed COVID-19.","start_date":"20-Mar","end_date":"22-Mar","source_id":"NCT04318444","title":"Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13296,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":180,"country":"Denmark; Denmark; Denmark","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Infection","control":"","out_primary_measure":"Days to clinical improvement from study enrolment","start_date":"31-Mar-20","end_date":"1-May-21","source_id":"NCT04321096","title":"The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13297,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":290,"country":"Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infection; Pneumonia, Viral; Acute Respiratory Distress Syndrome","control":"","out_primary_measure":"Ventilator-free days","start_date":"1-Apr-20","end_date":"30-Aug-20","source_id":"NCT04327401","title":"COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CODEX (Alliance Covid-19 Brasil III)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13298,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":600,"country":"France; France; France; France; France; France; France; France; France; France; France; France; France; France; France; France","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Covid19","control":"","out_primary_measure":"Proportion of asymptomatic children or children with mild respiratory symptoms","start_date":"20-Apr","end_date":"20-Jun","source_id":"NCT04318431","title":"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children, a Cross-sectional, Prospective, Multicentre, Observational Study in Primary Care.","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13299,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":1116,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Number patients developing severe infection or death","start_date":"20-Mar","end_date":"20-Dec","source_id":"NCT04323631","title":"Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13300,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":10,"country":"","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"SARS CoV-2 Infection","control":"","out_primary_measure":"Ventilator Free Days; Duration of supplemental oxygen use","start_date":"20-Mar-20","end_date":"20-Mar-21","source_id":"NCT04319731","title":"A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13301,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":330,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19 Pneumonia","control":"","out_primary_measure":"Clinical Status Assessed Using a 7-Category Ordinal Scale","start_date":"3-Apr-20","end_date":"30-Sep-21","source_id":"NCT04320615","title":"A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13302,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":180,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Disease 19 (Covid 19)","control":"","out_primary_measure":"CRP increase to 3 x upper limit of normal; Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R\u0026D committee; Maximal concentration of cardiac troponin","start_date":"6-Apr-20","end_date":"30-Sep-20","source_id":"NCT04326790","title":"The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13303,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Migraine Disorders; Stress; Anxiety","control":"","out_primary_measure":"Helpfulness of the session; Platform effectiveness","start_date":"20-Mar","end_date":"20-Dec","source_id":"NCT04319445","title":"Mindfulness During COVID-19 - Remote Mindfulness Sessions","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13304,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":2944,"country":"China","status":"recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"2019 Novel Coronavirus Infection","control":"","out_primary_measure":"new-onset COVID-19","start_date":"","end_date":"20-Jun","source_id":"NCT04320238","title":"An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13305,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":7576,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV-2; Coronavirus; COVID-19; 2019-nCoV; 2019nCoV","control":"","out_primary_measure":"Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases","start_date":"1-Apr-20","end_date":"21-Aug-21","source_id":"NCT04321928","title":"Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13306,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":60,"country":"France; France","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Severe Acute Respiratory Syndrome Coronavirus 2; Severe Acute Respiratory Distress Syndrome","control":"","out_primary_measure":"Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group","start_date":"1-Apr-20","end_date":"31-May-21","source_id":"NCT04333368","title":"Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13307,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":60,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; Respiratory Failure; Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere; SARS-CoV-2","control":"","out_primary_measure":"ventilator free days","start_date":"31-Mar-20","end_date":"15-Jun-20","source_id":"NCT04332666","title":"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13308,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":276,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID","control":"","out_primary_measure":"In-hospital mortality; Need for mechanical ventilation in the Intensive Care Unit","start_date":"20-Apr","end_date":"20-Oct","source_id":"NCT04332094","title":"Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13309,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":50,"country":"Italy","status":"not yet recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"SARS-COv2 Related Interstitial Pneumonia","control":"","out_primary_measure":"need of mechanical ventilation","start_date":"10-Apr-20","end_date":"10-Jul-20","source_id":"NCT04332042","title":"TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13310,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":1220,"country":"Canada; Canada; Canada","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections; Post-exposure Prophylaxis","control":"","out_primary_measure":"Microbiologic evidence of infection","start_date":"30-Mar-20","end_date":"31-Mar-22","source_id":"NCT04321174","title":"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13311,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":150,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Perceived Stress; Anxiety; Sleep Disturbance","control":"","out_primary_measure":"Perceived Stress Scale; Perceived Stress Scale; Perceived Stress Scale","start_date":"1-Apr-20","end_date":"30-Jul-20","source_id":"NCT04329533","title":"Effects of a Mobile Meditation App on Stress During Coronavirus (\\COVID-19\\\") Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial\"","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13312,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":440,"country":"Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections; Pneumonia, Viral","control":"","out_primary_measure":"Evaluation of the clinical status","start_date":"","end_date":"30-Aug-20","source_id":"NCT04321278","title":"Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13313,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":9,"country":"China","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"COVID-19; Acute Respiratory Distress Syndrome; Virus; Pneumonia; Acute Lung Injury","control":"","out_primary_measure":"Adverse reaction (AE) and severe adverse reaction (SAE); Changes of lung imaging examinations","start_date":"","end_date":"20-Dec","source_id":"NCT04331613","title":"Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13314,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":54,"country":"Italy; Italy; Italy; Italy","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV-2","control":"","out_primary_measure":"Treatment success","start_date":"20-Mar","end_date":"20-Sep","source_id":"NCT04324021","title":"A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNŒ≥) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13315,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":346,"country":"United States; United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Prone Positioning; High Flow Nasal Cannula; Acute Respiratory Distress Syndrome; Corona Virus Infection","control":"","out_primary_measure":"Treatment failure; Intubation rate","start_date":"6-Apr-20","end_date":"30-Jun-20","source_id":"NCT04325906","title":"Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13316,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"United States; United States; United States; United States; United States; United States; United States","status":"","randomized":"","n_arms":0,"blinding":"","population_condition":"SARS-CoV2 Infection","control":"","out_primary_measure":"","start_date":"","end_date":"","source_id":"NCT04323761","title":"Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13317,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":100,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections; Pneumonia, Viral","control":"","out_primary_measure":"Clinical improvement; Hospital discharge","start_date":"1-Apr-20","end_date":"30-Jun-20","source_id":"NCT04322565","title":"COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13318,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":104,"country":"Italy","status":"recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"Severe Acute Respiratory Syndrome (SARS) Pneumonia; Coronavirus Infections; ARDS, Human","control":"","out_primary_measure":"Composite primary end-point; death; Admission to ICU; Endotracheal intubation (invasive mechanical ventilation)","start_date":"23-Mar-20","end_date":"30-May-20","source_id":"NCT04323592","title":"Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13319,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":60,"country":"Italy","status":"recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"Pharmacological Action","control":"","out_primary_measure":"The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.","start_date":"16-Mar-20","end_date":"30-Apr-20","source_id":"NCT04320277","title":"Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13320,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":1000,"country":"Egypt","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Rate of recovery from positive to negative swaps; Fever to normal temperature in days; Resolution of lung inflammation in CT or X ray","start_date":"25-Mar-20","end_date":"10-May-20","source_id":"NCT04323345","title":"The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13321,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":15,"country":"United States; United States; United States","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Coronavirus Infection","control":"","out_primary_measure":"Pulse oximetry level","start_date":"27-Mar-20","end_date":"1-Jun-20","source_id":"NCT04326452","title":"The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13322,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":700,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV Infection; COVID 19; Acute Respiratory Distress Syndrome ARDS","control":"","out_primary_measure":"In-hospital mortality","start_date":"26-Mar-20","end_date":"20-Nov","source_id":"NCT04321616","title":"The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13323,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":436,"country":"France","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Covid-19 Infection; Hospitalization in Respiratory Disease Department","control":"","out_primary_measure":"Time (in days) to clinical improvement within 30 days after randomization","start_date":"20-Apr","end_date":"20-Jul","source_id":"NCT04331054","title":"Protective Role of Inhaled Steroids for Covid-19 Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13324,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":120,"country":"Italy","status":"recruiting","randomized":"non-randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections","control":"","out_primary_measure":"Mortality rate; Clinical status evaluated in agreement with guidelines","start_date":"","end_date":"30-Aug-20","source_id":"NCT04322344","title":"Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13325,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"Romania; Romania","status":"recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Angina Pectoris; Acute Coronary Syndrome; Coronary Syndrome; Coronary Artery Disease; Angioplasty; Stent Restenosis; Hypertension; Heart Failure, Systolic; Depression, Anxiety; Covid-19; Isolation, Social","control":"","out_primary_measure":"Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients; Number of patients included in this platform","start_date":"","end_date":"1-Oct-20","source_id":"NCT04325867","title":"Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13326,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":1300,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus","control":"","out_primary_measure":"Death, regardless of cause, or the use of intubation and invasive ventilation in the 14 days (day 14) following inclusion and the start of treatment (day 0)","start_date":"20-Apr","end_date":"20-Sep","source_id":"NCT04325893","title":"Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13327,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":630,"country":"Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil; Brazil","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infections","control":"","out_primary_measure":"Evaluation of the clinical status","start_date":"6-Apr-20","end_date":"30-Aug-20","source_id":"NCT04322123","title":"An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azytromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13328,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":300,"country":"France","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Infection","control":"","out_primary_measure":"Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner; Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale","start_date":"","end_date":"21-Jun","source_id":"NCT04327388","title":"An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13329,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":440,"country":"Brazil","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"SARS-CoV Infection; Severe Acute Respiratory Syndrome (SARS) Pneumonia","control":"","out_primary_measure":"Absolute mortality at day 28","start_date":"","end_date":"31-Aug-20","source_id":"NCT04323527","title":"Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13330,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":2500,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"All-cause mortality","start_date":"20-Mar","end_date":"30-Jun-20","source_id":"NCT04328480","title":"The ECLA PHRI COLCOVID Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13331,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":2414,"country":"Ireland","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Hypertension; COVID-19","control":"","out_primary_measure":"Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)","start_date":"","end_date":"1-Mar-21","source_id":"NCT04330300","title":"CORONAvirus Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers InvestigatiON: A Randomized Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13332,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":115,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Pneumonia, Interstitial","control":"","out_primary_measure":"reduction in oxygen and ventilation support","start_date":"1-Apr-20","end_date":"31-Dec-22","source_id":"NCT04333251","title":"Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13333,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":3500,"country":"United States","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19; Corona Virus Infection; ARDS; Acute Respiratory Distress Syndrome","control":"","out_primary_measure":"COVID-19-free survival","start_date":"1-Apr-20","end_date":"20-Aug","source_id":"NCT04328467","title":"Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13334,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":300,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus Infection","control":"","out_primary_measure":"Proportion of participants with normalization of fever and oxygen saturation by day 14","start_date":"1-Apr-20","end_date":"31-Aug-20","source_id":"NCT04326426","title":"COVIDL1: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13335,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":240,"country":"France; France; France; France","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Infection","control":"","out_primary_measure":"Survival without needs of ventilator utilization at day 14.; WHO progression scale \u003c=5 at day 4; Cumulative incidence of successful tracheal extubation (defined as duration extubation \u003e 48h) at day 14; WHO progression scale \u003c=7 at day 4","start_date":"","end_date":"31-Dec-21","source_id":"NCT04324073","title":"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13336,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"China","status":"completed","randomized":"","n_arms":0,"blinding":"","population_condition":"Gastrointestinal Disease; Infectious Disease","control":"","out_primary_measure":"Technical success","start_date":"","end_date":"","source_id":"NCT04320953","title":"Non-contact Endoscopy at Covid-19 Outbreak","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13337,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":200,"country":"Denmark","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Disease","control":"","out_primary_measure":"Time to independence from supplementary oxygen therapy","start_date":"4-Apr-20","end_date":"1-Jun-21","source_id":"NCT04322773","title":"Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13338,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":240,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Corona Virus Infection","control":"","out_primary_measure":"Survival without needs of ventilator utilization at day 14.; WHO progression scale \u003c=5 at day 4; Cumulative incidence of successful tracheal extubation (defined as duration extubation \u003e 48h) at day 14; WHO progression scale \u003c=7 at day 4","start_date":"31-Mar-20","end_date":"31-Dec-21","source_id":"NCT04331808","title":"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13339,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":226,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Virus Diseases; Infection Viral","control":"","out_primary_measure":"Number of days alive and discharged from hospital within 14 days","start_date":"1-Apr-20","end_date":"31-Mar-21","source_id":"NCT04322396","title":"Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13340,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":250,"country":"United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; United States; Australia; Australia; Australia; Australia; Korea, Republic of; Korea, Republic of; Korea, Republic of; Korea, Republic of; Korea, Republic of; Taiwan","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Lower Respiratory Tract Infection; Parainfluenza; Immunocompromised; COVID-19","control":"","out_primary_measure":"Percent of subjects who Return to Room Air (RTRA) (main study); Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)","start_date":"","end_date":"28-Dec-21","source_id":"NCT03808922","title":"A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13341,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":280,"country":"China","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Influenza Infection; SAD-RV Infection and COVID-19","control":"","out_primary_measure":"Percent of subjects who have returned to room air; Percent change of subjects return to baseline oxygen requirement","start_date":"20-Apr","end_date":"22-Sep","source_id":"NCT04298060","title":"A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13342,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":0,"country":"Canada","status":"active, not recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Respiratory Tract Infections; Corona Virus Infection","control":"","out_primary_measure":"Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects","start_date":"","end_date":"31-Mar-21","source_id":"NCT03331445","title":"An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults \u0026 Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13343,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":216,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Coronavirus; Pneumonia; Oxygen Toxicity","control":"","out_primary_measure":"The number of interventions; Duration of interventions","start_date":"6-Apr-20","end_date":"31-Oct-21","source_id":"NCT04320056","title":"Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13344,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"","intervention_type":"","intervention_name":"","n_enrollment":210,"country":"China; China; China; China; China; China; China; China","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"COVID-19","control":"","out_primary_measure":"Viral nucleic acid test negative conversion rate","start_date":"1-Apr-20","end_date":"15-Sep-20","source_id":"NCT04333589","title":"The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13345,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":6800,"country":"Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Australia; Belgium; Belgium; Belgium; Belgium; Canada; Canada; Canada; Croatia; Croatia; Croatia; Germany; Germany; Germany; Germany; Germany; Germany; Germany; Germany; Germany; Germany; Germany; Hungary; Hungary; Hungary; Ireland; Ireland; Ireland; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; Netherlands; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; New Zealand; Portugal; Portugal; Romania; Spain; Spain; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom; United Kingdom","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Community-acquired Pneumonia, Influenza, COVID-19","control":"","out_primary_measure":"All-cause mortality; Days alive and outside of ICU","start_date":"","end_date":"22-Jun","source_id":"NCT02735707","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13346,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":900,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"CPAP Ventilation; COVID-19; Emergency Departments","control":"","out_primary_measure":"Death or need of intubation","start_date":"6-Apr-20","end_date":"9-Nov-20","source_id":"NCT04326075","title":"EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13347,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"no","intervention_type":"","intervention_name":"","n_enrollment":82,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Hip Osteoarthritis; Knee Osteoarthritis; Mental Stress; Coronavirus","control":"","out_primary_measure":"Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.; Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.; Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.; Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","start_date":"31-Mar-20","end_date":"30-Jun-20","source_id":"NCT04329897","title":"Acceptance and Commitment Therapy Delivered by Automated Software Messaging","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13348,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":800,"country":"Canada","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Sepsis; Vitamin C; Intensive Care Unit; COVID-19; Pandemic; Coronavirus","control":"","out_primary_measure":"Number of deceased participants or with persistent organ dysfunction","start_date":"","end_date":"31-Dec-22","source_id":"NCT03680274","title":"Lessening Organ Dysfunction With VITamin C (LOVIT)","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13349,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":70,"country":"United States; United States; United States; United States; United States; United States; United States; Belgium; Belgium; Canada; Canada; France; France; France; Germany; Germany; Netherlands; Poland; Poland; South Africa; Spain; Spain; United Kingdom; United Kingdom; United Kingdom","status":"active, not recruiting","randomized":"","n_arms":0,"blinding":"","population_condition":"Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor; Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor; Hemophilia A","control":"","out_primary_measure":"Number of Participants Who Experienced at Least One Adverse Event by Severity, According to the World Health Organization (WHO) Toxicity Grading Scale; Number of Participants Who Experienced at Least One Thromboembolic Event; Number of Participants Who Experienced at Least One Event of Thrombotic Microangiopathy; Number of Participants with at Least One Laboratory Abnormality; Number of Participants Who Experienced at Least One Injection-Site Reaction by Severity, According to the WHO Toxicity Grading Scale; Number of Participants with Adverse Events Leading to Study Drug Discontinuation; Number of Participants Who Experienced at Least One Severe Hypersensitivity, Anaphylaxis, and Anaphylactoid Event; Change from Baseline in Respiratory Rate Over Time; Change from Baseline in Pulse Rate Over Time; Change from Baseline in Body Temperature Over Time; Change from Baseline in Systolic Blood Pressure Over Time; Change from Baseline in Diastolic Blood Pressure Over Time; Change from Baseline in Electrocardiogram (ECG) Parameters Over Time: QT, QTcB, QTcF, RR, PR, and QRS Intervals; Change from Baseline in Heart Rate Over Time, as Measured by Electrocardiogram (ECG); Model-Based Annualized Bleeding Rate for Treated Bleeds; Median Calculated Annualized Bleeding Rate for Treated Bleeds; Mean Calculated Annualized Bleeding Rate for Treated Bleeds","start_date":"","end_date":"19-Jul-22","source_id":"NCT04158648","title":"A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients With Mild or Moderate Hemophilia A Without FVIII Inhibitors","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13350,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"undecided","intervention_type":"","intervention_name":"","n_enrollment":4000,"country":"","status":"not yet recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Face-touching Behavior","control":"","out_primary_measure":"Frequency of face-touching","start_date":"30-Mar-20","end_date":"30-Apr-20","source_id":"NCT04330352","title":"\\STOP Touching Your Face\\\": a Randomized Controlled Trial of Brief Mindfulness-based Intervention\"","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false},{"cove_id":13351,"source":"clinicaltrials.gov","review_status":"prefilled automatically","results_available":"","ipd_sharing":"yes","intervention_type":"","intervention_name":"","n_enrollment":450,"country":"United States; United States","status":"recruiting","randomized":"randomized","n_arms":0,"blinding":"","population_condition":"Overweight and Obesity","control":"","out_primary_measure":"Body Fat; Body Mass Index (BMI)","start_date":"","end_date":"31-Jul-23","source_id":"NCT03710746","title":"Enhancing Effectiveness of a Dissonance-Based Obesity Prevention Program","url":"","is_covid":"","is_trial":"yes","is_observational":"no","is_duplicate":false}]